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GENERal INTROduCTION aNd OuTlINE Of ThE ThESIS
Liver Transplantation
The principal concept of organ transplantation is the replacement of a diseased organ with a 
healthy one from another individual. In recent decades, transplantation has saved the lives of 
thousands of people who otherwise were condemned to death because of their life-threatening 
diseases. Currently, liver transplantation is the treatment of choice for both acute and chronic 
liver failure. The first successful transplantation of a liver in human was performed by Thomas 
Starzl in 1967 1. In 1983 the National Institutes of Health (NIH) declare liver transplantation as 
an accepted therapy for end-stage liver disease 2. From the last two decades, most important 
indications for liver transplantation in Europe were cirrhosis (58%), cancer (13%), cholestatic 
diseases (11%) and acute hepatic failure (9%). Survival is excellent both in short term and 
long term transplant patients, with patient survival rates of approximately 81% one year after 
surgery, and 69% five years after transplantation (source: www.eltr.org).  
Graft rejection
With the surgical improvements achieved, it has become apparent that graft rejection is the 
next major hurdle to be overcome after transplantation. If pre-existing antibodies to donor’s 
blood group, HLA or other donorantigen are present in the recipient, an immunological 
cascade of hyperacute rejection can follow causing activation of complement and cytolytic 
cells, which finally result in necrosis of the vessel wall of the graft. Prior to kidney and heart 
transplantation, hyperacute rejection has largely been eliminated by routine cross match 
pre-screening 3. Second, acute cellular rejection involves infiltration of the transplanted graft 
by different immune cells. HLA differences between recipient and donor trigger the recruit-
ment of antigen presenting cells (APC) and T cells, follows by alloreactive T cell activation and 
proliferation, which result in rapid graft damage and destruction. In addition, different immune 
cells can infiltrate the graft involving granulocytes, macrophages, Natural Killer cells (NK cells), 
dendritic cells and T cells, all participating in the anti-donor response. In chronic rejection, graft 
damage by recipients’ immune response occurs very slowly, unlike the more rapid type of acute 
rejection. 
Comparing to other solid organs such as heart or kidney, the liver is an immune privileged 
organ with a lower incidence of graft rejection 4. In addition, liver transplants do not require 
HLA matching of donor to recipients, and in contrast to recipients of heart or kidney trans-
plants, it is estimated that about one third of liver transplant recipients with stable function 
can be totally withdrawn from immunosuppression 5-8. Still, identification of stable patients 
suitable for withdrawn is complex, and therefore lifelong treatment with immunosuppressive 
drugs is required in the majority of liver transplant patients in order to prevent rejection of the 
liver graft  9. 
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In the early nineties, acute rejection occurred in up to 75% of transplants patients, which is 
reversible with vigorous immunosuppressive regimen to treat immune mediated graft rejec-
tion 10. Lifelong dependency of immunosuppressive drugs comes with an enormous risk of 
serious side effects. These side effects are significant shortcomings of current anti-rejection 
therapies 11. Common side effects are hypertension, osteoporosis, cardiovascular diseases and 
renal insufficiency 9,12,13. Besides, by suppressing patients’ immune system in order to prevent 
graft rejection, patients suffer from major complications, such as infectious diseases and cancer. 
By this, the life expectancy of transplant patients is impaired significantly and therefore coun-
terbalances the success of transplantation. 
The immune response to the transplanted liver grafts
During evolution, the immune system developed a highly specialized and tightly regulated 
series of responses, the main function of which is described as discriminating between self and 
non-self 4. Transplantation of a liver graft is followed by activation of the immune system, which 
can be divided into two arms; namely innate and adaptive immunity. 
The innate immunity serves as the initial warning signal for the adaptive immunity and 
involves NK cells and APC, such as macrophages, B cells and dendritic cells (DC). These cells 
can respond rapidly to foreignness, but their ability to remember the antigen is limited. Macro-
phages, B cells and DC are “professional” APC and have certain shared characteristics including 
hematopoietic origin, expression of major histocompatibility complex (MHC) class II molecules, 
and the ability to activate and provide co-stimulatory signals to T cells. DC are the most potent 
APC and play a central role in the initiation of allograft rejection 14,15. However, liver resident 
cells, such as Kupffer cell, sinusoidal endothelial cells and stellate cells, with accessory immuno-
logical functions, may also play an important role in antigen presentation 16,17. 
Furthermore, NK cells are lymphocytes of the innate immune system that are involved in 
early defences against autologous cells undergoing various forms of stress, such as malignant 
transformation or infections 18. NK cell activation is the result of a balance between signals 
derived from activator and inhibitor receptors on NK cells 19. The inhibitor receptors inhibit 
killing of target cells by specific interaction with MHC class I molecules, that are constitutively 
expressed by most healthy cells, but their expression may be lost upon stress, such as during 
malignant transformation 20. By this pathway, NK cells are able to discriminate between normal 
and tumor cells and subsequently only kill the tumor cells without the necessity for priming 
(“the missing self hypothesis”). Recently, an increasing number of reports have suggested that 
the role of NK cells after transplantation is not as straight forward as was once thought. The 
traditional view is that NK cells are predominantly pro-inflammatory and are not sufficient to 
reject a solid allograft directly, but may contribute to early chemokine and cytokine production 
after transplantation supporting the rejection response 21,22. In contrast, NK cells have been 
implicated as playing a role in the induction of tolerance to organ allografts 23,24.
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Cross-talk between DC and NK cells can result in lysis, inhibition or maturation of DC by NK 
cells, and reciprocally, DC can activate or inhibit NK-cell functions. The final outcome of DC-NK 
cell interaction depends on the conditions in which both cell types encounter each other 25,26, 
and will subsequently determine the development of the following adaptive immune response. 
The adaptive immunity, which involves T and B cells, is not able to respond rapidly during 
the first encounter with foreign antigens. However, during subsequent encounter of the anti-
gen, the adaptive immunity can respond rapidly and with increased effectiveness due to the 
induction of memory T and B cells. One of the hallmarks identifying T cells is the T cell receptor 
(TCR) for antigens itself. The receptor is a heterodimer formed using two of four possible mol-
ecules: the α, β, γ or δ chain. Interestingly, the genes encoding the TCR chain are members of 
the immunoglobulin supergene family. This is a large family of genes, many of which are found 
on B, T and NK cells. Mature T cells are subdivided based on reciprocal expression of either the 
CD4 or CD8 glycoproteins. CD4+ T cells have MHC class II restricted TCR, and CD8+ T cells are 
MHC class I restricted in their antigen recognition 27. This means that recognition of exogenous 
antigens processed by APC is almost entirely dependent on CD4+ T cells. T cells are described to 
be highly self –MHC-restricted, which means that, in general, T cells are only activated by pep-
tides bound to self-MHC molecules, and not to foreign MHC molecules 28,29. Still, important in 
transplantation setting, a very high proportion of T cells will respond to foreign MHC molecules 
30. In fact, the frequency of these cells responding to foreign MHC molecules is up to 1/100 T 
cells. This is partially due to the fact that different alleles of the MHC genetic locus can be up 
to 98% identical, varying in only a couple of amino acids 10. As a result, foreign MHC can look 
remarkably like self-MHC. In our experiments, alloreactive response to foreign antigen is based 
on the activation of these alloreactive T cells responding to foreign MHC molecules directly, 
without antigen processing by the recipients own APC (direct pathway of allorecognition). 
Different cell types of adaptive and innate immunity are involved in the rejection of allografts. 
Rejection is a direct result of the transfer of donor-antigens by APC to the recipient’s lymphoid 
organs. Both donor DC and recipient DC can present alloantigen to T cells of the recipient. 
In case of interaction between donor DC and recipients T cell, the TCR of the recipient T cell 
will recognise the foreign MHC molecule on donor DC (direct pathway). In direct recognition, 
recipients’ T cell recognizes foreign MHC directly, without processing via antigen presenting 
cells. When DC and T cells, both from the recipient, interact, the recipients’ T cell will recognise 
the donor antigen displayed by the MHC of recipient DC (indirect pathway). (Figure 1)
It is generally accepted that the direct pathway predominates in the immediate aftermath 
of transplantation, when graft derived APC migrate to the surrounding lymphoid tissue, 
where they stimulate alloreactive T cells. As donor derived APC are relatively short lived 31, the 
indirect pathway of allorecognition is generally believed to predominates as the alloresponse 
progresses 32.
T cell activation by DC involves three important signals; i.e. signal 1, 2 and 3. All three signals 
are necessary for full T-cell activation, clonal expansion and attack of the graft. Signal 1 is the 
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Figure 1: Direct and indirect pathway of antigen presentation
Both donor DC and recipient DC can present alloantigen to T cells of the recipient. Direct pathway: interaction between donor DC and recipient T 
cell in which the TCR of the recipient T cell will recognise the foreign MHC molecule on donor DC (left). Indirect pathway: DC and T cells, both from 
the recipient, interact, the recipients’ T cell will recognise the donor antigen displayed by the MHC of recipient DC (right).
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Figure 2: T cell stimulatory requirements
Stimulation of T cells by DC involves three important signals; i.e. signal 1, 2 and 3. All three signals are necessary for full T-cell activation, clonal 
expansion and attack of the graft. Signal 1 involves an antigenic peptide presented by a MHC on the DC to the TCR. Signal 2 is the co-stimulatory 
signals and signal 3 consist of cytokine production.
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antigen-specific signal, which involves recognition of an antigenic peptide presented by a MHC 
on the DC to the T-cell receptor (TCR). The second signal (= Signal 2) is the co-stimulatory signal, 
which involves interaction of co-stimulatory molecules on DC and T cells 15. Signal 3 consists 
of cytokines produced by the DC, which can alter the direction in which the naive T cell will 
differentiate 14,33.  (Figure 2)
In experimental animal studies it has been shown that graft derived DC, expressing donor 
allo antigens, migrate into the recipients lymph nodes and spleen, where they interact with 
recipients’ T cells 10,34. This hypothesis is supported by the fact that in a murine heart and liver 
transplant model augmentation of donor DC can induce rejection 35. Once the APC encounter 
with naive alloreactive T cells, these T cells are activated and differentiate into effector T cells, 
which are primed to attack the transplanted liver graft. In addition, T cells with higher affinity 
for the donor antigens are being activated by APC, which results in development of highly 
reactive memory T cells 32. As a counterpart of this pathway leading to rejection, regulatory 
T cells (Tregs) prevent uncontrolled activation of effector T cells. Regulatory T cells expressing 
the lineage marker Foxp3 are considered to be the “central immune regulator” of numerous 
immune processes 36,37. Interestingly, Tregs play a critical role in induction and maintenance 
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Figure 3: Mechanism of liver allograft rejection
An ordered sequence of events is thought to lead to rejection. Immature donor DC migrate from the transplanted liver to the recipients’ lymphoid 
organs, including spleen and lymph nodes. In the lymphoid organs, donor DC and recipient T cell interact, and through its TCR the recipient T cell 
will recognise the foreign MHC molecule on donor DC directly leading to vigorous anti-donor T cell response with expansion of alloreactive effector 
T cells. T cells with higher affinity for the donor antigens will develop into highly reactive memory T cells. These cells can respond rapidly and 
with increased effectiveness to donor antigens, and thereby enhancing the rejection response. In contrast, some of the naïve T cell can evolve into 
regulatory T cells, which prevent uncontrolled activation of effector T cells, and thereby hampering the rejection response.
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of transplantation tolerance in experimental animal models, and allograft acceptance can be 
transferred from tolerant animals to naive animals by transferring Tregs 38-40. (Figure 3)
In summary, innate immunity contributes to the development of an appropriate adaptive 
immune response. Unfortunately, current immunosuppressive drugs mainly target adaptive 
immunity, and are less effective in altering innate immunity. Therefore, these drugs are only 
capable of controlling the effector immune response and are ineffective in shaping the regula-
tory part of the immune response.
Immunosuppressive drugs and tolerance induction in transplantation
A major challenge in transplantation immunology is to modulate the immune system of the 
recipient to tolerate the allograft in absence of immunosuppressive drugs. Current immunosup-
pressive regimens are effective in prevention of rejection as the incidence of acute liver rejec-
tion has decreased to approximately 15% 4. However, the necessity of lifelong treatment and 
the occurrence of life threatening side effects are significant causes of morbidity and mortality 
after liver transplantation. In addition, the development of allograft acceptance is hindered by 
non-specific nature of these immunosuppressive drugs 41. In experimental animal models, a 
few protocols have been developed to induce long term allograft acceptance in the absence 
of immunosuppression, however all these regimens were either not applicable or effective in 
humans. Protocol aimed at induction of allograft tolerance often entail aggressive ablation of 
recipients’ immune system such as total body irradiation, massive depletion of peripheral T 
cells, and subsequent reconstitution with donor or mixed donor and recipient bone marrow 
42-45.  Most approaches have severe side effects. In general, these protocols can save the graft, 
but harm the patient, and therefore unacceptable for wide spread use.
Classical immunosuppressive drugs used currently after liver transplantation are cortico-
steroids, calcineurin inhibitors (CNI), inhibitors of mTOR, various polyclonal or monoclonal 
antibodies 12. Protocols based on these drugs can prevent graft rejection effectively, but induce 
global immunosuppression. (Table 1)
Table 1: Currently available immuosuppressants
Immunosuppressants agent Immunosuppressant class
Corticosteroids General immunosuppressants
Cyclosporin, Tacrolimus Calcineurin inhibitors (CNI)
6-mercaptoprine, mycophenolate mofetil, azathioprine Anti-metabolites
Sirolimus, Everolimus Inhibitors of TOR
OKT3, IL-2R antibodies, Campath 1H Antibodies
FTY720, leflunomide, FK778, FK779 Novel agents
TOR = target of rapamycine
IL-2R = interleukin 2 receptor
* adapted from Perry et al., Clinical and Experimental Immunology, 139, 2005
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Calne and colleagues were the first to use cyclosporine to prevent graft rejection in human 
renal transplant patients 46. In 1978, they reported that rejection episodes were mild to mod-
erate degree after treatment with cyclosporine. The discovery of cyclosporine has changed 
transplantation practice as few other developments have. The cyclosporine dosing regimen 
based on body weight was effective in preventing acute rejection, but many patients devel-
oped severe infections or suffered from nephro- or hepatotoxicity, while other patients, using 
the same body weight-based dose, did not experience cyclosporine related side effects 47. The 
cyclosporine whole blood concentration two hours after administration (C2) has been shown 
to be the sampling point that correlates best with total drug exposure, and the probability of 
developing acute rejection after transplantation 48. However, limited data exist on the benefits 
and safety of C2 sampling strategies in stable patients long term transplant patients 
49,50.
The acquisition of allograft tolerance, a state of permanent engraftment in absence of 
global immunosuppression, remains the “holy grail” in clinical transplantation. Transplantation 
tolerance is defined as acceptance of donor allograft despite cessation of immunosuppressive 
therapy, while retaining the ability to reject third party allografts. Central tolerance refers to 
a tolerant state established through clonal deletion during the development of allo-antigen 
reactive T cells in the thymus, while peripheral tolerance is a tolerant state that is primarily 
established without intrathymic selection 43,44. Induction of peripheral tolerance involves modi-
fication in the activation process of mature alloreactive peripheral T cells. Peripheral allograft 
tolerance can be induced in various rodent experimental models using inbred donor and 
recipients strains. A variety of protocols including 9,10,29,41,45,51-56: 1) administration of depleting 
monoclonal antibodies targeting cell surface molecules such as CD4, CD8, CD25, LFA-1 or the 
TCR; 2) blockade of the co-stimulatory pathways of T cell activation, notably CTLA-4Ig, anti-
CD154 and anti-OX40L; 3) institution of pharmacological drug including steroids, rapamycin, 
cyclosporine; and 4) donor specific transfusion. Although these protocols can induce prolonged 
allograft survival, their impact on the acquisition of  true allograft tolerance can be different 57. 
In addition, the understanding of underlying mechanism is far from complete. 
Intravenous Immunoglobulins: monomeric IgG, dimers, and aggregates 
The history of potential therapeutic application of immunoglobulins in the treatment of 
human disease started in the 19th century by von Behring and Kitasato, who demonstrated that 
immune sera can ameliorate toxin mediated diseases 58. In the World War II, Cohn developed an 
alcoholic fractionation method to separate human plasma in four fractions of plasma proteins 
59. Fraction II, containing the bulk of human antibodies, showed the greatest clinical merit, 
and has been used widely for multiple clinical purposes 60. The immunoglobulin molecule, 
produced by B cells, consists of two light chain and two heavy chains. The distal ends of each 
light chain-heavy chain pair form an antigen binding site. The proximal ends of the heavy chain 
bind to Fc receptors on immune cells. 
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Intravenous immunoglobulin (IVIg) for therapeutic use is a polyspecific IgG preparation 
(> 95% IgG) purified from plasma pools of several thousand healthy donors. IVIg preparations 
primarily contain human IgG molecules, with small amounts of IgA and IgM. The distribution of 
IgG subclasses in IVIg is comparable to that of IgG in normal serum and the half-life of infused 
IVIg is approximately three weeks. IVIg are considered to be a safe preparation with no long 
term side effects. Although administration of IVIg can result in generalized reactions, such as 
headache, nausea and chills, in 1-15% of the patients. These adverse reactions are often mild 
and are relieved by NSAIDs or reducing the rate of infusion. 
Due to the large donor pool and different manipulations during the purification process 
of IVIg, complexes of anti-idiotype antibodies with complementary idiotypes can be formed 
61. Since dimers and aggregates in IVIg preparations can induce severe side effects, several 
precautions are taken during the production process to keep the content of multimers in IVIg 
preparations minimal 62. Excessive dimerization is prevented by methods such as keeping pH 
of the IVIg preparations low 61. Therapeutic IVIg preparations contain less than 1% aggregates 
and 3 to 15% IgG dimers 61,62. Nevertheless, IgG dimers 63 or multimers 64,65 present in the 
IVIg preparations have been shown to be responsible for the therapeutic efficacy of IVIg on 
macrophage-driven immune responses in different experimental models, such as Immune 
Thrombocytopenic Purpura (ITP) and Listeria monocytogenes infection. Moreover, the effects 
of IVIg in these models could be recapitulated by administration of antigen-antibody immune 
complexes, suggesting that complex IgG is responsible for the anti-inflammatory effects of IVIg 
66. Thus, while immune complexes are generally regarded as pro-inflammatory compounds, 
evidence is emerging that they can also mediate suppression of immune responses 67,68. IgG 
dimers are one of the active anti-inflammatory components in IVIg, which are not present in 
the immune repertoire of a single individual, but are formed in plasma pools due to idiotype-
anti-idiotype complex formation between IgG molecules from different individuals 61,63. Yet, 
preparations with elevated levels of aggregates may cause severe side effects, such as anaphy-
lactic reactions and thrombotic events. However, it is less likely that IgG dimers are responsible 
for the effects of IVIg on T cells. Moreover, some effects on DC in vitro could be recapitulated by 
F(ab)’ fragments and are probably related to natural antibodies against cytokines 
Fcγ receptors and neonatal Fc receptors
Fcγ receptors (FcγR) are immunoglobulin superfamily members recognizing the Fc part of IgG. 
FcγRI (CD64) binds IgG monomers with high affinity. FcγRI is an activating receptor expressed 
on macrophages, monocytes, neutrophils, eosinophils and DC. FcγRII (CD32) binds immune 
complexes with 1000-fold higher affinity for IgG-monomers. In humans two types of FcγRII 
have been identified: FcγRIIA, which is an activating receptor containing an ITAM motif in 
its cytoplasmic domain, and FcγRIIB which is an inhibitory receptor with in intracellular ITIM 
motif 69,70. Macrophages, monocytes, neutrophils, eosinophils and DC express both isoforms, 
while B cells only express the inhibitory isoform FcγRIIB. In mice only the inhibitory variant of 
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FcγRII is present 71. FcγRIII (CD16) binds immune complexes with much higher affinity than IgG 
monomers and is an activating receptor. Humans have two isoforms: FcγRIIIa, which is a trans-
membrane protein expressed on macrophages, monocytes, eosinophils, DC and NK-cells; and 
FcγRIIIb, which is a glycosyl-phosphatidylinositol (GPI)-linked form, expressed on human neu-
trophils. Mice express only FcγRIIIa. FcγRIV is a recently identified activating receptor involved 
in phagocytosis mediated by IgG2a and IgG2b antibodies 72. This receptor is expressed in mice, 
but not in humans. Neonatal Fc receptor (FcRn) is expressed in the endosomal compartment of 
intestinal epithelium, vascular endothelium and macrophages 73. It regulates serum IgG levels 
by binding pinocytosed IgG in the endosomes and recycling it to the cell surface, thereby 
rescuing it from degradation in lysosomes.70,71,74-76
Intravenous immunoglobulins and transplantation
IVIg were initially used as a substitution for immunoglobulins otherwise lacking in patients 
with primary immune deficiencies (PIDs) and secondary immune deficiencies. However, since 
the demonstration in 1981 that IVIg ameliorate ITP 77, IVIg are increasingly being used for the 
treatment of a wide range of autoimmune and systemic inflammatory diseases 78. In addition to 
antibody-mediated diseases, IVIg are also effective in several disorders caused by derailment of 
cellular immunity, like Kawasaki disease, dermatomyositis, multiple sclerosis (MS), graft versus 
host disease (GVHD) in recipients of allogeneic bone marrow transplants, and treatment of 
cellular rejection after organ transplantation 78-83. Clinically, the beneficial effects of IVIg extend 
beyond the half-life of infused IgG, therefore its effect is probably not merely due to a pas-
sive clearance or competition with pathogenic autoantibodies. Table 2  shows the reported 
immunomodulatory effects of IVIg 78. By virtue of a broad spectrum of antibodies, which reflect 
the natural antibody repertoire of the human population, the mechanisms of action of IVIg 
are multifaceted and complex. Most likely, the immunological effects of IVIg are not mutually 
exclusive, and work in synergy to contribute to effective therapy in various clinical settings. 
Together, these observations evoke the possibility that IVIg therapy induces changes to the 
cellular immunity. (Table 2)
Cellular immunity is defined as an immune response that does not involve antibodies or 
complement, but rather involves the activation of macrophages, APC, NK cells, antigen-specific 
cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. His-
torically, the immune system was separated into two branches: humoral immunity, for which 
the protective function of immunization could be found in the humor (cell-free bodily fluid or 
serum) and cellular immunity, for which the protective function of immunization was associ-
ated with cells 84. 
In order to shorten the waiting time for solid organ transplantation and to improve graft sur-
vival, sensitized patients with high titers of donor-specific anti-HLA antibodies are treated with 
IVIg, often in combination with plasmapheresis, anti-lymphocyte antibody or immunoadsorp-
tion techniques 85-88. Also, IVIg is used to facilitate transplantation of ABO incompatible organs 
Ch
ap
te
r 1
18
89. After organ transplantation, IVIg has been used successfully for treatment of antibody medi-
ated rejection 90. In renal transplant patients, IVIg is effective as treatment of steroid-resistant 
cell mediated rejection 80,82. 
To prevent re-infection of the liver graft with the hepatitis B virus (HBV) after liver trans-
plantation, an anti-HBV surface antigen-specific IVIg (anti-HBs IVIg) is administered as prophy-
lactics to HBV-positive liver transplant recipients 91. Anti-HBs IVIg is a pooled hyperimmune 
immunoglobulin G preparation obtained from selected donors with high levels of reactivity 
to hepatitis B surface antigen 92. Strikingly, treatment with anti-HBs IVIg proves to have an 
additional beneficial effect above preventing HBV recurrence, which forms the basic concept 
behind this thesis. Upon clinical observation, we observe that patients treated with anti-HBs 
IVIg had a two-until three-fold lower risk of liver graft rejection 93. This suggests that IVIg may 
be effective in prevention of allograft rejection as suggested already in 1996 94. Since long term 
IVIg treatment has proved to have no side effects 95, using IVIg to substitute or replace current 
immunosuppressive drugs may benefit the long term survival of transplant patients in favour 
of a lower rate of complications. IVIg could be a powerful treatment for controlling the acute 
rejection process after liver transplantation. However, before clinical application can be imple-
mented, the means by which IVIg exerts its therapeutic effects in immune mediated process of 
rejection involving complex cell-cell interactions needs to be verified. 
Table 2: Immunoregulatory effects of Immune Globulin
Effects on Immunoregulatory effects
Fc receptors Blockade of Fc receptors on macrophages and effector cells
Induction of antibody dependent cellular toxicity
Induction of inhibitory Fcγ receptor IIB
Inflammation Attenuation of complement-mediated damage
Decrease in immune complex mediated inflammation
Inhibition of activation of endothelial cells
Neutralization of microbial toxins
Reduction of corticosteroid requirement
B cells and antibodies Control of emergent bone marrow B cell repertoire
Negative signalling through Fcγ receptors
Selective down- and up regulation of antibody production
Neutralization of circulating autoantibodies by antiidiotypes
T cells Regulation of the production of T cell cytokines
Neutralization of T cell superantigens
Cell growth Inhibition of lymphocyte proliferation
Regulation of apoptosis
* adapted from Kazatchkine and Kaveri, N Engl J Med, 345, 2001
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aIMS aNd OuTlINE Of ThE ThESIS
Since current immunosuppressive regimens have reduce the rejection rate significantly, the 
new priority is reduction in toxicity of global immunosuppression, while maintaining equiva-
lent efficacy in controlling rejection. To reach this purpose, the development of safer and more 
effective protocols using the recently introduced immunosuppressive agents is needed.
Although, the established beneficial effects of IVIg in diseases mediated by autoantibodies 
may be explained by several mechanisms including neutralization and accelerated clearance 
of autoantibodies, and prevention of their binding to Fcγ receptors (FcγR) on phagocytes 78. 
The question remains how IVIg exerts its effect on the different cells of the innate and adaptive 
immune system, which can explain the beneficial effects of IVIg in disorders caused by dys-
regulated cellular immunity. Better understanding of the effects of IVIg on the cellular rejection 
response may help us identify new therapeutic potential of IVIg, which form a basis to develop 
less toxic immunosuppressive protocols after liver transplantation. 
Aim I:  First, in order to develop a safer protocol using a conventional agent, cyclosporine, the 
benefits and drawbacks of cyclosporine dosing based on C2 levels compared with con-
ventional C0 level monitoring was studied in stable liver transplant patients. (chapter 2)
Aim II:  explore the therapeutic potential of non classical immunosuppressive drugs with fewer 
side effects; anti – HBs Ig. We determined whether anti – HBs Ig has an additional immu-
nomodulatory effect, in that it can prevent acute allograft rejection in liver transplant 
recipients. (chapter 3)
Aim III:  investigate in depth the immunomodulatory mechanisms of action of IVIg in vitro and 
in vivo in experimental animal models. Both the effects of IVIg on innate immunity 
(chapter 4, 5 and 6) and adaptive immunity (chapter 4 and 7) will be investigated. Focus 
will be on the IVIg effect on various cell types that play an important role in the cellular 
rejection response. 
In chapter 8, the immunomodulatory effects of IVIg on both innate and adaptive cellular immu-
nity are reviewed, and in chapter 9 the results of this thesis are summarized. 
The results from this thesis may form an underlying principle or a discussion platform how to 
embrace IVIg in future immunosuppressive protocols after liver transplantation.
Ch
ap
te
r 1
20
REfERENCES
 1. Starzl TE, Groth CG, Brettschneider L, et al. Extended survival in 3 cases of orthotopic homotransplan-
tation of the human liver. Surgery. 1968;63:549-563.
 2. Liver transplantation. National Institutes of Health Consensus Development. Natl Inst Health Consens 
Dev Conf Summ. 1983;4:15 p.
 3. Dragun D, Rudolph B. Novelties in diagnostics and therapy of antibody mediated rejection. Nephrol 
Dial Transplant. 2007;22 Suppl 8:viii50-viii53.
 4. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver 
Dis. 2009;29:91-101.
 5. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. 
Transplantation. 1997;63:243-249.
 6. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after 
liver transplantation. Hepatology. 1998;27:926-933.
 7. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver trans-
plant recipients. Transplantation. 2001;72:449-454.
 8. Pons JA, Yelamos J, Ramirez P, et al. Endothelial cell chimerism does not influence allograft tolerance 
in liver transplant patients after withdrawal of immunosuppression. Transplantation. 2003;75:1045-
1047.
 9. Beaudreuil S, Samuel D, Rouas-Freiss N, Durrbach A. New aspect of immunosuppressive treatment 
in liver transplantation. How could you induce tolerance in liver transplantation? Transpl Immunol. 
2007;17:98-107.
 10. Martinez OM, Rosen HR. Basic concepts in transplant immunology. Liver Transpl. 2005;11:370-381.
 11. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 
1999;353:1083-1091.
 12. Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin 
Exp Immunol. 2005;139:2-10.
 13. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J 
Med. 2003;349:931-940.
 14. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
 15. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 
2000;18:767-811.
 16. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147-163.
 17. Shimizu H, Kataoka M, Kimura F, et al. Role of Kupffer cells in tolerance induction after portal venous 
administration of alloantigen. Hepatogastroenterology. 2009;56:783-787.
 18. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
 19. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495-
502.
 20. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 
2008;9:503-510.
 21. Obara H, Nagasaki K, Hsieh CL, et al. IFN-gamma, produced by NK cells that infiltrate liver allografts 
early after transplantation, links the innate and adaptive immune responses. Am J Transplant. 
2005;5:2094-2103.
 22. Uehara S, Chase CM, Kitchens WH, et al. NK cells can trigger allograft vasculopathy: the role of hybrid 
resistance in solid organ allografts. J Immunol. 2005;175:3424-3430.
 23. Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a perforin-
dependent mechanism. Nat Med. 2005;11:1059-1065.
 24. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-
presenting cells. J Exp Med. 2006;203:1851-1858.
General introduction and outline of the thesis 21
 25. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of den-
dritic cells by natural killer cells. J Exp Med. 2002;195:335-341.
 26. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction 
between natural killer cells and dendritic cells. J Exp Med. 2002;195:327-333.
 27. Paul WE. Fundamental Immunology: Wolters Kluwer Health.
 28. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant. 2001;1:97-102.
 29. Walsh PT, Strom TB, Turka LA. Routes to transplant tolerance versus rejection; the role of cytokines. 
Immunity. 2004;20:121-131.
 30. van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R. Cytotoxic human CD4(+) T cells. Curr Opin 
Immunol. 2008;20:339-343.
 31. Bosma BM, Metselaar HJ, Mancham S, et al. Characterization of human liver dendritic cells in liver 
grafts and perfusates. Liver Transpl. 2006;12:384-393.
 32. Chiffoleau E, Walsh PT, Turka L. Apoptosis and transplantation tolerance. Immunol Rev. 2003;193:124-
145.
 33. Caux C, Massacrier C, Vanbervliet B, Barthelemy C, Liu YJ, Banchereau J. Interleukin 10 inhibits T cell 
alloreaction induced by human dendritic cells. Int Immunol. 1994;6:1177-1185.
 34. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce 
tolerance or immunity? Trends Immunol. 2002;23:445-449.
 35. Steptoe RJ, Fu F, Li W, et al. Augmentation of dendritic cells in murine organ donors by Flt3 ligand 
alters the balance between transplant tolerance and immunity. J Immunol. 1997;159:5483-5491.
 36. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat 
Immunol. 2008;9:239-244.
 37. Matarese G, De Rosa V, La Cava A. Regulatory CD4 T cells: sensing the environment. Trends Immunol. 
2008;29:12-17.
 38. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3:199-
210.
 39. Bushell A, Wood K. GITR ligation blocks allograft protection by induced CD25+CD4+ regulatory T cells 
without enhancing effector T-cell function. Am J Transplant. 2007;7:759-768.
 40. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: 
CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol. 2002;168:1080-1086.
 41. Wood KJ, Stepkowski S. Transplantation tolerance--discussion. Transplant Proc. 2001;33:3819-3820.
 42. Nikolic B, Sykes M. Mixed hematopoietic chimerism and transplantation tolerance. Immunol Res. 
1997;16:217-228.
 43. Nikolic B, Sykes M. Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol. 
1997;9:634-640.
 44. Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14:417-424.
 45. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity. 2001;14:407-
416.
 46. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver 
donors. Lancet. 1978;2:1323-1327.
 47. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipi-
ents of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2:1033-1036.
 48. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal 
transplantation. Transplantation. 2001;72:1024-1032.
 49. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with 
cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. 
Transplantation. 1999;68:1839-1842.
 50. Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term manage-
ment of renal transplant recipients. Transplantation. 2003;75:2086-2090.
Ch
ap
te
r 1
22
 51. Vincenti F. Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen 
in renal transplant:6-month efficacy and safety. American Transplant Congress 2004, Boston. 2004.
 52. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116-126.
 53. Sebille F, Vanhove B, Soulillou JP. Mechanisms of tolerance induction: blockade of co-stimulation. 
Philos Trans R Soc Lond B Biol Sci. 2001;356:649-657.
 54. Monti P, Scirpoli M, Maffi P, et al. Rapamycin monotherapy in patients with type 1 diabetes modifies 
CD4+CD25+FOXP3+ regulatory T-cells. Diabetes. 2008;57:2341-2347.
 55. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohe-
matopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplanta-
tion. 2002;74:1405-1409.
 56. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after 
blocking CD40 and CD28 pathways. Nature. 1996;381:434-438.
 57. Li X. STB. Mechanisms of tolerance. In: Norman D.J. TLA, ed. Primer on transplantation (ed second); 
2001.
 58. Behring E, Kitasato, S. Uber das Zustandekommen der Diphtherie-immunität und der tetanus-
immunität bei thieren. Dtsch Med Wochenschr. 1890;16:1113-1114.
 59. Cohn EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH. Chemical, Clinical, and Immunological 
Studies on the Products of Human Plasma Fractionation. I. The Characterization of the Protein Frac-
tions of Human Plasma. J Clin Invest. 1944;23:417-432.
 60. Cohn E. Blood proteins and their therapeutic value. Science. 1945;101:51-56.
 61. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism 
of action of intravenous immune globulin in autoimmune diseases. Immunol Rev. 1994;139:159-172.
 62. Bleeker WK, Teeling JL, Verhoeven AJ, et al. Vasoactive side effects of intravenous immunoglobulin 
preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhy-
drolase. Blood. 2000;95:1856-1861.
 63. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin 
preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombo-
cytopenia. Blood. 2001;98:1095-1099.
 64. Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma 
responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007;26:67-78.
 65. Bazin R, Lemieux R, Tremblay T, St-Amour I. Tetramolecular immune complexes are more efficient than 
IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol. 
2004;127:90-96.
 66. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for 
soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune 
disease? J Clin Invest. 2005;115:155-160.
 67. Pinheiro da Silva F, Aloulou M, Skurnik D, et al. CD16 promotes Escherichia coli sepsis through an 
FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med. 
2007;13:1368-1374.
 68. Boekhoudt GH, Frazier-Jessen MR, Feldman GM. Immune complexes suppress IFN-gamma signaling 
by activation of the FcgammaRI pathway. J Leukoc Biol. 2007;81:1086-1092.
 69. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibi-
tory Fc receptor. Science. 2001;291:484-486.
 70. Mackay M, Stanevsky A, Wang T, et al. Selective dysregulation of the FcgammaIIB receptor on memory 
B cells in SLE. J Exp Med. 2006;203:2157-2164.
 71. Takai T. Fc receptors and their role in immune regulation and autoimmunity. Journal of Clinical Immu-
nology. 2005;25:1-18.
 72. Hirano M, Davis RS, Fine WD, et al. IgEb immune complexes activate macrophages through Fcgam-
maRIV binding. Nat Immunol. 2007;8:762-771.
 73. Zhu X, Peng J, Chen D, et al. Calnexin and ERp57 facilitate the assembly of the neonatal Fc receptor for 
IgG with beta 2-microglobulin in the endoplasmic reticulum. J Immunol. 2005;175:967-976.
General introduction and outline of the thesis 23
 74. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system 
by intravenous immunoglobulin. Trends Immunol. 2008;29:608-615.
 75. Maltais LJ, Lovering RC, Taranin AV, et al. New nomenclature for Fc receptor-like molecules. Nat 
Immunol. 2006;7:431-432.
 76. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 
2006;24:19-28.
 77. Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic throm-
bocytopenic purpura in childhood. Lancet. 1981;1:1228-1231.
 78. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with 
intravenous immune globulin. N Engl J Med. 2001;345:747-755.
 79. t Hart BA, Hintzen RQ, Laman JD. Multiple sclerosis - a response-to-damage model. Trends Mol Med. 
2009;15:235-244.
 80. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant 
rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation. 
2001;72:419-422.
 81. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in 
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:117-130.
 82. Casadei DH, del CRM, Opelz G, et al. A randomized and prospective study comparing treatment with 
high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with 
steroid-resistant rejection. Transplantation. 2001;71:53-58.
 83. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre 
syndrome. Lancet Neurol. 2008;7:939-950.
 84. Lewis JMCaRE. Historical Atlas of Immunology (ed first edition): Taylor & Francis; 2007.
 85. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with 
anti-HLA antibodies. Transpl Int. 2004;17:1-8.
 86. Bunchman TE, Parekh RS, Kershaw DB, et al. Beneficial effect of Sandoglobulin upon allograft survival 
in the pediatric renal transplant recipient. Clin Transplant. 1997;11:604-607.
 87. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC. Effect of induction therapy proto-
cols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. 
Am J Transplant. 2006;6:2384-2390.
 88. Rowshani AT, Bemelman FJ, Lardy NM, Ten Berge IJ. Humoral immunity in renal transplantation: clini-
cal significance and therapeutic approach. Clin Transplant. 2008;22:689-699.
 89. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney 
transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am 
J Transplant. 2005;5:145-148.
 90. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney 
transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003;3:653-664.
 91. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B 
immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplanta-
tion compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6:741-748.
 92. Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms 
of action. Liver Transpl. 2005;11:1469-1480.
 93. Kwekkeboom J, Tha-In T, Tra WM, et al. Hepatitis B immunoglobulins inhibit dendritic cells and T cells 
and protect against acute rejection after liver transplantation. Am J Transplant. 2005;5:2393-2402.
 94. Farges O, Saliba F, Farhamant H, et al. Incidence of rejection and infection after liver transplantation 
as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. 
Hepatology. 1996;23:240-248.
 95. Bayry J, Thirion M, Misra N, et al. Mechanisms of action of intravenous immunoglobulin in autoim-
mune and inflammatory diseases. Neurol Sci. 2003;24 Suppl 4:S217-221.

Cha pter 2
Clinical outcome after cyclosporine dose 
reduction based on C2 levels in long term 
liver transplant patients
Clinical Transplantation 2005:19:537-542
Thanyalak Tha-In 1, Dennis A. Hesselink 2, Hugo W. Tilanus 3, Lara Elshove 1, 
Anneloes L. Wilschut 1, Bettina E. Hansen 1,4, Teun van Gelder 5 and Herold J. 
Metselaar 1
1 Department of Gastroenterology and Hepatology, 2 Department of Internal 
Medicine, Renal Transplant Unit,3 Department of Surgery, 4 Department of 
Epidemiology & Biostatistics and 5 Department of Hospital Pharmacy, Clinical 
Pharmacology Unit.
Ch
ap
te
r 2
26
SuMMaRY
Recent studies suggest that cyclosporine dose adjustment based on C2 levels results in 
improvement of renal function. This study investigates the effect on renal function after 
cyclosporine dose reduction based on the C2 levels in long term liver transplant patients. In 
60 patients (> 1yr after transplantation), C2 levels were assessed (target 600 ng/ml ±20%). 
Dose reduction was performed when C2 > 720 ng/ml. Serum creatinine concentrations were 
measured and creatinine clearance was calculated. Twenty-three patients (38%) had C2 values 
> 720 ng/ml. After dose reduction, mean cyclosporine dose decreased by 25% (p<0.01). Mean 
C2 value decreased by 42% (p<0.01). Serum creatinine concentrations remained stable. After 
dose reduction two patients experienced recurrence of primary biliary cirrhosis, in one patient 
auto immune hepatitis recurred and rejection was diagnosed in one patient. In conclusion, 
high cyclosporine C2 concentrations above 720 ng/ml are common in long term liver transplant 
patients. Dose reduction of 25% did not improve kidney function and was accompanied by 
immune activation.
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INTROduCTION
Renal dysfunction after transplantation is considered a problem for transplant recipients as it 
may progress towards end-stage renal failure requiring dialysis or renal transplantation 1,2. The 
incidence of chronic renal failure is reported to be as high as 7 to 21 percent in five years after 
transplantation of a non-renal organ. Forty-six percent of these patients in who end stage renal 
failure developed were placed on a waiting list for kidney transplantation 3. In liver transplant 
patients, the incidence of chronic renal failure is 18 percent and seems to be higher compared 
with heart, lung and heart-lung transplant patients. Diabetes mellitus, hypertension and hepa-
titis C infection were independent risk factors for renal failure 3.
Monitoring cyclosporine blood levels to avoid under dosing or toxicity is one of the essential 
issues in the follow up of long term liver transplant patients. Traditionally, cyclosporine dose is 
adjusted based on the pre-dose level (C0). However, there is accumulating evidence that the 
cyclosporine concentration 2 hours after administration (C2) is a more sensitive tool for optimis-
ing cyclosporine dosing 4,5. The C2 level may be the most accurate predictor of the area under 
the curve (AUC) as a measure of total cyclosporine drug exposure 4. Recent studies report a 
decreased incidence of acute rejection as well as a decrease in cyclosporine related side effects, 
in organ transplant patients by using C2 monitoring instead of the conventional C0 monitor-
ing 6,7. Dose reduction in overexposed patients according to C2 levels is reported to result in 
improvements in renal function and blood pressure in stable long term renal, liver and heart 
transplant patients 8-10. 
So far, one study has examined the effects of dose adjustment based on C2 levels in liver 
transplant patients more than one year after transplantation 9. In our center, the incidence of 
renal dysfunction increases after onset of treatment with calcineurin inhibitors. In 177 patients 
we observed that 50.1% of the patients had a glomerular filtration rate below 60 ml/min two 
years after liver transplantation (unpublished data). This is then followed by a slow but continu-
ing deterioration of renal function.
Therefore, we analysed the effects of dosage individualisation by C2 monitoring in liver 
transplant patients more than one year after transplantation. The aim of this study was twofold. 
First, we investigated the effects of dose reduction based on the C2 levels on the renal function 
in long term liver transplant patients, and second, we evaluated the possible risks accompany-
ing cyclosporine dose reduction. 
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PaTIENTS aNd METhOdS
Patients
In February 2002, 60 stable liver transplant patients who received their first liver transplant 
between April 1988 and January 2001, were included in the study. The characteristics of the 
patients are presented in Table 1. Patients with stable allograft function, who had received their 
transplant at least one year earlier and who had microemulsion cyclosporine as maintenance 
immunosuppressive drug, were eligible to participate in this study. A written informed consent 
was signed by all participants. (Table 1)
Immunosuppression
Standardized immunosuppression protocols were used. All patients had previously been 
monitored by trough level (C0). Cyclosporine was initiated within 24 hours post-reperfusion 
and adopted according to trough level between 200 and 400 ng/ml during the first 3 months 
and then between 100 and 200 ng/ml as maintenance therapy. Moreover, cyclosporine dosage 
was adjusted in case of rejection or cyclosporine related toxicity.
In September 1995, conversion from oil based cyclosporine, Sandimmune (Novartis, Basel, 
Switzerland), to the microemulsion formulation of cyclosporine, Neoral (Novartis), took place 
in our center. Before replacement of Sandimmune by Neoral, 20 patients were initially treated 
with Sandimmune. At the time of inclusion in this study, 38 patients (63.3 %) were on Neoral 
monotherapy, 13 patients (21.7 %) were treated with Neoral and prednisone, five patients (8.3 
%) were treated with Neoral, prednisone and azathioprine, two patients were treated with 
Neoral and azathioprine, one patient was treated with Neoral and mycophenolate mofetil 
(MMF) and one patient was treated with Neoral, prednisone and MMF.
Study design
At the beginning of the study all sixty patients had their C0 and C2 levels assessed. For the pur-
pose of this study, target C0 level was defined as 125 ng/ml (± 20%). Target C2 level was defined 
as 600 ng/ml (± 20%) 11. Cyclosporine dose reduction was performed when C2 value exceed 720 
ng/ml using the formula: new dose = (old dose * 600) / actual C2 level 
12. Cyclosporine dosage 
Table 1: Patients characteristics
all patients Group 1
(C2 ≥720 ng/
ml)
Group 2
(C2 < 720 ng/
ml)
p-value
Gender (M/F) 25/35 9/14 16/21 NS
Mean age at transplantation (yr) 47.11 ± 11.64 46.65 ±7.91 47.40 ± 13.55 NS
Mean time post-transplant (yr) 5.97 ± 3.20 5.09 ± 2.82 6.51 ± 3.34 NS
Liver disease (HBV, HCV, ALD, PBC, other) (n) 10/3/5/25/17 3/0/2/11/7 7/3/3/14/10 NS
Conversion from sandimmune to neoral (n) 20 8 12 NS
M: male, F: female, yr: years, HBV: hepatitis B, HCV: hepatitis C, ALD: alcoholic liver disease, PBC: primary biliary cirrhosis
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was left unaltered in patients whom C2 level was more than 20% below target (< 480 ng/ml) 
in order to avoid cyclosporine overexposure in stable patients. Patients were divided into two 
subgroups based on whether cyclosporine dose reduction is performed. Patients in group 1 
had C2 values above 720 ng/ml and the dose of cyclosporine was reduced. Patients in group 2 
had C2 values below 720 ng/ml and the dose of cyclosporine was left unchanged.
In order to assess changes in renal function, serum creatinine concentrations were collected 
six months before inclusion and measured at 2 weeks, 4 weeks, 8 weeks, 3 months and 6 
months after cyclosporine dose reduction. In addition, the creatinine clearance was calculated 
using the Modification of Diet in Renal Disease Study (MDRD) formula 13. Clinical outcome was 
monitored by routine biochemical measurements at similar visit. Graft rejection and recurrence 
of liver diseases were diagnosed by increased levels of aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase and bilirubin and were confirmed by histological 
examination of a liver biopsy.
Cyclosporine concentration measurement
After drawing the pre dose whole blood sample (C0), patients were asked to take their cyclo-
sporine. Then, blood was drawn at 2 hours ± 15 minutes after cyclosporine intake. After collec-
tion of the blood samples, cyclosporine concentrations were determined using the Emit 2000 
assay (Syva company, Dade Behring inc., Cupertino, CA) on a Cobas Mira Plus analyzer (Roche 
diagnostic systems).
Statistical analysis
The statistical analysis was conducted using the SPSS statistics software SPSS/PC 11.1. The 
paired  t-test was used. The Pearson’s correlation coefficient between C0 and C2 was calculated. 
Differences in the distribution of gender, age at transplantation, time since transplantation, 
liver disease and conversion from Sandimmune® to Neoral® between group 1 and group 2 were 
assessed with the chi-2 test for categorical variables and student’s t-test for continuous vari-
ables. P-values less than 0.05 were considered statistically significant. All data are represented 
as mean ± standard deviation.
RESulTS
The mean pre dose level (C0) was 122.12 ± 54.92 ng/ml and the mean C2 level was 652.13 ± 
274.30 ng/ml. A wide range of C2 values was detected between 188 and 1510 ng/ml). The cor-
relation between C0 and C2 was weak (R = 0.587). Twenty-three patients had C2 values above 
720 ng/ml, 16 patients had C2 values within the target range of 480 - 720 ng/ml and 21 patients 
had C2 values below 480 ng/ml. Interestingly, eleven of the 23 patients (48%) with high C2 had 
C0 values below or within 100-150 ng/ml. (Table 2)
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Accordingly, 23 patients detected with high C2 level (> 720 ng/ml), were selected for cyclo-
sporine dose reduction. However, three of 23 patients did not agree with dose reduction and 
were not included in prospective part of the study. Dose reduction was performed in twenty 
patients (group 1). In 37 patients, with the C2 level within or below desired target range, cyclo-
sporine dosage was not reduced (group 2).
After 6 months of follow up, the mean cyclosporine dose of group 1 decreased from 3.58 ± 
0.95 mg/kg/day to 2.69 ± 0.91 mg/kg/day, representing a 25% reduction in cyclosporine dos-
age (p< 0.01). The corresponding mean C2 decreased from 933.9 ± 209.0 ng/ml to 545.3 ± 228.3 
ng/ml (p< 0.01), showing a 42% decrease in the mean C2 value 6 months after dose reduction. 
Seventy-five percent of the patients were on target after 2 weeks. (Figure 1)
The mean creatinine concentration, creatinine clearance, systolic blood pressure and lipids 
level of group 1 remained stable during follow up. None of the patients had developed end 
stage renal failure. Mean creatinine concentration six months before inclusion was measured 
and did not differ from the mean creatinine concentration at time of inclusion (six months 
before inclusion: 1.4±0.4 mg/dL versus at time of inclusion: 1.3±0.4 mg/dL (NS)). Mean diastolic 
blood pressure decreased significantly after cyclosporine dose reduction (p=0.01). In group 2, 
the renal function, blood pressure and lipids level remained unchanged. Results of group 1 
and 2 before and after follow up are presented in Table 3. Mean creatinine clearance of group 1 
during the six months follow up is demonstrated in Figure 2. (Table 3 and Figure 2)
In group 1, patient 1 experienced cellular rejection after 3 months follow up, which was 
histologically classified as RAI 6. Corticosteroid pulse therapy was additionally given as treat-
ment and cyclosporine dosage was not changed. The C2 level at the time of diagnosis was 800 
ng/ml. In patient 2 and 3 recurrence of primary biliary cirrhosis was diagnosed, respectively 
during the 8 weeks and 6 months visit. This was histologically confirmed. Both patients were 
treated with ursodeoxycholic acid and the cyclosporine dosage of patient 3 was increased. The 
C2 levels at the time of diagnosis were respectively 555 ng/ml in patient 2 and 680 ng/ml in 
patient 3. In patient 4 autoimmune hepatitis recurred in week eight. Following, patient had an 
increase of cyclosporine dosage and allopurinol was given as treatment. The C2 level at the time 
of diagnosis was 640 ng/ml. Patients 1, 2 and 3 were on cyclosporine monotherapy and patient 
4 was treated with cyclosporine and prednisolone. 
Patients 1, 2, and 3 had a C2 value below the C2 target range during one visit. All events were 
before the diagnosis of rejection or recurrence. Respectively, patient 1 had a C2 level of 180 ng/
ml at week four, patient 2 had a C2 level of 470 at week four and patient 3 had a C2 level of 395 
ng/ml at week eight after cyclosporine dose reduction.
In group 2, no rejection or recurrence of immune mediated liver diseases was observed.
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dISCuSSION
This study of C2 monitoring in 60 stable liver transplant patients at more than one year after 
transplantation showed that high cyclosporine C2 concentrations is common in this group of 
patients. Overexposure was observed in 23 of the 60 patients (38%). Eleven of the 23 patients 
(48%) had C0 values below or within target range, indicating the limitations of C0 monitoring 
in detecting drug overexposure. In addition, our findings confirm indicate that C2 monitoring 
is a better measurement for cyclosporine overexposure in long term liver transplant patients.
In earlier publications, Cole et al. reported cyclosporine overexposure of 49% in renal trans-
plant patients more than three months after transplantation 8. In liver transplant patients, an 
overexposure of 68% was documented in patients more than six months after transplantation 
14. In two studies on stable renal transplant patients more than one year after transplantation, 
one described a C2 level exceeding 800 ng/ml in 29% of the patients and another observed C2 
Table 2: C0 and C2 
C0/ C2 Low C2
(≤ 480 ng/ml)
Normal C2
(480-720 ng/ml)
High C2
(≥720 ng/ml)
Total
Low C0 15 5 1 21
Normal C0 5 8 10 23
High C0 1 3 12 16
Total 21 16 23 60
C0: trough level of cyclosporine
C2: cyclosporine concentration 2 hours after administration
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Figure 1: Cyclosporine dose and C2 level (group 1) 
0,0
1,0
2,0
3,0
4,0
0 14 28 42 56 70 84 98 11
2
12
6
14
0
15
4
16
8
18
2
Time in days
C
yc
lo
sp
or
in
e 
do
se
 
(m
g/
kg
/d
ay
)
0
200
400
600
800
1000
C
2 
(n
g/
m
l)
mean Cyclosporine dose mean C2
 
 4
Figure 1: Cyclosporine dose (mg/kg/day) and C2 level (ng/ml) of group 1
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above 850 ng/ml in 18% of the patients 15,16. Our study showing cyclosporine overexposure of 
38% in stable liver transplant patients is in line with these findings.
Despite the linear relation in the used formula, a discrepancy was observed in our study 
between the cyclosporine dose and the measured C2 level. In renal transplant patients after 
dose reduction of 27.5%, Cole et al. observed a 37.3% decrease in mean C2 value 
8. In liver 
transplant patients, Langers et al. reported that a dose reduction of 26.9% resulted in a 25.8% 
decrease in mean C2 value measured on day 2 after dose reduction 
14. We noticed that the 
discrepancy between the cyclosporine dose and the measured C2 level in our study is consider-
able compared to studies mentioned above. This may be due to high within-patient variability. 
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Figure 2: Mean creatinine clearance of group 1 (ml/min)
Table 3: Renal function, bloodpressure and lipids level before and after follow-up
T=0 T=6 months p-value
Group 1 serum creatinine (mg/dL) 1.3±0.4 1.4±0.4 NS
(C2 ≥720 ng/ml) creatinine clearance (ml/min/1.73m
2) 55.2±18.1 53.0±19.1 NS
(n=20) systolic bloodpressure (mmHg) 148±20 144±21 NS
diastolic bloodpressure (mmHg) 92±8 83±11 0.01
Total cholesterol (mmol/l) 5.3±0.7 5.6±1.6 NS
Triglycerides(mmol/l) 2.0±1.1 1.9±1.4 NS
Group 2 serum creatinine (mg/dL) 1.4±0.4 1.4±0.4 NS
(C2 <720 ng/ml) creatinine clearance (ml/min/1.73m
2) 53.2±20.2 53.1±21.1 NS
(n=37) systolic bloodpressure (mmHg) 143±19 139±16 NS
diastolic bloodpressure (mmHg) 85±14 85±9 NS
Total cholesterol (mmol/l) 5.4±1.1 5.5±1.5 NS
Triglycerides(mmol/l) 1.9±0.6 1.9±1.4 NS
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In addition, differences in studied patient population where the time post transplantation and 
the use of co-medication differ between groups should be taken in consideration.
After dose reduction we observed a decline in mean diastolic blood pressure in group 1. This 
was in line with findings of previous studies in long term renal, heart and liver transplant 
patients 8-10. The mean serum creatinine concentration and mean creatinine clearance remained 
unchanged in our study. Since the mean creatinine concentration six months before enrolment 
is comparable to those at the time of inclusion, we consider that there was no slope decline 
of renal function in group 1 post-transplantation. Thus, the stabilised renal function during 
follow up was probably not due to cyclosporine dose reduction. In contrast to other studies in 
non-renal transplant patients, we did not observe improvement in kidney function six months 
after cyclosporine dose reduction based on C2 levels. In liver transplant patients, Langers et al 
reported a significant improvement of 11.6% (p = 0.016) in creatinine clearance at more than 
six months after transplantation (target C2 was 600 ± 15%) 
14. In two studies of Cantarovich et 
al., in one study a 5.1% (p = 0.006) decrease in mean serum creatinine level was observed after 
cyclosporine dose reduction based on C2 level in liver transplant patients at more than one 
year after transplantation. Their target C2 was between 300 and 600 ng/ml 
9. A second study 
of Cantarovich et al in heart transplant patients at more than one year after transplantation, a 
2.3% decrease of serum creatinine was reported after dose reduction based on C2 level aiming 
between 300 and 600 ng/ml 10. The lack of improvement in renal function in our study may 
be related to the C2 target range we used, as this was higher than in the mentioned studies. 
Consistent with this idea Cantarovich et al. reported an increase of mean serum creatinine level 
by 16% when a C2 target level between 700 and 1000 ng/ml was used 
9.  Therefore, the selected 
C2 range is crucial in order to observe effects of dose adjustment based on C2 levels performed 
in long term liver transplant patients. Furthermore, our population had received a liver trans-
plant at least 1 year before the enrolment. Consequently, irreversible damage to the kidney, 
and its management by the reduction of cyclosporine dose already took place at the discretion 
of the attending hepatologist. The reversibility of cyclosporine nephrotoxicity is most likely 
to be more prominent early after transplantation. Cole et al. reported a significant decrease 
of serum creatinine level in 54% of renal transplant patients at more than three months after 
transplantation by performing cyclosporine dose reduction based on C2 levels 
8. Therefore, 
early introduction of dose adjustment based on C2 is probably more effective. 
However, during follow up we observed a brief period of increase in mean creatinine clear-
ance in the first four weeks after cyclosporine dose reduction. These improvements in renal 
function were temporary. We hypothesize that this event is an acute response of the kidney 
to a lower cyclosporine dose, which can not be maintained due to irreversible damage in the 
kidney. Therefore, we doubt the necessity of a longer follow-up. 
It is noteworthy that cyclosporine dose reduction in long term liver transplant patients may 
lead to allograft rejection and recurrence of autoimmune hepatitis or primary biliary cirrhosis. 
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This is attributable to a period of cyclosporine underexposure, which could not be confirmed, 
as the C2 levels at the time of diagnosis were within the target range. However, a short period of 
low immune suppression can not be excluded. In addition, patients using no or a small amount 
of co-medication are probably susceptible to experience complications of low immune sup-
pression. Fluctuation of C2 levels during follow up may easily cause immune activation as the 
patients are using only cyclosporine or cyclosporine and prednisolone as immunosuppressive 
therapy. Therefore, the use of co-medication should be taken in consideration when cyclo-
sporine dose adjustment is performed. When a patient is on cyclosporine monotherapy dose 
reduction should be done with caution, and it is probable that the target C2 levels for this group 
of patients is higher than 600 ng/ml (±20%).
So far, none of the related studies in stable renal transplant patients reported such side 
effects 8,16. After late conversion from C0 to C2 monitoring of cyclosporine in paediatric living 
donor liver transplant recipients, rejection was reported in one patient (1,7%) 17. In adult stable 
liver transplant patients, rejection was reported in two patients after dose reduction 14. The area 
under the curve (AUC) in these patients was below target. The authors performed cyclosporine 
dose reduction in liver transplant patients at more than six months after transplantation with 
19.4% of the patients on cyclosporine monotherapy 14. In our study 63.3% (38/60) of the patients 
(more than one year after transplantation) are on cyclosporine monotherapy and 6.7% (4/60) 
of the patients had complications of immune activation. Hence, the problem of underexposure 
to immune suppressive drug after cyclosporine dose reduction based on C2 levels is expected 
to be more prominent in long term transplant patients, since the number of patients who are 
using no co-medication is enlarging as the post transplantation time increase.
In conclusion, cyclosporine dose reduction based on C2 levels in liver transplant patients 
at more than one-year post transplantation is less effective than in earlier stages, and renal 
function may not be influenced. We realise that the risks of rejection and recurrence of auto-
immune liver diseases are not to be underestimated, especially in patients on cyclosporine 
monotherapy. By using C2 target range of 600 ng/ml (±20%) no benefit in renal function was 
observed after cyclosporine dose reduction in long term liver transplant patients.
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SuMMaRY
The efficacy of anti-viral intravenous immunoglobulins (anti-HBs IVIg and anti-CMV IVIg) in pre-
venting acute rejection after liver transplantation was assessed in a retrospective analysis, and 
correlated to their effects on immune cells in vitro. HBs Ag-positive liver graft recipients (n = 40) 
treated prophylactically with anti-HBs IVIg had a significantly lower incidence of acute rejection 
compared with recipients without viral hepatitis (n = 147) (12% versus 34%; p = 0.012), while 
the incidence of rejection in HCV-positive recipients (n = 29) was similar to that in the control 
group. Treatment with anti-CMV IVIg (n = 18) did not protect against rejection. In vitro, anti-HBs 
IVIg suppressed functional maturation of and cytokine production by human blood-derived 
dendritic cells (DC) at concentrations similar to the serum concentrations reached during anti-
HBs IVIg treatment of liver graft recipients. In addition, anti-HBs IVIg inhibited allo-antigen- and 
lectin-stimulated proliferation of peripheral T cells. Anti-CMV IVIg suppressed functional DC 
maturation and alloantigen-stimulated T-cell proliferation, but not lectin-driven T-cell prolif-
eration. In conclusion, anti-HBs IVIg protects against acute rejection after liver transplantation, 
probably by functional inhibition of the two principal immune cells involved in allograft rejec-
tion, DC and T cells.
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INTROduCTION
Intravenous immunoglobulins (IVIg) are therapeutic preparations of IgG derived from plasma 
pools of either healthy blood donors or individuals with high titers of antibodies against certain 
viruses. IVIg containing specific antibodies against CMV (anti-CMV IVIg) are used to prevent 
transplantation-associated CMV infection, and anti-HBV surface antigen specific IVIg (anti-
HBs IVIg) are administered as prophylaxis to Hepatitis B Virus (HBV) positive liver transplant 
recipients to prevent infection of the graft with HBV. Non-specific IVIg have anti-inflammatory 
properties, which are exploited in their application in the treatment of autoimmune disorders 
(reviewed in 1). Among the disorders responding to IVIg treatment are not only autoantibody 
mediated diseases, but also T-cell mediated immuno-pathological conditions, like multiple 
sclerosis 2, indicating that IVIg may suppress T-cell activation or function. 
In the context of transplantation, prophylactic treatment with non-specific IVIg was found to 
decrease the incidence of acute graft versus host diseased (GVHD) after clinical bone marrow 
transplantation 3, and in an experimental settings, in which GVHD was induced by lymphocyte 
transfer 4. In addition, IVIg are effective in the treatment of steroid resistant acute rejection 
after kidney transplantation 5,6. So far, It is unknown whether IVIg are effective as prophylaxis 
for acute rejection after organ transplantation. In line with this possibility, two papers have 
reported that treatment of liver graft recipients with anti-HBs IVIg or anti-CMV IVIg protects 
against acute rejection 7,8, but a study from another liver transplant center failed to confirm the 
mentioned protective effect 9.
Non-specific IVIg have been shown to inhibit the in vitro equivalent of acute rejection, the 
mixed lymphocyte reaction (MLR) 10,11. One report suggests that virus specific IVIg have MLR-
suppressive capacity too 12. Inhibition of MLR by IVIg may be due to suppression of the T cells or 
the Antigen Presenting Cells (APC) or both. It has been observed that non-specific IVIg suppress 
proliferation 13 and cytokine production 13-15 by human T-cells in vitro. In addition, non-specific 
IVIg have been found to inhibit the differentiation of dendritic cells (DC) from human mono-
cytes , and their maturation in vitro 16. As DC migrating from the organ graft are considered as 
the principal APC priming T-cell reactivity against donor antigens after organ transplantation 
17, this finding merits further study as a potential explanation for the beneficial effect of IVIg on 
allograft rejection. Whether anti-viral IVIg have similar effects on DC is so far unknown.
The aims of the present study were to determine whether the anti-viral IVIg used in our 
center protect against acute rejection after liver transplantation, and whether these hyperim-
mune anti-viral IVIg affect the function of principal immune cells involved in allograft rejection, 
i.e. DC and T-cells. 
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PaTIENTS aNd METhOdS
Intravenous immunoglobulins
Anti-HBs IVIg (Hepatect® or Hepatect CP®) and anti-CMV IVIg (Cytotect®) were obtained from 
Biotest Pharma, Dreieich, Germany. For all three preparations only healthy individuals are 
accepted as donors. Individuals selected for donation of anti-CMV plasma have been naturally 
infected by CMV, and have high titers of CMV-IgG (9-15 Paul-Ehrlich-CMV-Units/ml plasma). For 
Hepatect and Hepatect CP plasma from healthy individuals who are vaccinated with a standard 
HBV vaccine are selected for donation (40 - 60 IU anti-HBsAg IgG/ml). When indicated these IVIg 
were dialyzed twice against large volumes of culture medium (RPMI) at 4°C to remove stabiliz-
ing agents and to obtain neutral pH. After dialysis, IgG concentration was determined by the 
Tina-quant® immuno-turbidimetric assay (Roche Diagnostics, Mannheim, Germany). 
Study population
A retrospective analysis was performed on recipients of a primary orthotopic liver graft within 
the Erasmus Medical Center between January 1992 and October 2002. Patients treated with 
ATG or OKT-3 as part of their induction immunosuppressive therapy (n = 21) were excluded 
from the study cohort. In addition, patients with a follow-up of less than 5 days (n = 30) were 
excluded. The remaining 234 liver transplant recipients were grouped into four categories 
(Table 1): 
1.  HBs Ag-positive patients transplanted for either liver cirrhosis due to chronic HBV infection 
(n = 31) or for fulminant (n = 9) HBV infection. All these patients had been treated with Hepa-
tect® or Hepatect CP® as prophylaxis; 
2.  CMV IgG negative recipients transplanted with a graft from a CMV IgG positive donor, and 
were treated with Cytotect® as a prophylaxis for CMV-infection (n = 18); 
3. patients transplanted for chronic HCV infection (n = 29); 
4. all other recipients (n = 147). 
Table 1: Patient and donor characteristics of the study groups.
p-value 1.anti-HBs Ig 2. Anti-CMV Ig 3. HCV 4. other
Number of patients 40 18 29 147
sex (m/f) 0.047 27/13 7/11 19/10 71/76
age (mean±sd) 0.017 47±10 43±14 53±8 46±13
donor sex (m/f) 0.727 23/17 11/7 15/14 73/73
donor age (years) 0.123 44±13 37±15 39±13 38±14
Graft ischemia time (hours) 0.089 10.3±3.0 12.3±3.3 9.9±3.6 10.4±3.0
Year of transplantation <0.001 1999 (1993- 2002) 1995 (1992-1998) 1998 (1994-2002) 1998 (1992-2002)
Immunosuppresssion
(with IL-2 rec. mAb)
0.003 20/40 (50%) 0/18 (0%) 11/29 (38%) 59/147 (40%)
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Clinical data were gathered from an existing computerized database. Two of the anti-HBs 
IVIg-treated patients had co-infection with HCV, and two other anti-HBs IVIg-treated patients 
had also been treated with anti-CMV IVIg. These patients were classified into the anti-HBs IVIg-
treated category. Median follow-up of the patients was 38 months (range: 5 days – 118 months). 
Treatment with anti-HBs IVIg and anti-CMV IVIg, and acute rejection
Anti-HBs IVIg (10,000 IU) was administered intravenously during the anhepatic phase of the 
transplantation procedure, and on days 1 and 2 after liver transplantation. During the next 5 
days, anti-HBs IVIg was given i.v. once daily until serum HBsAg was not detectable. Thereafter 
anti-HBs IVIg treatment aimed at maintaining serum anti-HBs IVIg concentrations above 500 
IU/l. Anti-CMV IVIg was given intravenously during the anhepatic phase (150 mg/kg), and post-
operatively on day 2, week 1, 2, 5, 8, 11. Doses of 100 mg/kg were given. As primary end point of 
the analysis, clinically evident acute rejection, was defined as biopsy proven rejection (Snover-
grade ≥ 2, or RAI-score ≥ 6) with a rise in transaminases and/or bilirubin, which responded 
to treatment. Rejection was treated with methylprednisolone, and in some patients OKT3 or 
rabbit ATG was given additionally. 
Determination of serum level of anti-HBs IVIg and anti-CMV IVIg
Serum anti-HBs IVIg were determined by AUSAB AxSYM (Abbott Laboratories, North Chigaco, 
IL, USA). Complete serial data of post-transplant serum anti-HBs IVIg titers, i.e. measured at daily 
intervals during the first 3 weeks after transplantation, and weekly during the next 12 weeks 
were available from 17 anti-HBs IVIg treated liver transplant recipients. Since these patients 
were anti-HBs IVIg negative before transplantation, it was assumed that increments in anti-HBs 
IVIg level reflected the anti-HBs IVIg treatment. Hepatect CP concentrations (mg/ml) were cal-
culated from the anti-HBs IVIg titers (IU/l) by using the mean specific activity of Hepatect CP(0.5 
IU/mg). Anti-CMV IVIg titers were determined by VIDAS (BioMérieux, Marcy-l’Etoile, France) in 
archival sera obtained at weekly intervals during the first month after transplantation from 8 
Cytotect  treated liver graft recipients. Since these patients were anti-CMV IVIgG-negative before 
transplantation, it was assumed that serum anti-CMV IVIgG post-transplantation reflected the 
Cytotect titers. Cytotect concentrations were calculated using the relative fluorescence values 
of a standard curve of serial dilutions of Cytotect (50 – 0.78 mg/ml). 
Effect of anti-HBs IVIg and anti-CMV IVIg on DC
DC were purified from fresh heparinized blood of healthy volunteers by positive selection 
with PE conjugated anti-CD1c mAb and anti-PE MACS beads using MS columns, after deple-
tion of B cells with CD19 conjugated MACS beads, and separation over LD-columns (Miltenyi 
Biotec, Bergisch Gladbach, Germany), as described previously 18. The purity of DC (defined as 
CD1c+CD20- cells) as analyzed by flow cytometry was 97±2%. To analyze the effects of anti-HBs 
IVIg on DC maturation, DC (1x104/200μl) were stimulated for 24 hours at 37°C with TNFα (25 ng/
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ml) and IL-1β (50 ng/ml) (both from Strathmann Biotech, Hannover, Germany) in RPMI supple-
mented with penicillin (100 U/ml), streptomycin (100 mg/ml) (all from Gibco BRL Life Technolo-
gies, Breda, The Netherlands), 10% fetal bovine serum (Hyclone, Logan, UT, USA) and GM-CSF 
(500U/ml; Leucomax, Novartis Pharma, Arnhem, The Netherlands). Anti-HBs IVIg, anti-CMV IVIg, 
or human serum albumin (HSA, CLB, Amsterdam, The Netherlands) were added in different 
concentrations to the cultures. For determination of their maturation status, DC were labeled 
with CD1c-PE, anti-HLA-DR-FITC, CD20-PERCP, CD86-APC (all from BD Biosciences, Heidelberg, 
Germany), CD80-FITC (Beckman Coulter Immunotech, Marseille, France), CD83-APC (Caltach, 
Burlingame, CA, USA) or appropriate isotype control mAb, and analyzed by flow-cytometry.
To determine the effects of anti-viral IVIg on the acquisition of allogeneic T-cell stimulatory 
capacity, different numbers of DC (5, 2.5, and 1.25 x 103 cells per well of a 96-well flat bottom 
plate) were stimulated to mature with TNF-a, IL1-β and GM-CSF for 24 hours in the absence 
or presence of anti-HBs IVIg, anti-CMV IVIg or HSA. The next day, the culture medium was 
aspirated, DC were washed two times with culture medium to remove additives, and 1.5 x 105 
allogeneic T cells were added. In all experiments with DC, one T-cell preparation was used, 
which was enriched by Ficoll gradient centrifugation and nylon wool filtration from a buffy 
coat of one healthy blood donor. This preparation contained 83% CD3+ cells. After 5 days, T-cell 
proliferation was assessed by determination of the incorporation of 0.5 mCi [3H]thymidine 
(Radiochemical Centre, Amersham, Little Chalfont, UK) during 18 hours. Each condition was 
tested in triplicate, from which means were calculated. These means were used in the analyses.
For the analysis of cytokine production, purified DC were cultured at a concentration of 
4x104 cells per 200 μl RPMI supplemented with 10% fetal bovine serum and GM-CSF, and stimu-
lated with either polyriboinosinic-polyribocyticylic acid (poly I:C); 20 μg/ml; Sigma-Aldrich, St. 
Louis, MA) and recombinant human IFN-γ (1000 U/ml), or with Staphylococcus aureus Cowan 
strain I (SAC; 75 μg/ml, Calbiochem, San Diego, CA), in the absence or presence of anti-HBs IVIg 
or HSA. After 24 hours cell-free supernatants were harvested and the levels of TNF-α and IL-10 
were determined by specific sandwich ELISA using pairs of mAb and recombinant cytokine 
standards from Biosource International (Camarillo, CA, USA). The concentration of IL-12 was 
determined using a commercial ELISA-kit (Diaclone, Besancon, France).
Effect of anti-HBs IVIg and anti-CMV IVIg on T cells
T cells were enriched from buffy coats of healthy blood donors by Ficoll gradient separation 
and immunomagnetic depletion of monocytes, NK cells and B cells by labelling the cells with 
CD14-PE, CD56-PE (both from BD Biosciences) and CD19-PE (from Beckman Coulter Immuno-
tech) followed by incubation with anti-PE MACS beads and separation over MS columns. The 
four independent T-cell preparations used in these experiments contained on the average 68 
± 11% CD3+ cells. Spleen APC were enriched from human spleen tissue obtained from a multi 
organ donor by Ficoll gradient separation and immunomagnetic depletion of T cells and NK 
cells by labelling the cells with CD3-PE and CD56-PE (both from BD Biosciences) followed by 
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incubation with anti-PE MACS beads and separation over MS columns. T cells (1.5 x 104 per 200 
ml RPMI supplemented with 10% FCS) were either stimulated with phytohemagglutinin (PHA, 
5 mg/ml; Murex, Paris, France) or with splenic APC (1.5 x 104) in the presence or absence of anti-
HBs IVIg (Hepatect CP), anti-CMV IVIg or HSA. After 5 days, T-cell proliferation was assessed by 
determination of the incorporation of 0.5 mCi [3H]thymidine (Radiochemical Centre, Amersham, 
Little Chalfont, UK) during 18 hours. Each condition was tested in triplicate from which means 
were calculated. These means were used in the analyses.
Statistical analysis
Differences in immunosuppressive therapy or gender between the study groups were ana-
lyzed by the Chi-square test and differences in numerical values by the Kruskal Wallis test. The 
actuarial incidence of acute rejection was determined by the Kaplan Meier technique, using 
the time to the first rejection episode as end-point, and censoring for graft failure or death. 
Multivariate analysis was performed using the Cox’s proportional hazard model. The effects of 
anti-viral IVIg in vitro were analysed by the wilcoxon test for paired data or the student t-test for 
paired data. A p-value < 0.05 was considered as indicating significant difference. 
RESulTS
Patient characteristics
The effect of treatment with anti-viral IVIg on the occurrence of acute rejection was analysed 
retrospectively by grouping the liver transplant recipients (n=234) into two categories. One 
that had been treated with anti-viral IVIg and two as control categories. The two anti-viral IVIg 
treated categories were: HBsAg positive liver graft recipients, which had been treated with 
anti-HBs IVIg as prophylaxis for infection of the graft with HBV (group 1), and recipients that 
had been treated with anti-CMV IVIg as a prophylaxis for CMV infection (group 2). HCV positive 
recipients served as a control group for viral infection in the liver as original liver disease (group 
3). The incidence of acute rejection the mentioned three groups was compared with that in 
the control group, which was formed by all other recipients (group 4). Characteristics of the 
patients and their donors are summarized in Table 1. 
The study groups differed significantly in the distributions of recipient gender and age, 
year of transplantation and immunosuppressive therapy and, with borderline significance in 
graft ischemia time. The difference in year of transplantation between the groups was due to 
the fact that all patients treated with anti-CMV IVIg had been transplanted in the early study 
period, before 1999, because CMV prophylaxis with anti-CMV IVIg had been replaced in 1998 by 
Ganciclovir. With regard to immunosuppressive induction therapy, the patients were grouped 
in those who had been treated with a calcineurin inhibitor (either Cyclosporin A or Tacrolimus), 
low-dose corticosteroids, either or not supplemented with azathioprine (n=144), and those 
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who had been treated additionally with an anti-IL-2 receptor monoclonal antibody (mAb), 
either Basiliximab (Novartis Pharma, Basel, Switzerland) or Daclizumab (Roche Pharmaceuticals, 
Basel, Switzerland) (n=90). The difference in immunosuppressive therapy between the patient 
categories is again detected in the anti-CMV IVIg treated group. None of the patients included 
in this category had received anti-IL-2 receptor mAb, because the use of anti-CMV IVIg was 
stopped just before anti-IL-2 receptor mAb treatment was introduced. 
Anti-HBs IVIg and anti-CMV IVIg concentrations in serum of liver transplant recipients
Treatment of HBsAg positive liver transplant patients with anti-HBs IVIg resulted in relatively 
high concentrations of anti-HBs IVIg in their serum (Figure 1), which peaked at day 4 after 
transplantation to a mean level of 8 mg/ml, than declined to about 2 mg/ml at day 9, and sub-
sequently slowly decreased to about 0.5 mg/ml at week 8. No sera were available from the first 
six post-transplant days of the anti-HBs IVIg-treated patients, but at day 7 post-transplantation 
the anti-CMV IVIg serum concentrations were about two times lower compared to anti-HBs IVIg 
concentrations in anti-CMV IVIg-treated recipients. (Figure 1)
Incidence of acute rejection in the study groups
The overall three months cumulative incidence of acute rejection was 31%, but differed signifi-
cantly between the patient groups (overall log rank p-value = 0.026). Figure 2A shows that the 
HBsAg-positive patient treated with anti-HBs IVIg treated had a significant lower incidence of 
acute rejection compared to control group 4 (12% versus 34%; p=0.012, log rank test), while the 
anti-CMV IVIg-treated and HCV positive recipients did not differ from control group (group 4) Chapter 3 
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Figure 1 Anti-HBs IVIg and anti-CMV IVIg serum concentrations in liver graft recipients.
Mean (± SEM) post-transplant serum concentrations of anti-HBs IVIg (Hepatect CP) in HBsAg-positive liver graft recipients treated with Hepatect 
CP(n=17) and of anti-CMV IVIg (Cytotect) in recipients treated with Cytotect (n=8).   
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Figure 2 Cumulative incidence (Kaplan-Meier curves) of acute rejection in different categories of liver graft recipients. 
A. Cumulative incidence of acute rejection during the first three months after liver transplantation in HBsAg-positive recipients treated with 
anti-HBs IVIg (n=40), anti-CMV IVIg-treated recipients (n=18), HCV positive recipients (n=29), and all other recipients (other; n=147).
B. Influence of the period in which the transplantation was performed on the cumulative incidence of acute rejection. Patients were grouped 
into two-year periods, except the last period which was the year 2002. 
C. Cumulative incidence of acute rejection in different groups of liver graft recipients transplanted before September 1998. HBs Ag-positive 
recipients treated with anti-HBs IVIg (n=14), anti-CMV IVIg-treated recipients (n=18), HCV-positive recipients (n=14), other recipients (n=65).
P-values depicted are from paired comparisons with control group 4 (log-rank test).
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(50%; p = 0.19, 28%; p = 0.65, respectively). The incidence of rejection within the HBsAg-positive/
anti-HBs IVIg-treated category was reduced, both in recipients transplanted for liver cirrhosis 
due to chronic HBV infection (4 out of 31 patients experienced rejection) as in patients trans-
planted for fulminant acute HBV infection (1 out of 9 experienced rejection), indicating that the 
lowered incidence of rejection was not confined to patients with persistent chronic infection. 
As is shown in Figure 2B, the incidence of acute rejection decreased significantly during the 
study period (log rank ptrend < 0.001). All anti-CMV IVIg-treated patients had been transplanted 
in the early years of the study period. In order to exclude the bias introduced by the differ-
ence in transplantation period between the study groups, a subgroup analysis on the effect of 
anti-CMV IVIg was performed on patients transplanted before August 1998. This subgroup (n 
= 111) consisted of 14 HBsAg-positive/anti-HBs IVIg-treated, all 18 anti-CMV IVIg-treated-, 14 
HCV-positive, and 65 control recipients. As is shown in Figure 2C, in this subgroup analysis the 
cumulative incidence of rejection in the anti-CMV-treated category was equal to that of control 
group 4 (50% versus 49% p = 0.93), while the incidence of acute rejection of anti-HBs IVIg 
treated recipients differed with almost statistical significance from that of the control group. 
Figure 2 A-C) 
All patients treated with anti-CMV IVIg were CMV IgG negative recipients receiving livers 
from CMV IgG positive donors. A possible protective effect of anti-CMV IVIg on acute rejec-
tion might have been masked if these patients would have been more susceptible to acute 
rejection. To investigate this possibility, the association between this recipient/donor combina-
tion and acute rejection was analyzed in patients of control group 4, and transplanted after 
August 1998, when anti-CMV IVIg prophylaxis was no longer given to patients. In this period 
19 liver transplantations from CMV IgG positive donors into CMV IgG negative recipients was 
performed within control group 4. The incidence of rejection in these patients was comparable 
to that in patients of control group 4 not belonging to this specific recipient/donor combina-
tion (5/19 (26%) versus 13/63 (21%); p=0.75, Fisher’s exact test). Together, these data show that 
treatment with anti-CMV IVIg did not protect against acute rejection. 
Multivariate analysis of factors influencing the incidence of acute rejection
To investigate whether the differences in risk of acute rejection between the patients catego-
ries were independent of other factors in which the study groups differed (immunosuppressive 
therapy, year of transplantation, recipient sex and age, and graft ischemia time), a Cox regres-
sion analysis was performed in which these variables were entered together with the patient 
categories. Table 2 shows that of these factors only the HBs Ag-positive/anti-HBs IVIg-treated 
patient group and the year of transplantation were independently and significantly associated 
with the risk of acute rejection. In HBsAg-positive/anti-HBs IVIg treated patients the rate of 
acute rejection was reduced by 61% as compared to patients in control group 4, while in each 
year between 1992 and 2002 the risk of rejection was reduced by a factor 13% compared to the 
year before. (Table 2) 
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Effect of anti-viral IVIg on DC
To establish whether anti-viral IVIg suppress functional maturation of DC, immature DC isolated 
from blood of healthy volunteers were stimulated in vitro with pro-inflammatory cytokines (IL-
1β and TNF-α) to mature in the presence or absence of anti-HBs IVIg or anti-CMV IVIg. After 24 
hours, T cells from an unrelated donor were added to the DC to assess their allogeneic T-cell 
stimulatory capacity. Freshly isolated immature blood DC had a poor allogeneic T-cell stimula-
tory capacity, which was strongly upregulated during cytokine-driven maturation (data not 
shown). Figure 3A shows that the addition of anti-HBs IVIg during maturation in a concentra-
tion comparable to the peak concentration reached in the serum of HBsAg positive liver graft 
recipients (9 mg/ml) significantly suppressed the acquisition of allogeneic T-cell stimulatory 
capacity in DC. An equal amount of another human serum protein, HSA, slightly enhanced the 
capacity of DC to stimulate allogeneic T-cell proliferation. To exclude that the observed inhibi-
tion of DC function was due to stabilizing agents present in, or to the low pH of the anti-HBs 
IVIg preparation, anti-HBs IVIg were first dialyzed against a large volume of culture medium. 
The dialyzed preparation showed similar suppression of allogeneic T-cell stimulatory capacity 
(data not shown). 
The suppressive effect of anti-HBs IVIg on functional DC maturation was concentration 
dependent. A concentration of 3.5 mg/ml anti-HBs IVIg suppressed the acquisition of allostimu-
latory activity in DC less potently, while a concentration of 0.5 mg/ml had no effect (Figure 3B). 
Anti-CMV IVIg also suppressed the acquisition of allogeneic T-cell stimulatory capacity in DC 
(Figure 3C). 
To investigate the mechanism by which anti-HBs IVIg suppressed allogeneic T-cell 
stimulatory capacity of DC, expressions of the DC maturation marker CD83, HLA-DR, and co-
stimulatory molecules were determined. Expressions of all four molecules were upregulated 
Table II: Multivariate analysis of factors univariately associated with acute rejection. 
Hazard ratio 95% CI p  value
Patient categories
group 1 (anti-HBs Ig-treated) 0.39a 0.16 - 0.99 0.047
group 2 (anti-CMV Ig-treated) 0.91a 0.43 - 1.95 0.807
group 3 (HCV-positive) 1.16a 0.54 - 2.51 0.707
Other variables
Year of transplantation 0.87 0.78 - 0.98 0.017
Immunosuppression 
(+ anti-IL-2 rec mAb)
0.57b 0.26 - 1.28 0.177
Recipient sex (female) 1.15c 0.72 - 1.84 0.562
Recipient age 0.98 0.97 – 1.00 0.088
Graft ischemia time (hours) 0.95 0.88 – 1.03 0.185
Reference categories: agroup 4 (all other patients); bno anti-IL-2 rec. mAb; cmale recipients.
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Vervanging 4 (figure 3, chapter 3) 
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Figure 3 Effect of anti-viral IVIg on the acquisition of allogeneic T-cell stimulatory capacity in DC upon stimulation with pro-inflammatory cytokines.
Purified blood DC were stimulated in vitro with IL-1β, TNF-α and GM-CSF for 24 hours in the presence or absence anti-HBs IVIg (Hepatect CP), anti-
CMV IVIg (Cytotect), or HSA. After 24 hours, the additions were removed, and T cells from an unrelated healthy individual were added to determine 
the allostimulatory capacity of DC. Data are depicted as means ± SEM from n independent experiments with DC from different donors.
A. Effect of anti-HBs IVIg and HSA both at 9 mg/ml (n = 9)
*= p-values <0.03; **=p-values <0.01; paired t-test. 
B. Effect of 0.5 and 3.5 mg/ml anti-HBs IVIg (n = 6). *= all p-values <0.04; paired t-test
C. Effect of anti-CMV IVIg at 9 mg/ml (n = 5). *= all p-values <0.02; paired t-test
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during DC-maturation. Anti-HBs IVIg suppressed the upregulation of CD80 and CD83, but not 
of HLA-DR and CD86 (data not shown).  (Figure 4)
Anti-HBs IVIg also suppressed cytokine production by DC. As is shown in Figure 5, anti-HBs 
IVIg suppressed the production of TNF-α, IL10 and IL12 by DC stimulated with poly I:C and IFN-
g, or with SAC, in a dose-dependent fashion, while HSA had no effect. To exclude the fact that 
the reduced concentrations of cytokines in the supernatants of DC incubated with anti-HBs IVIg 
were due to an blocking effect of anti-HBs IVIg on cytokine detection in ELISA, anti-HBs IVIg 
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Figure 4 Effect of anti-HBs IVIg on the upregulation of CD80 and CD83 on DC during stimulation with pro-inflammatory cytokines. 
DC purified from blood of healthy volunteers were stimulated in vitro with IL-1β, TNF-α and GM-CSF for 24 hours in the absence or presence of 
anti-HBs IVIg (Hepatect CP) or HSA (both 9 mg/ml). 
A. Flow cytometry histograms showing the upregulation of CD80 and CD83 during DC-maturation. Dotted lines represent IgG isotype control 
binding, thin solid lines CD80- or CD83-expression on freshly isolated DC, dashed lines expression after maturation in the absence of anti-HBs 
IVIg, and thick solid lines expression after maturation in the presence of anti-HBs IVIg. 
B. CD80 and CD83-expression before and after maturation in the absence or presence of anti-HBs IVIg or HSA. Results are expressed as mean 
fluorescence intensities ± SEM from eight experiments with DC from different individuals. 
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was added to recombinant IL-10, IL-12 or TNF-a in the ELISA-plates and subsequently cytokines 
were quantified. No inhibitory effect of anti-HBs IVIg on the detection of these cytokines was 
observed compared to cytokines measured in the absence of anti-HBs IVIg. (Figure 5 A and B)
Effect of anti-viral IVIg on T cells
Anti-HBs IVIg, both as pharmaceutical formulation and after dialysis against culture medium, 
strongly suppressed T-cell proliferation induced by stimulation with PHA (Figure 6A). In contrast, Vervanging 5 (chapter 3 figuur 5)  
 
Figure 5: Effect of anti-HBs IVIg on cytokine production by DC.
A. TNF-a was determined in culture supernatants of purified DC (4x104 per 200 ml) stimulated with SAC for 24 hours in the presence or absence 
of anti-HBs IVIg (Hepatect CP) or HSA. 
*: p=0.056; and **: p=0.018 compared with TNF-a-production in cultures without additions (t-test for paired data after log-transformation of 
the data) 
B. IL-12 was determined in supernatant of DC (4x104 per 200 ml) stimulated with poly (I:C) and IFN-g for 24 hours, and IL-10 in culture 
supernatants of DC stimulated with SAC. 
*: p=0.025; and **: p=0.053 (t-test for paired data after log-transformation of the data) .
Data are depicted as means ± SEM from three independent experiments with DC from different donors.
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anti-CMV IVIg did not inhibit PHA induced T-cell proliferation (Figure 6B). However, when T-cells 
were stimulated with allogeneic splenic APC, both anti-HBs IVIg and anti-CMV IVIg suppressed 
T-cell proliferation (Figure 6C). 
Vervanging 6 (chapter 3 figuur 6) 
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Figure 6: Effect of anti-viral IVIG on T-cell proliferation stimulated by PHA or allogeneic APC.
A. Peripheral blood T-cells were stimulated with PHA in the presence or absence of anti-HBs IVIg (Hepatect CP; 9 mg/ml) as a pharmaceutical preparation 
or after dialysis and [3H]-thymidine incorporation was determined 5 days later (n=4). 
B. The effect of anti-CMV IVIg (Cytotect; 9 mg/ml) as a pharmaceutical preparation or after dialysis on PHA-stimulated T-cell proliferation (n=4). 
C. Peripheral blood T-cells were stimulated with allogeneic splenic APC in a ratio of 1:1 in the presence or absence of dialyzed anti-HBs IVIg or Cytotect 
(both at 9 mg/ml). [3H]-thymidine incorporation was determined 5 days later (n=3).  
Data are depicted as means ± SEM from n independent experiments with T-cells from different donors.
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dISCuSSION
This study shows that the incidence of acute rejection in HBsAg-positive liver transplant 
patients treated with anti-HBs IVIg was significantly lower as compared to patients transplanted 
with non-viral liver diseases. This phenomenon may be due to the large proportion of patients 
with chronic HBV infection within this category. Patients chronically infected with HBV or HCV 
have certain immune dysfunctions, like functional impairments in their DC 18,19. However, we 
consider this explanation highly unlikely. First, the HCV-positive liver graft recipients, which all 
had a chronic infection, showed a similar risk of rejection as patients without viral hepatitis. 
Secondly, the reduced incidence of rejection was not confined to patients with chronic HBV-
infection, but was also observed in patients transplanted for acute fulminant HBV infection, 
which are not immunocompromised. Thirdly, in a study on risk factors for acute rejection in 
liver transplant recipients, Wiesner et al 9 did not find a lower incidence of acute rejection in 
HBV infected patients. However, the patients included in that study were  transplanted in three 
USA centers between 1990 and 1994, and published data show that during this period in at 
least two of these centers the HBsAg+ recipients were either not treated with anti-HBs IVIg 20 or 
were treated with a low dosage regimen 21. In contrast, two other studies 7,8 in which HBsAg+ 
liver transplant recipients were treated with the same high-dose regimen of anti-HBs IVIg as 
our patients 22, confirm our data and report a reduced risk of acute rejection in these patients. 
Therefore, we propose that the reduced risk of acute rejection in HBsAg+ recipients is not due to 
chronic infection with the HBV virus, but due to the treatment with anti-HBs IVIg. 
In contrast to Farges et al 7 we did not observe any effect of anti-CMV IVIg treatment on the 
incidence of acute rejection. This discrepancy may be related to differences in treatment regi-
mens and/or the anti-CMV IVIg preparations used in both studies. The patients included in the 
study of Farges received a higher dose of anti-CMV IVIg 23 as compared to our patients. Unfor-
tunately, resulting serum levels were not reported, and therefore cannot be compared with 
those reported in our study. In our patients, the serum concentrations of anti-CMV IVIg were 
considerably lower as compared to serum anti-HBs IVIg concentrations, and did not exceed 2.5 
mg/ml. This concentration is probably too low to be effective, since comparable concentrations 
of anti-HBs IVIg had only mild effects on functional DC maturation in vitro. In addition, although 
the anti-CMV IVIg preparation used in the present study inhibited functional DC maturation 
and APC stimulated T-cell proliferation, it did not suppress T-cell proliferation induced by a poly-
clonal stimulus. This indicates that the anti-CMV IVIg preparation may not inhibit T cells directly, 
but probably only via APC. In the study of Farges et al anti-CMV IVIg from another manufacturer 
was used 23, which probably may have a stronger capacity to suppress T-cells directly. 
To investigate the mechanism behind the reduced risk of acute liver graft rejection in anti-
HBs IVIg treated recipients, we focused on the influence of anti-HBs IVIg on the key cells of the 
immune system involved in allograft rejection, i.e. DC and T cells. The present study shows that 
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anti-HBs IVIg, in concentrations similar those reached in the serum of liver graft recipients, sup-
presses functional cytokine-driven maturation of immature blood DC. The resulting DC showed 
a reduced capacity to stimulate allogeneic T-cell proliferation. This was not due to an effect of 
anti-HBs IVIg on the T cells added to the DC, since the anti-HBs IVIg was thoroughly washed 
away before the T cells were added. Given the importance of CD80 as a co-stimulatory molecule 
in T-cell activation, the reduced upregulation of this molecule may be at least partly responsible 
for the reduced allostimulatory capacity of DC maturated in the presence of anti-HBs IVIg. In 
addition anti-HBs IVIg also inhibited production of cytokines by DC upon stimulation by micro-
bial components. Bayry et al 16 showed similar data using DC derived from monocytes in vitro. 
However, such DC differ in several aspects from DC present in vivo 24. The present study is the 
first to show that an anti-viral IVIg-preparation inhibits critical functions of ex vivo derived DC. 
The mechanism by which IVIg suppress DC function is at present unclear. Upregulation of 
the inhibitory Fcg receptor IIB after, which binding of anti-HBs IVIg to this receptor invokes 
inhibitory signals to the DC, a mechanism which has been shown to be involved in the benefi-
cial effects of non-specific IVIg in an experimental animal model of immune trombocytopenia 
25, is an attractive hypothesis.  
Anti-HBs IVIg also strongly suppressed T-cell proliferation stimulated by both PHA as by 
allogeneic APC. It is reported that non-specific IVIg have an inhibitory effect on mitogen- and 
antigen driven T-cell proliferation and cytokine production 13,15,26. Our data show that an 
anti-HBs IVIg preparation has similar effects on T cells, but that the anti-CMV IVIg preparation 
tested inhibited T-cell proliferation primed by an allo-antigen, but not by PHA, which is a 
non-specific polyclonal T-cell activator. This indicates that anti-CMV IVIg does not inhibit T-cell 
proliferation directly. The different immunomodulatory properties of these two preparations of 
anti-viral IVIg may be related to different production procedures. The anti-HBs IVIg preparation 
(Hepatect CP) used in the present study is purified by HPLC and virus-inactivated by treatment 
with caprylic acid, tri-n-butyl phosphate and polysorbat 80. The anti-CMV IVIg (Cytotect) is 
not purified by HPLC and is treated with beta-propiolacton and subjected to nanofiltration for 
virus-inactivation. Especially the treatment with beta-propiolactone influences the molecular 
structure of the IgG molecules by alkylation and acylation of certain amino acids in the IgG 
molecules 27. According to information from the manufacturer 18% of the IgG molecules in 
Cytotect are modified during the production process. We think that the lack of a direct effect 
on T cells by anti-CMV IVIg has to do with the mentioned chemical modification. Apparently, 
this does not negatively influence it’s Fab-mediated activity as Cytotect has excellent CMV-
neutralizing properties 28. 
In conclusion, prophylactic treatment with anti-HBs IVIg protects against acute rejection 
after liver transplantation, probably by targeting the two principal immune cell types involved 
in graft rejection, DC and T cells. IVIg, if slowly infused, have almost no serious side effects 29. 
Therefore, anti-HBs IVIg and, if these have similar immunomodulatory efficacy, also non-specific 
IVIg, may be attractive agents for immunosuppressive therapy after liver transplantation.
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SuMMaRY
Prophylactic administration of anti-HBs intravenous immunoglobulins (anti-HBs IVIg) in hepati-
tis B infected liver transplant patients protects against acute rejection. To explore the suitability 
of intravenous immunoglobulins (anti- HBs IVIg) as prophylaxis of acute rejection and Graft 
versus Host Disease (GVHD) after allograft transplantation, the effects of IVIg and calcineurin 
inhibitors (CNI) on human blood-derived T cells and DC were compared. After mitogenic and 
allogeneic stimulation, T cell proliferation and cytokine production were determined in presence 
or absence of IVIg or CNI. In addition, immature blood dendritic cells (DC) were stimulated, and 
allogeneic T-cell stimulatory capacity, cell death and phenotypic maturation were established 
in presence or absence of IVIg or CNI. We observed that both IVIg and CNI equally inhibited 
proliferation and IFN-γ production of T cells after stimulation. CD8+ T cells were preferentially 
affected by both IVIg and CNI. Like CNI, addition of IVIg at later time points after T-cell activa-
tion suppressed mitotic progression of responding T cells. Furthermore, IVIg treated DC were 
suppressed in their capacity to stimulate allogeneic T-cell proliferation by 73±12%, whereas DC 
function was not affected by CNI. The decreased allogeneic T-cell stimulatory capacity of IVIg 
treated DC correlated to induction of cell death in DC and decreased up-regulation of CD40 and 
CD80. From these observations, we concluded that IVIg functionally inhibit the function of two 
principal immune cell types involved in rejection and GVHD, i.e. T-cells and DC, in vitro, while 
CNI only suppress T-cell function. By targeting both T cells and DC, IVIg may be a promising 
candidate for immunosuppressive treatment after allograft transplantation.
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INTROduCTION
To prevent Graft versus Host Disease (GVHD) after allogeneic hematopoietic stem cell trans-
plantation (HSCT), treatment with immunosuppressive drugs is needed. In addition, solid 
organ transplant recipients require lifelong immunosuppressive treatment in order to prevent 
graft rejection. In these patients, calcineurin inhibitors (CNI), Cyclosporin (CsA) and Tacrolimus 
(TAC), are the cornerstones of current immunosuppressive therapy. Common adverse effects 
of these drugs are hypertension, diabetes, hypercholesterolemia, nephrotoxicity, infections 
and malignancies 1-7. These drug related morbidities impair the life expectancy of transplant 
recipients significantly. Therefore, one of the main focus in transplantation research is to find 
immunosuppressive regimens, which have no or reduced side effects. 
Recently we have reported that prophylactic administration of anti-HBs intravenous immu-
noglobulins in hepatitis B-infected liver transplant patients protected against acute rejection 8. 
Intravenous immunoglobulins (IVIg) are pharmaceutical preparations of human IgG molecules 
prepared from pools of plasma. Non-specific IVIg are prepared from plasma pools of healthy 
blood donors, and anti-viral types of IVIg from plasma pools of individuals with high titers of 
antibodies against particular viruses. Clinically, IVIg exert a broad range of immunomodula-
tory functions, and are increasingly being used for the treatment of autoimmune and systemic 
inflammatory diseases (reviewed in 9). In the context of transplantation, IVIg were reported to 
be effective as treatment of steroid-resistant acute rejections after kidney transplantation 10,11. 
In addition, prophylactic treatment with non-specific IVIg was found to decrease the incidence 
of GVHD after bone marrow transplantation 12,13. Still, optimal treatment regimens and mecha-
nisms of action of IVIg in the transplantation setting are poorly defined. 
Optimal immunosuppression should target the different immune cells involved in the 
rejection response. Initiation of the immune response against alloantigens is due to a course of 
action in which dendritic cells (DC) serve as potent antigen presenting cells (APC), and activate 
resting T cells 14-17. In vitro, it has been reported that non-specific IVIg suppress proliferation 
and cytokine production by human T cells stimulated by mitogens or alloantigens 18-21. In addi-
tion, non-specific IVIg have been found to inhibit the differentiation and function of human 
monocyte-derived DC (Mo-DC) in vitro 22. Thus, IVIg may have the potential to suppress the 
function of the two most important cell types, i.e. DC and T cells, which are involved in immune 
activation after transplantation. 
Since long term IVIg treatment has no significant side effects 9, inclusion of IVIg in immu-
nosuppressive protocols after transplantation may enable dose reduction of CNI, and thereby 
contribute to a lower rate of complications. However, the immune suppressive activities of IVIg 
have never been compared to that of CNI, which are the first of choice in current immuno-
suppressive regimens. CNI are extremely potent inhibitors of T-cell proliferation and cytokine 
production. Whether CNI also inhibit DC function is less clear. Most reports show that CNI do 
not affect DC differentiation from human monocytes, and that functional activities of treated 
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Mo-DC were unaltered 23,24. However, whether these results can be translated to the in vivo 
situation is unclear, since these studies were performed with Mo-DC which differ in several 
aspects from DC present in situ 25. 
To explore the suitability of IVIg as a potential immunomodulatory agent to be used as immu-
nosuppressive agent after HSCT or solid organ transplantation, we compared the immuno-
modulatory effects of IVIg and CNI on human blood-derived T-cells and DC in detail. 
MaTERIalS aNd METhOdS
Intravenous immunoglobulins (IVIg) and calcineurin inhibitors (CNI)
Human IVIg (Intraglobin®CP) were a kind gift from Biotest Pharma (Dreieich, Germany). In the 
experiments two different batches of non-specific type of IVIg were used. IVIg preparations 
were dialyzed twice against large volumes of culture medium (RPMI) at 4°C using Slide-A-lyzer® 
gamma irradiated dialysis cassette (Pierce, Rockford, USA). This is to remove stabilizing agents 
and to obtain neutral pH. After dialysis, IgG concentration was determined by the Tina-quant® 
immuno-turbidimetric assay (Roche Diagnostics, Mannheim, Germany). CsA and TAC were 
provided by Novartis Pharma AG, Basel, Switzerland and by Fujisawa Holland BV, Houten, The 
Netherlands, respectively. CsA was dissolved in a 1:1 mixture of ethanol and 10% Tween-20 
in water. Clinically relevant peak levels of IVIg and calcineurin inhibitors were selected for the 
experiments: IVIg 10 mg/ml, CsA 600 ng/ml and TAC 60 ng/ml. The concentration of the IVIg 
selected for the experiments was within range of serum anti-HBs immunoglobulins in liver 
transplant patients treated with anti-HBs IVIg in our center. This concentration (10 mg/ml; 
0.06mM) protects against acute rejection 8. Similar increments in serum IgG concentration are 
obtained in patients treated with IVIg at 1-2 g/kg for autoimmune disorders 26-28. In addition, 
clinical relevant peak levels of calcineurin inhibitors were selected for the experiments; CsA 600 
ng/ml 29,30 and TAC 60 ng/ml 31.
Isolation of immune cells 
DC were purified from fresh heparinized blood of healthy volunteers. After Ficoll density gradi-
ent separation and depletion of B cells with CD19-conjugated immunomagnetic beads and 
separation over Large Depletion (LD)-columns (Miltenyi Biotec, Bergisch Gladbach, Germany), 
DC were isolated by positive selection with PE-conjugated anti-CD1c mAb and anti-PE immu-
nomagnetic beads using Medium Seperation-columns, as described previously 32. The purity of 
DC (defined as CD1c+ CD20- cells) as analyzed by flow cytometry was 91 ± 5 %.
For T-cell experiments, T cells were enriched from the residual B- and DC-depleted cells left 
over after DC isolations. Immunomagnetic depletion of monocytes and NK cells was performed 
by labelling the cells with CD14-PE and CD56-PE (both from BD Biosciences) followed by 
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incubation with anti-PE immunomagnetic beads, and separation over Large Seperation (LS)-
columns. These T-cell preparations contained on the average 92 ± 5% CD3+ cells. Contaminat-
ing cells consisted largely of granulocytes. For determination of allogeneic T-cell stimulatory 
capacity of DC, a batch of T cells was prepared from a buffy coat of a healthy blood bank donor 
by nylon wool filtration. This preparation contained 83% CD3+ cells and 10% CD56+ cells. 
Spleen antigen presenting cells (APC) were enriched from human spleen tissue obtained from 
a multi-allograft donor by Ficoll gradient separation and immunomagnetic depletion of T cells 
and NK cells by labelling the cells with CD3-PE and CD56-PE (both from BD Biosciences) fol-
lowed by incubation with anti-PE immunomagnetic beads and separation over LD columns. The 
mixture of APC used in all experiments consisted of 67% B-cells, 7% monocytes and 5.4% DC.
Effects of IVIg and CNI on T-cell proliferation and cytokine production 
Triplicate incubations of T cells (1.5 x 105) in 200 ml RPMI per well supplemented with penicillin 
(100 U/ml), streptomycin (100 mg/ml) (all from Gibco BRL Life Technologies, The Netherlands) 
and 10% fetal bovine serum (FCS; Hyclone, UT, USA) were either stimulated with phytohemag-
glutinin (PHA, 5 mg/ml; Murex, France) or with allogeneic spleen APC (1.5 x 105) and cultured in 
the presence or absence of IVIg, human serum albumin (HSA, Sanquin, The Netherlands), CsA, 
or TAC in flat bottom plates. After 5 days, T-cell proliferation was assessed by determination of 
the incorporation of 0.5 mCi [3H] thymidine (Radiochemical Center, Little Chalfont, UK) during 
18 hours.
To determine the effects of IVIg and CNI on T-cell expansion and frequency of responding 
precursors, T cells were labeled with 2µM carboxyfluorescein diacetate succinimidyl ester (CFSE) 
(Molecular Probes, Eugene, OR) per 5 X 106 cells for 10 minutes at 37 °C.  Labelled T cells (1.5 x 
105) were stimulated with PHA (5 mg/ml) or with allogeneic spleen APC (1.5 x 105), and cultured 
in the presence or absence of IVIg, CsA, or TAC. After 6 days, T-cell divisions were analyzed by 
flow cytometry after labeling the cells with CD3-PE (Beckman Coulter Immunotech, France) and 
CD8-APC (DAKO, Glostrup, Denmark). CFSE-flow cytometry data were analyzed by ModFit TM 
software version 3.0 (Verity Software House, Topsham, USA). Spacing between the generations 
was set using the most distinct peaks, and was always about 19 channels, and CFSE fluorescence 
intensity histograms of CD3+, CD3+CD8+ or CD3+CD8- cells were made by the program. The 
software calculated the proliferation Index (PI), which is the sum of the cells in all generations, 
divided by the computed number of original parent cells, thus indicating the extent of T-cell 
expansion. If PI is one, this indicates that no T-cell division took place during the course of the 
culture. In addition, precursor frequency (%prec) was calculated, which is the percentage of T 
cells, which underwent at least one division during the course of the experiment.  
To determine whether ongoing division of T cells can be inhibited by IVIg or CNI, CFSE 
labelled T cells were stimulated with PHA (5 mg/ml) and the tested agents were added to culture 
at day 0, 1, 2, 3, 4 or 5. T-cell apoptosis was determined with Annexin V-APC (BD Biosciences, 
Germany) staining.
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To study T-cell activation and cytokine production, T cells were stimulated with PHA (5 mg/
ml) or with spleen APC (1.5 x 105) in the presence or absence of IVIg, CsA, or TAC. At day 3 and 
day 6 of culture, cell-free supernatants were harvested and the levels of interferon-γ (IFN-γ) and 
IL-4 were determined by ELISA (U-CyTech, Utrecht, The Netherlands). To exclude blocking effects 
by IVIg on IFN-γ detection in the ELISA, IVIg were added to recombinant IFN-γ in the ELISA 
plates. No effect of IVIg on IFN-γ detection was observed. In addition, T cells were harvested 
at day 6 and re-stimulated with PMA and ionomycin calcium during 6 hours at 37° degrees in 
the presence of Brefeldin A (all from Sigma; Missouri, USA). Cells were labelled with CD2-RD 
mAb (Beckman Coulter Immunotech, France) and CD8-PerCp (BD Biosciences, Germany) and, 
after permeabilization with Intraprep reagent (Beckman Coulter Immunotech, France), with 
FITC-conjugated anti-IFN-γ mAb (BD Biosciences, Germany), and analyzed by flow cytometry. 
Furthermore, T cells harvested on day 6 were analyzed for their expression of CD25 using a 
CD25-PE mAb (BD Biosciences)
Effects of IVIg and CNI on allogeneic T-cell stimulatory capacity of DC 
To determine the effects of IVIg and CNI on the acquisition of allogeneic T-cell stimulatory 
capacity of DC, different numbers of immature blood DC (5, 2.5, and 1.25 x 103 cells per well of a 
96-well flat bottom plate) (Greiner, Netherlands) were stimulated to maturate with TNFα (25 ng/
ml) and IL-1β (50 ng/ml) (both from Strathmann Biotech, Hannover, Germany) in RPMI supple-
mented with penicillin (100 U/ml), streptomycin (100 mg/ml), 10% FCS and GM-CSF (500U/ml; 
Leucomax, Novartis Pharma, The Netherlands) for 18 hours in the absence or presence of IVIg, 
CsA or TAC. The next day, the culture medium was aspirated, DC were washed two times with 
culture medium to remove additives, and 1.5 x 105 nylon wool-enriched allogeneic T-cells were 
added. In all experiments with DC, one T-cell batch obtained from one healthy blood donor was 
used. Cell free supernatants were collected at 72 hours after start of the culture, and the levels 
of IFN-γ were determined by ELISA. After 5 days, T-cell proliferation was assessed by determina-
tion of the incorporation of 0.5 mCi [3H] thymidine during 18 hours. 
Cell death analysis and maturation of DC
DC (4x104/200μl) were stimulated for 18 hours at 37°C with TNFα, IL-1β and GM-CSF in the pres-
ence or absence of IVIg. After 18 hours DC were washed, and 1.5 x 105 allogeneic T-cells were 
added. Using flow cytometry, the percentages of cell death were determined by analyzing the 
proportions of 7-aminoactinomycin D (7AAD)+ cells (BD Biosciences, Germany) within CD1c+ 
cells before culture, and 18, 48 and 72 hours after start of the culture. To determine the matura-
tion kinetics DC were labeled with CD1c-PE, anti-HLA-DR-PerCp, CD86-APC, CD40-APC (all from 
BD Biosciences, Germany), CD80-FITC (Beckman Coulter Immunotech, France), or biotinylated 
anti-PD-L1 (eBioscience, San Diego, USA) followed by streptavidin-APC (BD Biosciences, Ger-
many), or appropriate isotype control mAb. CD1c+ 7AAD- DC were analyzed for the expression 
of surface molecules using flow cytometry and data were processed using CellQuest software. 
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Statistical analysis
In each individual experiment, proliferation and cytokine production was tested in triplicate 
from which means were calculated. The means from independent experiments were used in 
the analyses. Statistical analyses were performed by the two-sided student t-test for paired data 
using software package SPSS version 10.1 (SPSS, Chicago, IL). P-values < 0.05 was considered 
significant. 
RESulTS
Effects of IVIg and CNI on T-cell proliferation
IVIg inhibited PHA stimulated T-cell proliferation in a concentration dependent manner, while 
HSA had no effect. Maximal suppression by IVIg was observed at 10 mg/ml, by CSA at  800 
ng/ml and by TAC at  60 ng/ml (Figure 1A).  The IVIg concentration of 10 mg/ml was used in 
further experiments. IVIg suppressed PHA induced T-cell proliferation on the average by 87%, 
CsA (600 ng/ml) by 92%, and TAC (60 ng/ml) by 93% (Figure 1B). After allogeneic stimulation 
IVIg inhibited T-cell proliferation by 81%, CsA by 93% and TAC by 91% (Figure 1C). 
To study whether IVIg and CNI interfere with the recruitment of precursor cells or with the 
expansion of already recruited T cells, T-cell division was monitored by CFSE-staining. IVIg and 
CNI equally suppressed the number of divisions and the expansion of the T cells after PHA 
stimulation (Figure 2A and B). In addition, IVIg and CNI equally reduced the proportion of pre-
cursor T cells (%prec) responding to PHA (Figure 2C). Likewise, after stimulation with allogeneic 
splenic APC, IVIg and CNI inhibited T-cell expansion (Figure 2D) and the proportion of precursor 
T cells responding to allogeneic stimulation (Figure 2E) to a similar extent. 
To determine whether IVIg or CNI preferentially affect proliferation of CD4+ or CD8+ T-cell 
subsets, CFSE dilution was determined for CD3+/CD8- and CD3+/CD8+ T cells separately. This 
analysis revealed that IVIg and CNI inhibited equally CD3+/CD8- and CD3+/CD8+ T-cell division 
after PHA stimulation (data not shown). However, after allogeneic stimulation both IVIg and 
CNI preferentially inhibited proliferation of CD8+ T cells (PI: 2.49 ± 0.49 in control, 1.10 ± 0.1  in 
IVIg,  1.13 ± 0.2  in CsA and  1.08 ± 0.1  in TAC treated conditions (p < 0.05 ) (% precursors: 14.39 
± 3.9  in control, 0.8 ± 0.3  in IVIg,  0.9 ± 0.8  in CsA and  1.2 ± 0.5  in TAC treated conditions (p 
< 0.05 ). Expansion of CD8+ T cells was completely inhibited, while some CD3+/CD8- helper T 
cells divided and reached similar numbers of generations as in the untreated conditions (Figure 
3). This resulted in an increased CD4/CD8-ratio at the end of the cultures in the presence of IVIg 
(CD4/CD8: 4.5±0.9), CsA (CD4/CD8: 5.2±1.1) or TAC (CD4/CD8: 4.4±0.8) compared with control 
cultures (CD4/CD8: 2.7±0.6; p < 0.03). (Figure 3)
To compare the ability of IVIg and CNI to inhibit mitotic progression of already proliferating T 
cells, IVIg or CNI were added at different time points after PHA stimulation. Suppression of T-cell 
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division was maximal when IVIg or CNI were added at the initiation of the cultures, but also 
addition at later time points resulted in suppression. Later addition affected T-cell expansion 
and the proportions of precursor T cells (%prec) responding to the stimulus significantly when 
added at day 0, day 1 or day 2  (Figure 4 A and B). A possible explanation for the reduced T cell 
proliferation when cultured with IVIg is induction of apoptosis of T cells. Annexin V staining was 
conducted on day 5 after T cells were stimulated with PHA in presence or absence of IVIg. Of 
IVIg treated T cells, 45.9 ± 4.1% were Annexin V positive compared to the control in which 28.4 
± 4.7 % of  T cells were Annexin V positive (p < 0.05; n=3). The suppression of T-cell proliferation 
by IVIg is at least partially due to induction of apoptosis. 
Effects of IVIg and CNI on T-cell cytokine production
The mode of action of IVIg on T-cell activation includes inhibition of T-cell activation, since 
IVIg suppressed the up-regulation of CD25 (Figure 5A). To compare the effects of IVIg and 
Vervanging Chapter 4-6 
 
Vervanging 7 
 
 
A
C
0
20000
40000
60000
80000
100000
CTRL IVIg CsA TAC
3H
 in
co
rp
or
at
io
n
(c
pm
)
** ** **
0
10000
20000
30000
40000
50000
60000
CTRL IVIg CsA TAC
**
** **
NS NS
NS
NS NS
NS
3H
 in
co
rp
or
at
io
n
(c
pm
)
B
IVIg&HSA (mg/ml) 0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 25
CSA (ng/ml)
TAC (ng/ml)
0 100 200 300 400 500 600 700 800 900 1000
0 10 20 30 40 50 60 70 80 90 100
0
20000
40000
60000
80000
100000
120000
140000
IVIg HSA CSA TAC
Ch 4, fig 1
 
 
 
 
Figure 1: Effects of IVIg and CNI on T-cell proliferation
A. Human T cells were stimulated with PHA in presence of various concentrations of IVIg, CsA, TAC or HSA. After 5 days [3H]thymidine incorporation 
was determined (n = 3). 
B. Comparison of the effects of IVIg (10 mg/ml), CsA (600 ng/ml) and TAC (60 ng/ml) on T-cell proliferation after PHA stimulation (n=7).
C. Comparison of the effects of IVIg (10 mg/ml), CsA (600 ng/ml) and TAC (60 ng/ml) on T-cell proliferation upon stimulation with allogeneic 
spleen antigen presenting cells (APC) (n=7). 
Data are depicted as means ± SD from independent experiments.
** P < 0.01 compared to control conditions
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CNI on cytokine secretion by T cells, IFN-γ and IL-4 concentration ware determined in cell free 
supernatants of stimulated T cells at day 3 and day 6. As is shown in Figures 5 B and C, both 
after stimulation with PHA and with allogeneic APC IFN-γ synthesis was suppressed by IVIg. The 
extent of suppression was comparable to that of CNI. In allogeneically stimulated T-cell cultures 
the secretion of the Th2 cytokine IL-4 was determined. IL-4 production was reduced compared 
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Figure 2: Effects of IVIg and CNI on T-cell recruitment and expansion
T-cell division was monitored by flow cytometric analysis of CFSE-dilution after 6 days, and analyzed by ModFitTM software.
A-C: The effects of IVIg (10 mg/ml), CsA (600 ng/ml) or TAC (60 ng/ml) on proliferation of T-cells stimulated with PHA. A: Histograms of CFSE 
dilution from one representative experiment. Day 0: all T-cells are in parent peak (black). Day 5: T-cell division visualized by dilution of CFSE over 
daughter cells in absence or presence of tested agents. B: Proliferation Index (PI), which indicates the extent of T-cell expansion as calculated by 
ModFit TM software. C: Precursor frequency (%prec), which is a measure for the percentage of T cells responding to the stimulus. The results are 
means ± SD of five independent experiments.
* P < 0.05  ** P <0.01 compared to control conditions
D-E: T cells were stimulated with allogeneic antigen presenting cells (APC) in presence or absence of IVIg (10 mg/ml), CsA (600 ng/ml) or TAC (60 
ng/ml). D: Proliferation Index (PI), and E: Precursor frequency (%prec). The results are means ± SD of five independent experiments.
* P < 0.07 compared to control conditions
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to IFN-γ production (1.17 ± 0.77 ng/ml in control conditions), but was also inhibited by IVIg 
(0.42 ± 0.28 ng/ml) and TAC (0.16 ± 0.06) to a comparable extent (n = 3). 
To determine whether the tested agents inhibited only the rate of IFN-γ secretion, or the 
proportion of T cells producing IFN-γ, PHA and allogeneic stimulated T cells were harvested at 
day 6 and re-stimulated with PMA and ionomycine. Thereafter, IFN-γ production was analyzed 
by flow cytometry. IVIg and CNI both suppressed the numbers of T cells producing IFN-γ after 
PHA stimulation (Figure 5D). Since we had observed that after allogeneic APC stimulation IVIg 
and CNI preferentially affected CD8+ T cell proliferation, the proportions of cells producing 
IFN-γ were analyzed separately for the CD2+/CD8- and CD2+/CD8+ T cell subsets. Figure 5E 
shows that IVIg and CNI reduced the numbers of helper, as well as the numbers of cytotoxic T 
cells producing IFN-γ. These data show that IVIg and CNI inhibit not only the production rate 
similarly, but also the number of T cells capable of producing IFN-γ.  
Effects of IVIg and CNI on allostimulatory capacity of DC
To establish the effects of IVIg and CNI on the function of DC, immature blood DC were stimu-
lated in vitro with pro-inflammatory cytokines (IL-1β and TNF-α) in the presence or absence 
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Figure 3: Effects of IVIg and CNI on cytotoxic and helper T-cell division
The effects of IVIg, CsA or TAC on CFSE-dilution in helper CD3+/CD8- and cytotoxic CD3+/CD8+ T-cells after stimulation with allogeneic APC. The 
histograms are from one experiment representative for four independent experiments.
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of IVIg or CNI. After 18 hours, T cells from an unrelated donor were added to the DC to assess 
their allogeneic T-cell stimulatory capacity. Freshly isolated immature blood DC had a poor 
allogeneic T-cell stimulatory capacity, which was strongly up-regulated during cytokine driven 
maturation (data not shown). Addition of IVIg to DC during their maturation suppressed their 
acquisition to stimulate allogeneic T cell proliferation by 73 ± 12% (n = 6; p < 0.01). A lower 
concentration of IVIg inhibited DC function in a lesser extent (data not shown). In contrast, DC 
matured in presence of CsA (600 ng/ml) or TAC (60 ng/ml) were not affected in their stimulatory 
capacity of allogeneic T cells (Figure 6A). Determination of IFN-γ in supernatants harvested 3 
days after addition of T cells to pre-treated mature DC, revealed that co-cultures of T cells with 
IVIg treated DC produced significantly less IFN-γ in comparison to the co-cultures of T cells with 
control DC (2.0 ± 1.2 ng/ml in IVIg treated condition versus control 4.1± 0.8 ng/ml; p < 0.05, n = 
4), supporting the reduced allogeneic T-cell activation by IVIg treated DC.  
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 Figure 4: Effects of IVIg and CNI on mitotic progression of proliferating T cells
CFSE labelled T cells were stimulated with PHA, and IVIg (10 mg/ml), CsA (600 ng/ml) or TAC (60 ng/ml) were added to culture at day 0,1,2,3,4 
and 5. CFSE-dilution was determined after 6 days and proliferation Index (PI) (A) and precursor frequency (%prec) (B) were calculated. The results 
are means ± SD of four independent experiments.
* P < 0.05  ** P < 0.01 compared to control conditions
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Effects of IVIg on DC viability and immunophenotypic maturation 
To analyze whether the reduced T-cell stimulatory capacity of IVIg treated DC was due to IVIg 
induced cell death of DC, percentages of 7AAD+ cells within the CD1c+ DC population and 
expression of maturation markers were determined in freshly isolated DC (= time point 0) and 
at time points 18, 48 and 72 hours. Until time point 18 hr the DC were matured with TNFα, 
IL-1β and GM-CSF in the presence or absence of IVIg, but without T cells present. Thereafter, 
supernatants were removed, and allogeneic T cells were added. In short, the conditions were 
comparable to the conditions in the allogeneic T-cell stimulation experiments described above. 
As is shown in Figures 6 B and C, immediately after maturation no difference in DC viability was 
observed between IVIg-treated DC and control DC.  But at 48 hours, which is 30 hours after IVIg 
had been removed and allogeneic T cells had been added, a significant increase of cell death 
was observed in IVIg maturated DC. On the contrary, when untreated DC were cultured with T 
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IFN-γ  
Figure 5: Effects of IVIg and CNI on T-cell activation and cytokine production
A. T cells were stimulated with PHA in the presence or absence of IVIg (10 mg/ml), and on day 6 CD25 expression was determined. Depicted are: 
CD25-expression on T cells stimulated in the absence of IVIg (gray histogram), presence of IVIg (open histogram with solid line), and isotype-
matched control histogram (open histogram with dotted line). 
B and C: T cells were stimulated with PHA (B) (N=6) or allogeneic splenic APC (N=4) (C), in presence or absence of IVIg, CsA or TAC, and after 3 and 
6 days IFN-γ concentration was determined in the supernatant. * P < 0.05 ** P < 0.01 compared to control conditions.
D and E. Six days after PHA-stimulation (D) or allogeneic APC stimulation (E) in presence or absence of IVIg, CsA or TAC the numbers of IFN-γ 
producing T cells was determined. T cells were harvested and re-stimulated with PMA and ionomycin and the proportion of T cells that produced 
IFN-γ was analyzed by flowcytometry. The percentages depicted in the pictures are means ± SD of three independent experiments. 
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Figure 6: Effects of IVIg and CNI on DC
A. Effect on allostimulatory capacity. Different numbers of immature blood DC (5, 2.5, and 1.25 x 103 cells per well) were stimulated with TNF-α 
(25 ng/ml) and IL-1β (50 ng/ml) and GM-CSF for 18 hours in the absence or presence of IVIg (10 mg/ml), CsA (600 ng/ml) or TAC (60 ng/ml). 
Subsequently, the culture medium was aspirated, DC were washed two times with culture medium to remove additives, and 1.5 x 105 allogeneic 
T cells were added. After 5 days, T-cell proliferation was assessed by determination of the incorporation of 0.5 mCi [3H]thymidine during 18 hours. 
Each condition was tested in triplicate from which means were calculated. These means were used in the analyses. The results are means ± SD of 
six independent experiments. * P<0.05 compared to control conditions.
B and C. Effect on cell death. DC (40 x 103 cells) were stimulated with TNF-α, IL-1β and GM-CSF for 18 hours in the absence or presence of IVIg (10 
mg/ml). Then, DC were washed two times to remove additives, and 1.5 x 105 allogeneic T-cells were added. B: Representative dot plots of 7AAD 
incorporation into CD1c+ DC maturated in the presence or absence of IVIg, two days after addition of the T cells. DC were gated on CD1c+ against 
side scatter. C: Percentages of 7AAD+ cells of CD1c+ cells determined before culture (imm), immediately after maturation (t = 18 hrs), one day 
(t = 48 hrs), and two days after addition of T cells (t = 72 hrs). Note that after t = 18 h, no IVIg was present in the cultures. Data are means ± SD 
of six independent experiments.
D and E. Effect on expression of co-stimulatory molecules. Expression of CD80 (D) and CD40 (E) on DC during the culture. Data are means ± SD of 
four independent experiments, respectively.  
* P < 0.05 ** P < 0.01 compared to control conditions.
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cells the viability remained stable. At 72 hours of culture, IVIg treated CD1c+ DC incubated with 
allogeneic T cells were 58 ± 6% 7AADpositive compared to the control in which 32 ± 4 % of 
CD1c+ DC were 7AAD+ (p < 0.01, n = 6). In addition, IVIg suppressed the up-regulation of CD80 
and CD40 molecules on DC (Figure 6D and 6E). The expression of HLA-DR, CD 86 and PDL-1 on 
IVIg treated DC did not differ from control DC (data not shown).  
dISCuSSION
This is the first study that compares the immunomodulatory effects of IVIg and CNI on the 
two principal human immune cell types involved in acute rejection and GVHD after allogeneic 
transplantation, i.e. T cells and DC.
Firstly, using two methods to determine T-cell proliferation, we found that the inhibitory 
effect of a clinically achievable concentration of IVIg on T-cell proliferation is similar to the effect 
of therapeutic peak concentrations of CNI. Similar concentrations of HSA had no effect on T-cell 
proliferation. This excludes that the suppressive effect of IVIg is merely due to an elevated 
protein concentration in the cultures. After PHA or allogeneic stimulation, both IVIg and CNI 
inhibited the recruitment of precursor cells and their expansion. Experiments in which IVIg and 
CNI were added at later time point after initiation of the T-cell cultures showed that both agents 
were capable of suppressing mitotic progression of already recruited T cells. In addition, IVIg 
and CNI were equally effective in suppression of IFN-γ and IL-4 production by T cells. Like CNI, 
IVIg inhibits T-cell activation, as shown by the suppression of CD25 up-regulation. Collectively, 
these findings show that IVIg can control T-cell activation after alloantigen presentation as 
effectively as CNI, even after its onset. 
The mechanism of action by which IVIg interfere with T-cell proliferation probably involves a 
direct effect of IVIg on the T cells, since not only alloantigen stimulated, but also PHA stimulated 
T cells were inhibited in their proliferation. The mechanism by which IVIg suppress activation of 
T cells is at present unknown. The direct inhibitory effect of IVIg on T cell proliferation is at least 
partly due to induction of apoptosis in T cells.  However, the increased rate of apoptosis cannot 
totally explain the strong inhibition of approximately 87% by IVIg. After allogeneic stimulation 
both IVIg and CNI preferentially inhibited the proliferation of CD8+ T cells. Since CD8+ T cells 
are the actual cells that destroy the transplanted allograft 33, this finding supports the notion 
that IVIg may be equally able to control rejection as CNI. Secondly, we observed that immature 
human blood-derived myeloid DC stimulated in presence of IVIg were suppressed in their 
capacity to stimulate allogeneic T cells. Our group reported similar results with anti-HBs IVIg 8. 
The present study shows that the suppression of DC function is not restricted to the anti-viral 
type of IVIg, but is also the case of non-specific type of IVIg. The suppressive effect of IVIg on DC 
was not due to the elevated protein concentration in the cultures, since addition of an equal 
concentration of HSA during DC-maturation had no effect on T-cell stimulatory capacity of DC 
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8. Bayry et al. showed that IVIg inhibit the differentiation, maturation and T-cell stimulatory 
capacity of human Mo-DC in vitro 9. Mo-DC differ in several aspects from myeloid blood CD1c+ 
DC present in situ 25. Nevertheless, the present report shows that the suppressive effect of IVIg 
on the allogeneic T-cell stimulatory capacity of blood DC is comparable to that on Mo-DC. How-
ever, whereas IVIg suppressed the up-regulation of co-stimulatory molecules on Mo-DC during 
maturation 22, IVIg had no immediate effects on immunophenotypic maturation of blood DC. 
We observed only a delayed effect on the up-regulation of CD40 and CD80, which became 
apparent after IVIg had been removed and allogeneic T cells had been added. The reduced 
T-cell stimulatory capacity of IVIg treated blood DC may also be caused by the induction of 
cell death in DC. Also this effect of IVIg was not observed immediately after DC maturation, 
but became apparent at later time points after IVIg had been removed and allogeneic T-cells 
had been added. To exclude non viable T cells from the analysis, we selected CD1c+ cells to 
identify the proportion of non-viable 7AAD+ DC. Therefore, underestimation of percentage of 
cell death in these cultures cannot be excluded, since DC will finally lose their CD1c expression 
when they lose their membrane integrity. Whether IVIg treatment itself induces delayed DC 
death, or whether IVIg interfere with T-cell regulated DC-survival is presently unclear. Sup-
porting the possibility that IVIg directly induces death of DC, IVIg has been reported to induce 
apoptosis in B cells 26,34.
Taken together, we propose that the impaired T-cell stimulatory capacity of blood DC, when 
treated with IVIg, is caused by induction of cell death and reduced up-regulation of CD40 and 
CD80. The present study shows that IVIg inhibit T-cell activation and suppress DC function. 
Interestingly, simultaneous targeting of T-cells and DC has been shown to result in tolerance 
induction in macaques 35. Therefore, IVIg-treatment may be able to contribute to graft toler-
ance.  However, this subject merits further investigation.
Most reports showed that CNI do not affect DC differentiation from monocytes 23,36. How-
ever, studies of the influence of CNI on the maturation of human DC have led to discrepant 
observations. While a few studies reported that the presence of CNI during maturation of 
human DC suppressed their capacity to stimulate allogeneic T cells 36,37, others observed no 
effect 23. Most of these studies were performed using Mo-DC. In this study we found that CNI do 
not suppress the acquisition of allogeneic T-cell stimulatory capacity during cytokine induced 
maturation of blood DC. 
In conclusion, IVIg have strong suppressive effects on human T cells and DC, while CNI only 
inhibit T cells. Therefore, by targeting both T cells and DC, we assume that IVIg will be superior 
in the control of acute rejection as GVHD in comparison to CNI. As IVIg are registered and safe 
drugs, we consider IVIg as a promising candidate for prophylaxis of rejection and GVHD prophy-
laxis in order to ensure a safe patient survival after allogeneic HSCT and organ transplantation. 
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SuMMaRY
The modes of action of intravenous immunoglobulins (IVIg) in exerting their immunomodula-
tory properties are broad and not fully understood. IVIg can modulate the function of various 
immune cells, including suppressing the capacity of dendritic cells (DC) to stimulate T cells. 
In the present study, we showed that DC matured in presence of IVIg (IVIg-DC) activated NK 
cells, and increased their IFN-γ production and degranulation. The activated NK cells induced 
apoptosis of the majority of IVIg-DC. In consequence, only in the presence of NK cells, IVIg-DC 
were 4-fold impaired in their T-cell priming capacity. This was due to NK-cell mediated Antibody 
Dependent Cellular Cytotoxicity (ADCC) to IVIg-DC, probably induced by IgG-multimers, which 
could be abrogated by blockade of CD16 on NK cells. Furthermore, IVIg-DC down regulated the 
expression of NKp30 and KIR receptors, and induced the generation of CD56brightCD16-CCR7+ 
lymph node type NK cells. Our results identify a novel pathway, in which IVIg induce ADCC of 
mature DC by NK cells, which downsizes the antigen presenting pool and inhibits T-cell prim-
ing. By influencing the interaction between DC and NK cells, IVIg modulate the ability of the 
innate immunity to trigger T-cell activation, a mechanism that can “cool down” the immune 
system at times of activation.
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INTROduCTION
Intravenous immunoglobulins (IVIg) are pharmaceutical preparations of human IgG purified 
from pools of plasma of thousands of donors. For decades IVIg have been established as treat-
ment of autoantibody mediated 1 and T-cell mediated inflammatory disorders 2. The distribu-
tion of IgG subclasses in IVIg is comparable to that of IgG in normal human serum, however, 
unlike IgG purified from a single individual, therapeutic IVIg preparations contain substantial 
amounts of IgG dimers and traces of multimers, due to the idiotype-anti-idiotype complex 
formation between IgG molecules from different individuals 3,4. In general, IVIg were shown to 
be effective in conditions in which the immune system is hyperactive, but still the mechanisms 
of action by which IVIg correct immune dysregulation are not fully understood. Various reports 
showed that the mode of actions of IVIg is multifaceted and complex, involving interference 
with different components of the immune system. Clinical and immunological improvements 
induced by IVIg treatment are reported to be profound and to extend the half-life of infused 
IgG, suggesting that IVIg can modify cellular immune reactivity for prolonged periods 1,5. 
Recently, we observed that hyperimmune IVIg against hepatitis B surface antigen (anti-HBs IVIg) 
protect against acute rejection after liver transplantation, indicating that IVIg treatment can 
modulate the T-cell mediated immune response against allo-antigens 6. We and others found 
that in vitro both anti-HBs IVIg and non-specific IVIg are able to suppress T-cell proliferation and 
cytokine production, and to impair the allogeneic T-cell stimulatory capacity of blood-derived 
and monocyte-derived DC 6-9, demonstrating that IVIg can suppress T-cell responses, both dur-
ing the priming phase as well as in the effector phase. The importance of DC as a cellular target 
of IVIg in vivo was recently shown in a murine model of immune thrombocytopenic purpura 
(ITP), in which treatment with IVIg could be replaced by adoptive transfer of IVIg-treated DC 10. 
With regard to the mechanism by which IVIg affects DC function, we found that the decreased 
T-cell stimulatory capacity of IVIg-treated DC (IVIg-DC) was associated with induction of cell 
death in mature DC. Interestingly, IVIg treatment itself did not induce DC death directly, as the 
increased death of IVIg-DC only occurred when cultured with other immune cells, i.e. T cells and 
NK cells 9. As activated NK cells are capable of killing DC in a number of circumstances 11,12, we 
hypothesized that NK cells may induce apoptosis of IVIg-DC during the initial phase of DC-NK 
cell encounter, i.e. before the T-cell activation. 
Interactions between DC and NK cells have been documented in a variety of settings, shed-
ding light on the complexity of the bi-directional interaction between these two cell types. 
Bajenoff et al. showed that NK cells are present in the medulla and the paracortex of lymph 
nodes, where they closely interact with DC. Upon receiving an inflammatory signal, NK cells 
interact with DC, and regulate co-localized T-cell responses 13. Cross-talk between DC and 
NK cells can result in lysis, inhibition or maturation of DC by NK cells, and reciprocally, DC can 
activate or inhibit NK-cell functions. The final outcome of DC-NK cell interaction depends on the 
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conditions in which both cell types encounter each other 12,14, and will subsequently determine 
the development of the following adaptive immune response. 
In this study, we investigated the mechanism by which IVIg modulate the interaction 
between DC and NK cells, and how this consequentially shapes T-cell priming. Our observations 
form the basis of a model to clarify how administration of IVIg may “cool down” hyperactivity of 
the cellular immune system for extended periods. 
MaTERIalS aNd METhOdS
Reagents
Human IVIg (Intraglobin® CP) were a kind gift from Biotest Pharma (Dreieich, Germany) and 
the humanized monoclonal antibody Herceptin® (Trastuzumab) was kindly provided by Roche 
Pharma (Mijdrecht, The Netherlands). Both preparations were dialyzed against large volumes 
of culture medium (RPMI) at 4°C using Slide-A-lyzer® gamma irradiated dialysis cassettes 
(Pierce, Rockford, USA) to remove stabilizing agents and to obtain neutral pH. After dialysis, 
IgG concentration was determined by the Tina-quant® immuno-turbidimetric assay (Roche 
Diagnostics, Mannheim, Germany). In all experiments IVIg were used in a concentration of 10 
mg/ml (0.06M). This is similar to increments in serum IgG concentration in patients treated with 
IVIg at 1-2 g/kg for autoimmune disorders 15-17. To detect binding of IVIg, biotinylated IVIg or 
rabbit F(ab’)2 anti-human IgG-FITC (DAKO Cytomation, Denmark) were used. The biotinylation 
was performed using D-biotinoyl-є-aminocaproic Acid N-hydroxysuccinimide ester (Roche 
Diagnostics, Indianapolis) according to manufacturer’s instructions. To exclude that the sup-
pressive effects of IVIg were merely due to an elevated protein concentration in the cultures, 
Human Serum Albumin (HSA) (Sanquin, Amsterdam, The Netherlands) was used as a negative 
control.
Isolation of immune cells 
DC, NK cells and T cells were purified from fresh heparinized blood of healthy individuals. After 
Ficoll density gradient separation and depletion of B cells with CD19-conjugated immunomag-
netic beads and separation over Large Depletion (LD)-columns (Miltenyi Biotec, Germany), DC 
were isolated by positive selection with PE-conjugated anti-CD1c mAb and anti-PE immuno-
magnetic beads using Medium Separation-columns, as described previously 6. The purity of DC 
(defined as CD1c+ CD20- cells) as analyzed by flowcytometry was above 95 %.
NK cells were negatively selected by the NK cell isolation Kit (Miltenyi Biotec) using LD-
columns. The purity of NK cells (defined as CD56+ CD3- cells) as analyzed by flowcytometry was 
above 95%.
T cells were enriched by immunomagnetic depletion of B cells, monocytes, DC, and NK cells. 
From the same healthy blood donor T cells were also isolated without NK cell depletion. The 
IVIg induce ADCC by NK cells 79
cells were labeled with CD19-conjugated immunomagnetic beads, PE-conjugated anti-CD1c 
mAb (both from Miltenyi Biotec), CD14-PE, and either or not CD56-PE (both from BD Biosci-
ences, Belgium), followed by incubation with anti-PE immunomagnetic beads and separation 
over LD columns. The purified T-cell preparations contained 92% ± 4% CD3+ cells and < 0.3% 
CD56+ cells. Contaminating cells consisted of granulocytes. The T-cell preparation from which 
NK cells were not depleted contained 80% CD3+CD56- T cells and 12% CD3-CD56+ NK cells.
Effects of IVIg and NK cells on allogeneic T-cell stimulatory capacity of DC
If not otherwise mentioned, in all experiments with DC, immature human blood DC were stimu-
lated to mature with TNF-α (25 ng/ml) and IL-1β (50 ng/ml) (both from Strathmann Biotech, 
Germany) in RPMI supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), 10% 
FCS (Hyclone, UT, USA) and GM-CSF (500U/ml; Leucomax, The Netherlands) for 18 hours in the 
absence or presence of IVIg or HSA.
To determine the effects of IVIg on the acquisition of allogeneic T-cell stimulatory capacity of 
DC, and the role of NK cells in this process, different numbers of immature blood DC (5, 2.5, 1.25 
and 0.75 x 103 cells per well of a 96-well flat bottom plate) (Greiner, Netherlands) were stimu-
lated with TNF-α and IL-1β for 18 hours in the absence (CTRL-DC) or presence of 10 mg/ml IVIg 
(IVIg-DC). The next day, DC were washed, and either allogeneic T cells, which contained 12% NK 
cells (i.e. 1.2 x 105 plus T cells 0.18 x 105 NK cells), or 1.2 x 105 pure allogeneic T cells, were added. 
In all experiments with allogeneic T cells, one T cell and one T + NK cell batch obtained from the 
same healthy blood donor were used. For addition of autologous NK cells (Figure 5D), 0.18 x 105 
NK cells from the same donor as the DC, combined with 1.2 x 105 allogeneic T cells were added 
per well. After 5 days, proliferation was assessed by determination of the incorporation of 0.5 
mCi [3H] thymidine (Radiochemical Center, UK) during 18 hours. In addition, to determine the 
effects of IVIg on T cell and NK cell expansion separately, T cells (with or without NK cells) were 
labeled with 2 µM carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, 
OR) per 5 x 106 cells for 10 minutes at 37 °C. Labeled T cells with or without NK cells from the 
same donor were cultured with allogeneic CTRL-DC and IVIg-DC. After 6 days, T and NK-cell 
divisions were analyzed by flowcytometry after labeling the cells with CD3-PE and CD56-APC 
(both from Beckman Coulter Immunotech, France). CFSE-flowcytometry data were analyzed by 
ModFit TM software version 3.0 (Verity Software House, USA). The software calculated the prolif-
eration Index (PI), which indicates the extent of cell expansion, and the precursor frequency (% 
prec) which is the percentage of cells, which underwent at least one division.
To block the FcγRIII on NK cells, we added CD16 blocking antibody (clone 5D2; 10 μg/ml 
18), which was kindly provided by Dr. M. de Haas (Sanquin Research, The Netherlands) to the 
cultures.
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Detection of binding of IVIg to DC, DC apoptosis and NK-cell activation
To detect binding of IVIg to DC, DC were matured in the presence or absence of biotinylated 
IVIg for 18 hours in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with Ultraglu-
tamine with 4.5 g/l Glucose (BioWhittakerTM, Belgium), penicillin, streptomycin, 10% FCS and 
GM-CSF, TNF-α and IL-1β. DMEM was used instead of RPMI, since RPMI contains biotin. After 
DC were washed extensively to remove all non-bound IVIg-biotin, biotinylated IVIg on the DC 
membrane was detected using strepavidin-APC (BD Biosciences). To detect internalization of 
IVIg-biotin, first surface-bound biotinylated IVIg was detected using streptavidin-PerCP (BD 
Biosciences). Subsequently, residual free biotinylated IVIg on the cell surface was blocked using 
biotin-blocking reagent (Dako Cytomation, Denmark), DC were fixed and permeabalized with 
Intraprep permeabilization reagens (Beckman Coulter Immunotech), and intracellular IVIg-
biotin was detected using streptavidin-APC. Alternatively, FITC-conjugated rabbit anti-human 
IgG F(ab)2 was used to detect binding of non-biotinylated IVIg on the DC surface.
After maturation, the culture medium was aspirated, DC were washed two times with cul-
ture medium, and 2.4 x 105 allogeneic or autologous NK cells were added. The DC : NK ratio was 
1:6, which is between the ratio used in the mixed lymphocyte reaction performed with 5.000 
and 2.500 DC (Figure 1A). To determine apoptosis of stimulated DC in these DC-NK co-cultures, 
the number of active caspase-3 expressing CD1c+ DC was determined after 8 hours incuba-
tion with allogeneic NK cells by intracellular labeling with anti-active caspase-3-FITC mAb 
(BD Pharmingen) using Intraprep permeabilization reagens, after membrane labeling with 
PE-conjugated anti-CD1c mAb. Secondly, cell death of DC at 18 hours of co-culture of DC with 
NK cells was detected by Annexin V-APC staining combined with 7-AAD uptake in CD1c+ DC 
(both BD Biosciences, Germany), and analyzed by flowcytometry. In addition, we determined 
the absolute numbers of viable DC in the cultures at 18 and 48 hours after co-culture of mature 
DC with allogeneic NK cells by adding a fixed number of CalibriteTM 3 beads (BD Biosciences) to 
the cells and determining the ratio of 7AAD- DC to beads by flowcytometry. Absolute numbers 
of viable DC were calculated by multiplying this ratio by the absolute number of beads added 
to the cells 19.
After 48 hours of DC-NK cell co-culture, supernatants were collected for cytokine production, 
and NK cell activation was established using CD56-PE, CD69-APC and CD25-APC (all from BD 
Biosciences). Degranulation of NK cells was determined in 6-hours co-cultures of NK cells and 
DC by adding PE-conjugated CD107a mAb (BD Pharmingen) to the cultures, according to the 
protocol described in literature 20,21. To detect spontaneous degranulation, a control sample of 
NK cells without DC was included in all experiments. IFN-γ concentration in the supernatants 
was quantified by ELISA (U-CyTech, The Netherlands). 
Effect of IVIg-DC on NK-cell phenotype
To verify whether IVIg-DC promote phenotypical changes of NK cells, we cultured 1.0 x 104 
DC with 4.8 x 105 allogeneic T and 1.2 x 106 NK cells (ratio DC: T: NK is 1: 48: 12), and after 
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5 days we determined the expression of FcγRIII (CD16), Natural Cytotoxicity receptors (NCR), 
killer immunoglobulin like receptors (KIR) and lymph node homing chemokine receptors using 
CD16-PE (clone 3G8), NKG2A-PE, NKp30-PE, CD158a-APC, CD158b-APC (all from Beckman 
Coulter Immunotech, France), CXCR3-APC and CCR7-FITC (both from R&D systems, USA) on 
CD56+CD3- cells. We have checked whether IVIg prevented binding of the 3G8 mAb to NK cells 
by pre-incubating NK cells with 10 mg/ml IVIg at 4° C, and found that 3G8 binding was not 
affected by IVIg. 
Statistical analysis
In each individual experiment, proliferation and cytokine production was tested in triplicate 
from which means were calculated. In the results, means with SD from independent experi-
ments are depicted. Statistical analyses were performed by the wilcoxon test for paired data or 
the student t-test for paired data using software package SPSS version 10.1 (SPSS, Chicago, IL) 
as indicated in the legend. A two-sided p-value < 0.05 was considered as indicating significant 
difference.
RESulTS
Impaired allogeneic T-cell priming by IVIg-DC occurs only in presence of NK cells 
To study whether NK cells were involved in reduction of the capacity of IVIg-treated DC (IVIg-
DC) to prime allogeneic T cells, we matured DC by addition of IL-1β and TNF-α in presence 
or absence of 10 mg/ml IVIg for 18 hours. Then the additions were washed out, and either 
allogeneic T cells, which contained 12% NK cells, or pure allogeneic T cells, where the NK cell 
contamination level was below 0.3%, were added. When IVIg-DC were co-cultured with alloge-
neic T and NK cells, their capacity to prime allogeneic T cells was 4-fold impaired (p < 0.05, N = 
4). However, this effect was not observed when NK cells were absent in the cultures (Figure 1A). 
Using CFSE labeled cells, it was confirmed that the effect of IVIg treatment on the allogeneic 
T-cell stimulatory capacity of DC is dependent on the presence of NK cells, and that the reduced 
3H thymidine incorporation observed in Figure 1A indeed reflected lowered T-cell proliferation. 
(Figure 1A-C)
IVIg were present on the surface and in the cytoplasm of DC after maturation, and increase 
DC susceptibility for NK-cell mediated killing
Using biotinylated IVIg allowed clear detection of IVIg in the cytoplasm and on the surface of 
DC with strepavidin fluorochromes. Binding of IVIg-biotin was detected on the surface of 92 ± 
3 % of DC matured in the presence of biotinylated IVIg (N = 3). Untreated DC (CTRL-DC) or DC 
matured in the presence of HSA (HSA-DC) did not bind strepavidin-APC (Figure 2A). A second 
method using FITC-conjugated rabbit-anti-human IgG F(ab)2 to detect IVIg binding on DC, 
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showed equivalent findings, as 91 ± 9 % of the IVIg-DC were positively stained (N = 4) (Figure 
2B). 
To determine whether DC internalized IVIg during maturation, we first detected biotiny-
lated IVIg on the DC surface by strepavidin-PerCP. Thereafter, intracellular biotinylated IVIg was 
detected using strepavidine-APC (Figure 2C). We observed that 90 ± 4% of DC stained for both 
strepavidin-PerCP and strepavidin-APC, indicating that IVIg was present on the surface as well 
in the cytoplasm of the DC (N = 3) (Figure 2C). (Figure 2 A-C)
When allogeneic NK cells were cultured with IVIg-DC, the NK cells induced apoptosis of 
IVIg-DC, as shown by increased intracellular expression of active caspase 3 (CTRL-DC: 7 ± 2%, 
IVIg-DC: 14 ± 3%, HSA-DC: 7 ± 3%, p < 0.01, N = 6) after 8 hours of DC-NK cell encounter (Figure 
3A). Subsequently, after 18 hours of co-culture we observed increased DC death, as indicated 
by enhanced 7-AAD uptake in IVIg-DC (CTRL: 17 ± 8%, IVIg: 33 ± 9%, HSA: 18 ± 6% p < 0.01, N 
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Figure 1: Impaired allogeneic T-cell priming by IVIg-DC occurs only in presence of NK cells 
A: Indicated numbers of immature blood DC were stimulated with TNFα and IL-1β for 18 hours in the absence (CTRL-DC, solid line) or presence of 
10 mg/ml IVIg (IVIg-DC, dotted line). The next day, DC were washed, and allogeneic T-cells, which contained 12% NK cells, or the same number 
of allogeneic T-cells without NK cells were added. Proliferation was assessed after 5 days by determination of the incorporation of [3H] thymidine 
(N=4, * p < 0.05, ** p < 0.01; paired student t test)
B: Purified allogeneic T-cells and NK cells with CFSE were added and subsequently cultured with CTRL-DC (left) or IVIg-DC (right) at a DC: T: NK ratio 
of 1:48:12. At day 6 of co-culture, cells were onomyci with CD3-PE and CD56-APC, and the CFSE-dilution profile of CD3+CD56- T-cells was analyzed 
using ModFitTM software. CFSE analysis was also performed on CD56+CD3- NK cells, which is shown in figure 7A separately.
C: The same experiment, as depicted in B, but CFSE-labeled allogeneic T-cells without NK cells, were cultured with CTRL-DC (left) or IVIg-DC (right) 
at a DC: T ratio of 1 : 48. Proliferation index (PI) and percentage of precursor T-cells (% Prec) depicted in figures B and C are means ± SD from 4 
independent experiments. 
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= 9) (Figure 3B). The increased DC death was not the result of allogeneic differences, as autolo-
gous NK cells were also able to induce enhanced killing of IVIg-DC (CTRL: 16 ± 9%, IVIg: 35 ± 
10%, HSA: 17 ± 8% 7-AAD+ DC, p < 0.05, N = 4).  
In addition, Annexin V staining combined with 7AAD was performed. The proportion of 
AnnexinV+7AAD+ cells was increased in the IVIg-DC population (CTRL-DC: 15 ± 6 %, IVIg-DC: 
30 ± 15%, p < 0.05, N = 6), while the proportion of Annexin V-7AAD- IVIg-DC was reduced 
compared to CTRL-DC (CTRL-DC: 55 ± 12%, IVIg-DC: 40 ± 5%, p < 0.08, N = 6). To exclude that 
the effects of IVIg-treatment of DC were specific for DC stimulated with pro-inflammatory 
cytokines, we repeated the experiments with DC stimulated with LPS. Indeed, IVIg treatment 
during DC stimulation with LPS resulted in equivalent increases of DC death after addition of 
NK cells (data not shown). (Figure 3C and D)
Furthermore, after 18 and 48 hours of co-culture with allogeneic NK cells, we have deter-
mined the absolute numbers of viable 7AAD- DC in the cultures by flowcytometry after addition 
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Figure 2: Presence of IVIg on the surface and in the cytoplasm of DC after maturation 
A: DC were stimulated for 18 hours in absence (left plot) or presence of biotinylated IVIg (middle plot) or HSA (right plot). Using streptavidin-APC, 
binding of IVIg-biotin was detected on 92 ± 3 % of the surface of IVIg-DC after maturation (N = 3). 
B: DC were stimulated for 18 hours in absence (left plot) or presence of IVIg (middle plot) or HSA (right plot). Rabbit-anti-human IgG-FITC F(ab)2 
was used to detect IVIg binding on the DC membrane. This showed equivalent results (N = 4). 
C: To determine internalization of IVIg during maturation, biotinylated IVIg on the DC surface was detected by strepavidin-PerCP. Thereafter, 
residual free biotinylated IVIg on the cell surface was blocked using biotin blocking reagent, DC were fixed and permeabilized and intracellular 
biotinylated IVIg was detected using strepavidin-APC. We observed that IVIg was present on the surface as well in the cytoplasm of the DC (N=3).
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of known numbers of CalibriteTMbeads. After co-culture with NK cells the absolute numbers of 
viable IVIg-DC were profoundly reduced compared to CTRL-DC (18 hours: IVIg-DC: 2046 ± 1173, 
CTRL-DC: 17181 ± 1266, 48 hours: IVIg: 968 ± 266, CTRL: 10318 ± 1363, p <0.05, N = 7) (Figure 
3E).
Bijlage 2 
Figure 3: IVIg treatment increases the susceptibility of matured DC for NK-mediated killing
A: After maturation with IL-1β and TNF-α, DC were cultured with allogeneic NK cells at the ratio 1:6. Eight hours thereafter, intracellular expression 
of active Caspase-3 in CTRL-DC (■), IVIg-DC (▲) and HSA-DC (▼) was determined (N = 6, wilcoxon test for paired data * p < 0.05 compared to 
CTRL-DC, NS = not significant).
B: After 18 hours of co-culture, DC-death was monitored by 7-AAD uptake in CTRL- DC (■), IVIg-DC (▲) and HSA-DC (▼) (N = 9, wilcoxon test 
for paired data ** p < 0.01, compared to CTRL-DC, NS = not significant).
C and D: After 18 hours of co-culture of matured DC with allogeneic NK cells, DC-apoptosis was monitored by Annexin V staining combined with 
7-AAD (N = 6, wilcoxon test for paired data § p < 0.08, * p < 0.05 compared with CTRL-DC, NS = not significant). Panel D shows plots of one 
representative experiment out of 6 experiments. 
E: After 18 and 48 hours of co-culture of 40.000 matured DC with allogeneic NK cells (DC: NK ratio 1:6) cells were harvested from the cultures and 
fixed numbers of CalibriteTM beads were added. Absolute numbers of viable DC were calculated by determining the ratio of 7AAD- DC to beads and 
then multiplying this ratio by the number of beads in the tube. Data is depicted as mean with SE, wilcoxon test for paired data * p < 0.05, N=7)
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IVIg-DC trigger NK-cell activation, IFN-γ production and degranulation
To investigate the effect of IVIg-DC on NK-cell activation and cytokine production, allogeneic 
NK cells were co-cultured with IVIg-DC, HSA-DC or CTRL-DC. After 48 hours of co-culture, we 
observed that IVIg-DC promoted activation of allogeneic NK cells as determined by CD69 expres-
sion (CTRL: 29 ± 16 %, IVIg: 81 ± 6 % and HSA: 41 ± 6 %, p < 0.01, N = 6) and CD25 expression 
(CTRL: 3 ± 0.8%, IVIg: 31 ± 11% and HSA: 4 ± 1 %, p < 0.01, N = 5) on NK cells (Figure 4A and 4B). 
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Figure 4: IVIg-DC trigger NK-cell activation, IFN-γ production and degranulation
A: IVIg-DC, HSA-DC or CTRL-DC were cultured for 48 hours with allogeneic NK cells (ratio DC: NK was 1:6) after which CD69 (top plot) and 
CD25-expression (lower plot) on CD56+ cells were determined. Depicted are NK cells activated by IVIg-DC (grey histogram), by CTRL-DC (black 
histogram), and staining with an irrelevant isotype control mAb of NK cells activated by IVIg-DC (dotted histogram). Similar NK-activation was 
observed when DC: NK ratio was changed to 1:3 or 1:1 (data not shown).
B: IVIg-DC, HSA-DC or CTRL-DC were washed to remove additives, and cultured for 48 hours with allogeneic NK cells (black bars). CD69 expression 
(* p < 0.05, wilcoxon for paired data, N = 6) and CD25 expression (* p < 0.05, wilcoxon for paired data, N = 5) on NK cells were significantly 
enhanced after co-culture with IVIg-DC. Treatment of NK cells with 10 mg/ml IVIg or HSA in absence of DC (white bars) had only minor activating 
effects on NK cells.
C:  IFN-γ concentration was determined in cell-free supernatants of DC-NK co-cultures. In the supernatants of NK cells stimulated with CTRL-DC or 
HSA-DC, no IFN-γ could be detected, while in the supernatants of NK cells stimulated with IVIg-DC, high IFN-γ levels were detected (** p < 0.01, 
wilcoxon for paired data, N = 7).
D: Expression of the lytic granule membrane protein CD107a on the NK-cell surface after 6 hours of co-culture of matured allogeneic CTRL-DC, 
IVIg-DC or HSA-DC (* p < 0.05, wilcoxon test for paired data, N = 5). 
E. Representative dot plots showing CD107a expression on NK cells cultured for 6 hours without DC (negative control), NK cells stimulated with 
PMA and ionomycine (2.5 ug/ml and 0.5 ug/ml) (positive control), NK cells co-cultured with CTRL-DC, and NK cells co-cultured with IVIg-DC.
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In contrast, 48 hours treatment of NK cells with 10 mg/ml of IVIg in absence of DC had 
marginal activating effects on NK cells, showing that full NK-cell activation requires both DC 
and the IVIg-treatment of DC prior to co-culture with NK cells. Moreover, supernatants collected 
at 48 hours from the co-cultures of IVIg-DC and NK-cells contained high levels of interferon γ 
(IFN-γ) (IVIg-DC and NK-cells: 2.4 ± 0.2 ng/ml), while in the supernatants of NK cells cultured 
with CTRL-DC or HSA-DC, no IFNγ could be detected (N = 7) (Figure 4C). IL10 production was 
not detectable in all collected supernatants. Again, the increased activation and cytokine pro-
duction of NK cells was not due to allogeneic differences, since experiments performed with 
autologous NK cells showed equivalent results (data not shown).  
To elucidate whether IVIg-DC stimulate NK-cell degranulation, we determined the expres-
sion of the lytic granule membrane protein CD107a on the NK cell surface. About 10% of NK 
cells cultured without DC spontaneously expressed CD107a, and CTLR-DC did not induce 
degranulation above this background. We observed an increased surface expression of CD107a 
on NK cells only after they had been co-cultured with IVIg-DC (CTRL-DC: 10 ± 4 %, IVIg-DC: 17 
± 5%, HSA-DC: 10 ± 3 %, p < 0.05, N = 5) (Figure 4D and E). The enhanced degranulation of lytic 
granules by NK cells after co-culture with IVIg-DC supports the conclusion that NK cells are 
responsible for the enhanced killing of IVIg-DC.  
Impaired allogeneic T-cell priming is due to ADCC of IVIg-DC by NK cells
To investigate whether NK-cells recognize IVIg treated DC via their FcγRIII (CD16), a CD16-block-
ing antibody (clone 5D2) was added into DC-NK cell cultures. The increased NK-cell-mediated 
killing of IVIg-DC, as assessed by 7-AAD uptake in DC, was significantly reduced from 37 ± 7 % 
to 28 ± 3 % of CD1c+ DC (p < 0.05, N = 5) when the CD16-blocking antibody was added, while 
CD16 blockade had no effect on NK-cell mediated lysis of CTRL- and HSA-DC (Figure 5A). In 
addition, by blocking CD16, more viable IVIg-DC were present after co-culture with NK cells 
(Figure 5B). This indicates that the increased NK-cell mediated apoptosis of IVIg-DC by NK cells 
is largely due to FcγRIII-mediated Antibody Dependent Cellular Cytotoxicity (ADCC). 
ADCC of IVIg-DC by NK cells was indeed the main cause of the reduced T-cell priming capacity 
of IVIg-DC. When the 5D2 antibody was added to block the FcγRIII on NK cells during co-cultures 
of IVIg-DC and allogeneic T- and NK cells, the difference in allogeneic priming capacity between 
IVIg-DC and CTRL-DC was almost completely abolished (Figure 5C). Again, the impairment in 
T-cell priming of IVIg-DC was not the result of allogeneic differences between DC and NK cells, 
as autologous NK cells also killed IVIg-DC from the same donor and reduced the allogeneic 
T-cell priming. In addition, impairment of IVIg-DC function by autologous NK cells could be 
abrogated by addition of the 5D2 mAb (Figure 5D). Addition of an equivalent concentration of 
mouse-IgG2a mAb as a control for the 5D2 blocking antibody to the cultures did not restore the 
impaired T-cell stimulatory capacity IVIg-DC (data not shown).  
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 Figure 5: Impaired allogeneic T-cell priming is due to ADCC of IVIg-DC by NK cells
A: Matured CTRL-DC, IVIg-DC or HSA-DC were cultured for 18 hours with allogeneic NK cells (ratio 1:6) with (black bars) or without (white bars) 10 
µg/ml CD16-blocking antibody (5D2). DC-death was determined by 7AAD uptake. The increased death of IVIg DC was abrogated by blocking the 
FcγRIII on NK cells (* p < 0.05, NS = not significant, N = 5, wilcoxon test for paired data).
B: Matured CTRL-DC (white bars) and IVIg-DC (black bars) were cultured for 18 hours with allogeneic NK cells (ratio 1:6) with or without 10 µg/
ml 5D2 antibody. Absolute numbers of viable DC were calculated by determining the ratio of 7AAD- DC to detected beads and then multiplying 
this ratio by the number of beads in the tube. Data is depicted as mean with SE, wilcoxon test for paired data * p < 0.05, NS = Not significant (p 
= 0.14), N=7)
C: Matured IVIg-DC (dotted line) or CTRL-DC (solid line) were cultured for 5 days with allogeneic T-cells and allogeneic NK cells from the same 
donor in the absence (left graph) or presence (right graph) of CD16-blocking antibody (5D2) (10 µg/ml). Addition of 5D2 restored, the capacity of 
IVIg-DC to stimulate allogeneic T-cells (N = 6, wilcoxon test for paired data, ** p< 0.01, * <0.05). 
D: Matured IVIg-DC (dotted line) or CTRL-DC (solid line) were cultured for 5 days with allogeneic T-cells alone (left graph), or with allogeneic T-cells 
and autologous NK cells (right graph). In the latter case DC and NK cells are from the same donor. In addition, DC was cultured with autologous NK 
cells and allogeneic T-cells and CD16-blocking antibody (5D2) (10 µg/ml) was added to the culture (right below graft). Addition of 5D2 restored 
the capacity of IVIg-DC to stimulate allogeneic T-cells (** p< 0.01, * <0.05, N=3).
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IgG multimers, and not monomers, cause ADCC of IVIg-DC by NK cells
Using the fully humanized and glycosylated monoclonal antibody Herceptin (HRC), which 
contains only the complementary determining regions of a murine mAb that binds to human 
epidermal growth factor receptor 2 22,23, we asked whether human IgG monomers were able 
to promote DC lysis by NK cells. Herceptin treatment of maturing DC (HRC-DC) did not increase 
NK cell activation and DC lysis in co-cultures of DC and NK cells. However, when Herceptin was 
aggregated at 63° C for 30 minutes, which induces the formation of IgG aggregates 24, matura-
tion of DC in presence of the aggregated form of Herceptin promoted DC lysis by NK cells, and 
induced NK-cell activation (Figure 6A and 6B). This observation suggests that the stimulation of 
the reciprocal interaction between DC and NK cells by IVIg is not mediated by IgG monomers 
present in the therapeutic IVIg preparations, but by IgG multimers and/or dimers.  
IVIg-DC promote expansion of NK cells and induce CD56brightCD16-CCR7+CXCR3+ lymph node 
type NK cells
We showed that IVIg-DC, when co-cultured with allogeneic T cells and NK cells, have a 
decreased T-cell stimulatory capacity, and that this effect is dependent on the presence of NK 
cells. Moreover, looking at the proliferation of NK cells in these cultures using CFSE-dilution, 
we observed that IVIg-DC did not only activate the NK cells, but also promoted their prolifera-
tion. When IVIg-DC were co-cultured with T and NK cells 88 ± 3 % of all CD56+ cells, 91 ± 3 % 
of CD56 bright cells and 86 ± 4 % of CD56 dim cells had undergone more than one round of 
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Figure 6: IgG multimers, and not monomers, cause ADCC of IVIg-DC by NK cells
A and B: Culture medium (CTRL), IVIg, and humanized monoclonal antibody Herceptin (HRC), were heated at 63° C for 30 minutes (grey bars) or 
left untreated (black bars) before addition to immature blood DC during their maturation with pro-inflammatory cytokines. IVIg and HRC were 
added to the DC in a concentration of 10 mg/ml. After 18 hours of maturation, all additions were removed, and allogeneic NK cells were added 
at ratio DC: NK 1:6. Percentages of 7AAD+ DC (A) and CD69 expression on NK cells (B) were determined after 18 and 48 hours of DC-NK co-culture 
respectively. (N = 4, * p < 0.05, wilcoxon test for paired data)
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Figure 7: IVIg-DC promote expansion of NK cells and induce CD56brightCD16-CCR7+CXCR3+ lymph node type NK cells
A: CTRL-DC (upper plots) or IVIg-DC (lower plots) were cultured with CFSE-labeled allogeneic T-cells and NK cells at the ratio DC: T: NK 1: 48: 12 
and after 5 days proliferation was determined. Dotplots: the two upper quadrants show proliferation of NK cells (CD56+CD3-), the two lower 
quadrants show proliferation of the T-cells (CD56-CD3+). Histograms: proliferation of all NK cells (left histogram), CD56bright (middle histogram) 
and CD56dim NK cells (right histogram). The plots are representative for one out of four experiments. Percentages indicate proportions of NK cells 
that have undergone at least one division.
B. After the 5 days culture of NK cells with IVIg-DC, NK cells were stimulated with PMA and ionomycine (2.5 ug/ml and 0.5 ug/ml) and CD107a 
expression on CD56+CD16+ and CD56+CD16- subsets was determined.
C: After 5 days of culture with CTLR-DC, IVIg-DC or HSA-DC, percentages of CD56bright NK cells, and percentages of NK cells expressing CD16, KIR 
receptors CD158a and CD158b, lymph node homing chemokine receptors CCR7 and CXCR3, and Natural  Cytotoxicity Receptors NKG2A and NKp30, 
were determined. NK cells cultured with IVIg-DC upregulated CCR7 and CXCR3, and downregulated CD16, the KIR receptors and NKp30 (N = 4, * 
p < 0.05 compared to NK cells co-cultured with CTRL-DC, student t test for paired data). The percentages of cells are displayed within reference to 
the baseline percentage of expression of the markers on the NK cells before addition to culture. No expression of CXCR3 on NK cells was detected 
at this time point.
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division, compared to CTRL-DC co-cultures where 48 ± 13 % of all CD56+ cells, 59 ± 5 % of 
CD56 bright cells and 35 ± 10 % of CD56 dim started to proliferate (p < 0.05 for comparison of 
the proliferation of CD56+ NK cells, CD56 bright cells and CD56 dim cells upon stimulation with 
IVIg-DC compared to CTRL-DC; N = 4; Figure 7A). Thus, while CTRL-DC stimulated proliferation 
of CD56bright NK cells more strongly than proliferation of CD56dim cells, IVIg-DC promoted 
similar expansion of  CD56bright and CD56dim NK cells. NK-cell proliferation was not observed in 
co-cultures of DC and NK cells without T cells, showing that T cells, although dispensable for NK 
activation, were indispensable for NK cell proliferation. To dissect differences in cytotoxicity, we 
harvested NK cells from the cultures, and determined CD107a expression on both CD56+CD16+ 
and CD56+CD16- NK cell subtypes upon PMA/ionomycine stimulation. Indeed, a difference in 
CD107a-expression between the two NK subtypes, gained after 5 days of culture with IVIg-DC 
and T-cells, was detected. The CD16+ subset express a higher level of CD107a than the CD16- NK 
cells after stimulation (Figure 7B). We concluded that, while IVIg enhances the proliferation of 
both subsets, their cytotoxic profile is unchanged.  
In addition, the 5 days co-cultures of NK cells with IVIg-DC and T cells resulted in higher 
proportions of CD56bright NK cells in comparison with CTRL-DC. After cultures of CTRL-DC with 
T and NK cells, 5.4 ± 2 % of CD56+ cells were CD56bright , while upon cultures with IVIg-DC, 10.1 
± 2 % of the CD56+ cells were CD56bright  (Figure 7C). Moreover, upon stimulation with IVIg-DC 
higher percentages of NK cells expressed the lymph node homing chemokine receptors CCR7 
and CXCR3. Furthermore, NKp30, which is reported to be one of receptors involved in DC-NK cell 
interaction 25, was down-regulated when NK cells were co-cultured with IVIg-DC. The expres-
sion of CD16 and of the KIR-receptors, CD158a and CD158b, on NK cells was also reduced when 
NK cells are cultured with IVIg-DC and T cells. Together, these results show that in presence of T 
cells, IVIg-DC stimulated vigorous proliferation of NK cells, and promoted immunophenotypic 
changes resulting in an enrichment of CD56brightCD16-CCR7+ CXCR3+ lymph node type NK cells. 
dISCuSSION
The present study unravels the main mechanism of action by which IVIg hamper the process of 
T-cell priming by DC, i.e. by inducing Antibody Dependent Cellular Cytotoxicity (ADCC) of IVIg-
treated DC by NK cells. By binding to the DC surface, IVIg facilitate recognition of mature DC 
by NK cells via FcγRIII, resulting in activation of the NK cells. These NK cells acquire the capacity 
to kill the IVIg-DC by ADCC, thereby reducing in numbers the total stimulatory pool of mature 
DC. Interestingly, multimers, but not monomers of human monoclonal IgG, could recapitulate 
the effects of IVIg in our culture systems, suggesting that IgG multimers and/or dimers in IVIg 
preparations are the active components that induce NK-cell activation and DC lysis. In addition, 
IVIg-DC stimulate the proliferation of NK cells and induce CD56bright NK cells with lymph node 
homing properties, which can further shape the adaptive immune response.
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Clinically, IVIg have been shown to be effective for the treatment of a variety of immune-
mediated inflammatory diseases 1, but still its actual mode of action on the cellular components 
of the human immune system remains unclear. We showed that by modulating the interaction 
between two cell types of innate immune system, i.e. DC and NK cells, IVIg can affect the devel-
opment of the linked adaptive immune response. 
First, we demonstrated that IVIg bind to the surface of maturing DC. By using a blocking 
mAb for FcγRIII, we demonstrated that ADCC of IVIg-DC occurs due to binding of the Fc-region 
of cell-bound IgG to FcγRIII on NK cells. More specifically, since humanized monoclonal anti-
body multimers, but not monomers, could recapitulate the effects of IVIg on DC-NK interaction, 
death of DC is induced upon recognition of DC-bound IgG multimers by FcγRIII on NK cells. 
Indeed, binding of immune complexes to FcγRIII has been reported to induce target cell lysis 
by NK cells, through activation via an immunoreceptor tyrosine based activation motif 26. CD69 
is an early marker for NK cell activation, and was enhanced profoundly when NK cells were 
cultured with IVIg-DC. IVIg treatment of NK cells alone was not able to induce the same level of 
activation of NK cells. Although also the matured CTRL-DC alone were able to activate NK cells to 
some extent, which is in agreement with numerous reports 12,14,27,28, only NK activated by IVIg-
DC secreted substantial amounts of IFN-γ, and degranulated their cytotoxic granules. Therefore, 
both IVIg and DC were needed for full NK-cell activation. NK-cell activation and degranulation 
resulted in killing of the majority of DC matured in presence of IVIg, which could be largely 
abrogated by FcγRIII blockade. Therefore killing of IVIg-DC is predominantly attributable to 
ADCC mediated by activated NK cells. Since death of IVIg-DC was not completely abrogated 
by CD16-blockade, additional cytotoxic mechanisms may contribute to the profound killing 
of IVIg-DC in the presence of NK cells, e.g. cytotoxic effect of IFN-γ produced by the NK cells 29.
So far to our knowledge, this phenomenon has not been described as one of the potential 
modes of action of IVIg on the cellular immune system. Supporting our finding, administration 
of high doses of IVIg in patients with Kawasaki disease has been reported to increase the num-
bers of circulating NK cells, and to elevate ADCC activity of NK cells 30. However, this does not 
exclude that also other mechanisms may contribute to the impaired T-cell stimulatory capacity 
of IVIg-treated DC. In a previous study we observed that IVIg-treated blood DC, when cultured 
with T and NK cells, were suppressed in their up-regulation of co-stimulatory molecules CD40 
and CD80 9. In addition, IVIg have been shown to suppress differentiation of human monocytes 
to DC, and to inhibit maturation of monocyte-derived DC 8. Moreover, IVIg have been shown 
to induce regulatory activity in murine DC via activating Fcγ-receptors 10. However, according 
to the dramatic effect of CD16 blockade on the T-cell stimulatory capacity of IVIg-DC (Figure 5C 
and 5D), we reckon that NK-mediated DC killing is the most important mechanism of action by 
which IVIg reduces the T-cell stimulatory capacity of DC.
In vivo NK cells interact with DC in lymph nodes and in inflamed peripheral tissues 13,31-35, 
and the conditions in which DC and NK cells encounter can determine the following T-cell 
responses 12-14. Equipped to perform “DC editing”, NK cells can induce killing of immature DC, 
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that fail to undergo proper maturation. Since mature DC are resistant to lysis by NK cells, this 
is believed to provide help to create fully potent adaptive responses 32,36. However, while per-
forming their DC editing task, NK cells may, upon IVIg therapy, also recognize the mature IVIg-
DC as a target cell, as it is fully coated with IgG. In this case, the NK cell may kill the IVIg-coated 
mature DC, and thereby reduce the pool of immunogenic antigen presenting cells migrating 
from inflamed tissue to the lymph node, or present in the lymph node, and thereby dampen 
the following T-cell responses. 
It is intriguing, that our own IgG exerts predominantly pro-inflammatory properties, e.g. as 
inducer of complement- or cell-mediated cytotoxicity, while high-dose therapeutic IgG treat-
ment has anti-inflammatory effects. Our finding that humanized monoclonal IgG only caused 
NK-cell mediated ADCC of DC after heat-aggregation, may elucidate this discrepancy. We 
propose that the active anti-inflammatory components in IVIg are IgG-multimers and dimers, 
which are not present in human serum from one individual, but are formed in plasma pools due 
to idiotype-anti-idiotype complex formation between IgG molecules from different individuals 
3,4. This hypothesis is supported by studies that described IgG polymers in commercial IVIg 
preparations to be the active component in various immune mediated disease models 4,37. 
In addition, during normal physiological immune responses, IgG immune complexes can be 
formed, which may also stimulate NK-cell mediated lysis of DC, and thereby inhibiting T-cell 
activation. In the line of this thinking, accumulating evidence supports an immune regulatory 
role of immune complexes in physiological immune responses. In two different IVIg-treatable 
autoimmune disease models in rodents, i.e. ITP and arthritis, Siragam et al. demonstrated that 
both small soluble and large particulate immune complexes can mimic the therapeutic effects 
of IVIg treatment 38. Recently, it was shown that IgG immune complexes induce an IFN-γ refrac-
tory state in macrophages via binding to FcγRIII on their surface, thereby providing a potential 
mechanism for the immunosuppressive effects of immune complexes in IFN-γ driven inflam-
matory responses 39. 
Human CD56brightCD16- NK cells (NKbright) and CD56dimCD16+ NK cells (NKdim) are reported 
to have distinct functions. The NKdim subset exhibits primarily a cytotoxic effector function, 
whereas NKbright cells can produce immunoregulatory cytokines such as IFN-γ, tumor necrosis 
factor β (TNF-β), IL10, IL13 and GM-CSF 40,41. Surprisingly, IVIg-DC stimulated immunopheno-
typic changes in NK cells resulting in an increased proportion of NKbright cells, with reduced 
expression of CD16, NKp30 and the KIR receptors, CD158a and CD158b, and enhanced expres-
sion of the chemokine receptors CCR7 and CXCR3, which can mediate NK-cell migration to 
secondary lymphoid organs 31,42,43. Together, these immunophenotypic changes confirm the 
induction of lymph node type NK cells 31,44,45. To date the mechanism of action by which IVIg-
DC promote enrichment of the NKbright population is not understood. Since IVIg-DC stimulate 
proliferation of NKdim and NKbright cells to a similar extent, the enrichment of NKbright cells is not 
due to differential expansion. Most likely, it is due to differentiation from NKdim cells. NKbright 
cells maintain interactions with DC in lymph nodes for extended periods, are not cytotoxic, but 
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have immunomodulatory functions 13,34,46. Induction of NKbright cells may, therefore, constitute 
a mechanism of action by which immunomodulatory effects of IVIg treatment remain after IVIg 
have been cleared. 
Therefore, we speculate that in vivo IVIg treatment exerts its effect on cellular immunity by 
affecting NK-DC crosstalk. An immediate immunosuppressive effect is caused by promoting 
the interaction between cytotoxic NKdim cells and DC resulting in killing of mature DC. This 
is expected to occur mainly in inflamed non-lymphoid tissues 35. Recent evidence confirms 
that NK cells can prevent immune activation in vivo. NK cells regulated T-cell priming in a skin 
transplant model by killing donor antigen presenting cells 47, and NK-cell alloreactivity after 
hematopoietic stem cell transplantation from unrelated donors is associated with decreased 
incidence of Graft-versus-Host Disease 48,49.
In the light of our findings, we propose a model to clarify how administration of IVIg may 
dampen hyperactivity of the cellular immune system for extended periods. IgG multimers 
and dimers present in IVIg preparations stimulate NK cell mediated ADCC of mature DC, and 
thereby prevent proper T-cell priming. This model has also physiological relevance, in that it 
predicts that immunoglobulin-antigen immune complexes may contribute to the termination 
of the T-cell responses during clearance of infections and to maintain tolerance to self-antigens. 
As immune complexes emerge at the end of the humoral responses, physiological immune 
complexes as well as immune complexes in IVIg preparations may be the essential element 
that contributes to the termination or “cooling down” of the immune system after prolonged 
activation.
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SuMMaRY
Natural killer (NK) cells have the potential to display different functional activities after trans-
plantation.  The traditional view is that NK cells have the capacity to contribute to rejection by 
facilitating the activation/differentiation of leukocytes that destroy the graft.  In contrast, in the 
manuscript under review a novel role for NK cells was identified in the setting of co-stimulation 
blockade where alloreactive NK cells of recipient origin were found to have the capacity to kill 
donor derived antigen presenting cells (APC), thereby reducing T cell priming and promoting 
long term skin graft acceptance.
Functional Dichotomy of NK cells 99
INTROduCTION
A major challenge in transplantation immunology is to modulate the functional activity of dif-
ferent types of leukocytes, both to prevent allograft rejection and to promote the development 
of unresponsiveness/tolerance to the allograft. Immune cells, such as dendritic cells (DC) and T 
cells, can either be modified to express a regulatory phenotype or subsets of cells with regula-
tory activity can be identified. These regulatory populations can control or regulate rejection 
and, in some experimental models, induce long term graft acceptance.  The investigation under 
review explored the role of Natural killer cells (NK cells) in regulating T cell priming by donor 
antigen presenting DC in a skin transplant model 1.
Recently, an increasing number of reports have suggested that the role of NK cells after 
transplantation is not as straight forward as was once thought. The traditional view is that 
NK cells are predominantly pro-inflammatory and are not sufficient to reject a solid allograft 
directly, but may contribute to early chemokine and cytokine production after transplantation 
supporting the rejection response. In liver transplantation, the presence of NK cells has been 
shown to exacerbate rejection 2, and in a chronic rejection model NK cells can trigger allograft 
vasculopathy in T cell deficient recipients, but only after receiving adoptively transferred CD4+ 
T cells 3.
In contrast, NK cells have been implicated as playing a role in the induction of tolerance 
to organ allografts 1,4, while in hematopoietic stem cell transplantation (HSCT) the presence 
of NK cell alloreactivity in the graft-versus-host direction has been associated with a reduced 
incidence of leukemia relapse without causing graft-versus-host disease (GVHD) 5. Due to this 
functional dichotomy in the potential functional activities of NK cells, interest in understanding 
more precisely the interaction between antigen presenting cells (APC), NK cells and T cells in 
more detail to elucidate their role in responses to alloantigens has been stimulated. 
The challenge, unique for transplantation, is the allogeneic mismatch between donor and 
recipient. When major histocompatibility complex antigens are mismatched, donor derived 
APC can migrate from the graft and initiate T cell mediated rejection via the direct pathway of 
allorecognition. NK cell alloreactivity derives from a mismatch between inhibitory receptors 
for self-major histocompatibility complex (MHC) class I molecules expressed by the NK cells 
and the MHC class I ligands on the APC.  In humans, killer cell Ig-like receptors (KIRs) on NK 
cells discriminate between self and non-self HLA class I molecules, and in rodents the diverse 
repertoires of Ly49 receptors recognize groups of MHC class I.  Without prior antigen priming, 
NK cells sense the missing expression of the self-MHC class I alleles on the allogeneic target, and 
are activated (missing self recognition) 6.
The investigation reported in the manuscript under review identified a novel role for NK cells 
by demonstrating that they can influence the survival of donor derived APC, and thereby regu-
late T cell priming 1.  The data presented demonstrate that by killing donor derived dendritic 
cells thus NK cells can prevent rather than stimulate, rejection.
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METhOdS aNd RESulTS
Full-thickness skin grafts from DBA/2 (H2d) mice were transplanted to C57BL/6 (H2b) Rag-/- and 
C57BL/6 (H2b) (Rag-/- common γc-/-; Rag-/-γc-/-) double knockout mice. T cells and B cells are 
absent in both types of recipient used in the study as a result of the Rag mutation. Rag-/-γc-/- 
mice are also deficient for NK cells.  
The first observation reported in the manuscript demonstrated that the presence of NK 
cells prevented the survival of skin graft derived APC.  This suggested that NK cells present 
in the recipient could kill donor APC. Thirty days after transplantation of a DBA/2 skin graft to 
Rag-/- recipients, no donor APC were detected in the spleen, while in Rag-/-γc-/- mice that have 
no NK cells, APC of donor origin could still be detected.  When (DBA/2xB6)F1 DC were purified 
and adoptively transferred into Rag-/-, these DC survived even though NK cells were present. 
The (DBA/2xB6)F1 DC express both donor (H2b) and recipient (H2d) alloantigens and therefore 
express the self-MHC class I allele that can interact with the H2b-specific Ly49C/I inhibitory 
receptor on recipients NK cells inhibiting NK cell activation.  
It is important to note that NK alloreactivity in solid organ transplantation varies to some 
extent from the situation that arises after allogeneic haematopoietic stem cell (HSC) trans-
plantation.  After HSC transplantation, alloreactive NK cells, emerging from the donor stem 
cell graft, can control leukemia relapse and GvHD due to the graft-versus-leukemia effect and 
graft-versus-recipients-APC effect respectively 5.  In the setting of organ transplantation, the 
role of recipient derived NK alloreactivity against donor-graft derived APC is probably more 
prominent, since the percentage of donor NK cells migrating out of the graft, which can cause 
alloreactions to recipient APC, is minimal.  (Figure 1)  Second, NK cells are fully capable of reject-
ing HSC even in absence of T or B cells, while after solid allograft transplantation NK cells are 
thought to have a minor role in acute rejection, facilitating rejection by alloreactive T cells, but 
not playing a critical role.
Next, to determine if NK alloreactivity to graft derived APC affected T cell priming, DBA/2 
DC were purified and transferred in to Rag-/- and Rag-/-γc-/- . Two weeks later, the recipient mice 
were reconstituted with CFSE-labelled syngeneic C57BL/6 (H2b) T cells.  Vigorous T cell prolifera-
tion was detected in the spleen and extralymphoid sites in Rag -/-γc-/-, but not in Rag-/- mice.  
Furthermore, the authors studied the effect of triple costimulation blockade comprising 
treatment with CTLA-4Ig, anti-CD154 and anti-OX40L, on T cell activation and skin graft survival 
in the presence and absence of NK cells.  Depletion of NK cells from the recipient mice using 
a depleting anti-NK1.1 mAb rendered the triple costimulation blockade treatment completely 
ineffective at preventing the rejection response. All recipients depleted of NK cells and treated 
with triple costimulation blockade rejected their DBA/2 skin graft with a mean survival time of 
22 days, compared to survival of >100 days when NK cells were present. The intriguing question 
is: How NK cells influence the efficacy of triple costimulation blockade?
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To demonstrate that the requirement for NK cells to enable skin allograft survival is confined 
to MHC mismatched organ transplants, the authors transplanted both MHC mismatched 
DBA/2 (H2d) and minor mismatch 129/svJ (H2b) skin allografts on to the same C57BL/6 (H2b) 
recipients with or without triple costimulation blockade treatment.  When recipient NK cells 
were depleted, DBA/2 skin was again rejected promptly, while survival of the 129/svJ skin was 
not affected.  By examining the survival of the two different grafts in the same recipient, the 
authors showed convincingly that the recipient derived alloreactive NK cells can indeed affect 
the process of T cell priming during tolerance induction through costimulation blockade.
Discussion and significance
The paper under review highlights the importance of DC and NK cells interaction after organ 
transplantation. Interactions between DC and NK cells have been documented in a variety of 
settings previously, elucidating the complexity of the bi-directional interaction between these 
two cell types.  Bajenoff et al. showed that NK cells are present in the medulla and the paracor-
tex of lymph nodes, where they closely interact with DC 7. Cross-talk between DC and NK cells 
can result in lysis, inhibition or maturation of DC by NK cells, and reciprocally, DC can activate 
or inhibit NK cells. The final outcome of DC-NK cell interaction depends on the conditions in 
which the encounter between the two cell types takes place, and it will subsequently direct the 
development of the adaptive immune response. 
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Figure 1: Differences between HSC transplantation and solid organ transplantation regarding NK cell alloreactivity
After solid organ transplantation, the percentage of donor NK cells migrating out of the graft, which can cause alloreactions to recipient APC, is 
minimal.  While after HSC transplantation, alloreactive NK cells, emerging from the donor stem cell graft can kill leukemic cells and host APC.
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between the inhibitory receptors expressed by NK cells that recognise self-MHC class I mo lecules 
and the MHC class I ligands expressed by donor-derived APC. NK inhibitory killer cell Ig-like 
receptors (KIRs) discriminate between groups of HLA class I molecules. KIR2DL1 recognizes 
HLA-C alleles characterized by the lysine residue at position 80 (HLA-Cw4 and related group 2 
alleles), whereas KIR2DL2 and KIR2DL3 recognize HLA-C that have an asparagine residue at this 
position (HLA-Cw3 and related group 1 alleles).  KIR3DL1 is the receptor for HLA-Bw4 alleles. 
(Figure 2) NK cells that do not express KIRs express the CD94/NKG2A receptor instead. These 
NK cells generally do not display alloreactivity and recognize the poorly polymorphic HLA-E 
molecules 8. Most individuals possess a full complement of inhibitory KIRs.  The KIR2DL2 and 
KIR2DL3 receptors are present in all individuals, while the KIR2DL1 receptor for HLA-C group 2 
and the KIR3DL1 receptor are found in approximately 97% and 90% of individuals respectively. 
Therefore, only a small percentage of the population has a limited NK cell KIR receptor reper-
toire, and cannot mount NK alloreactions due to the specific KIR that is missing (reviewed in 9). 
NK cells are highly cytotoxic to target cells, however, evidence for NK cell mediated cytotoxicity 
to the parenchymal cells present in the graft itself is marginal.  Therefore, it is assumed that NK 
alloreactivity may be restricted to lymphohematopoietic targets, such as APC. (Figure 2)
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Figure 2: NK cell alloreactivity between donor APC and recipients NK cells
The KIR2DL2/3+ NK cell can not detect its ligand HLA-C (group 1) on the donor APC and according to the missing self hypothesis, this KIR2DL2/3+ 
NK cell will get activated and kill the donor APC. The table illustrate the variety of human inhibitory NK cell receptor and its ligand. The table is 
adapted from 8
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One outstanding question from the data presented is whether killing of donor-derived APC 
in skin graft recipients treated with triple costimulation blockade, is entirely attributable to NK 
allorecognition and activation. NK cells also express Fcγ receptor III (CD16), which recognizes 
IgG1 and IgG3 subclasses.  It is well established that NK cells can cause destruction of antibody 
coated target cell through antibody-dependent cell-mediated cytotoxicity (ADCC).  Each com-
ponent of the triple co-stimulation blockade treatment, anti-CD154, CTLA-4Ig and anti-OX40L 
has an Fc region and can bind to either the T cell or APC, and thus has the potential render 
the cells susceptible to ADCC killing by NK cells.  Thus, it is quite possible that at least part of 
the explanation for the long-term graft survival of the skin grafts induced by peri-transplant 
CTLA4-Ig + anti-CD154 + anti OX40L therapy, is that NK cells mediate ADCC, and thus, deplete 
both donor APC and recipient T cells.  Given the fact that CD154 on T cells is induced upon T cell 
activation, it is possible that this ADCC mediated by NK cells is relatively selective for those cells 
responding to alloantigen. (Figure 3) This hypothesis is entirely consistent with the data shown 
in Figure 4A in the manuscript since it is predicted that in the absence of NK cells, costimulation 
blockade would be ineffective.
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MHC II TCR
CD80/86 CD28/CTLA4
CD40 CD154
Recipient
T cell
OX40 L OX 40
Recipient NK
CD16
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Figure 3: The triple costimulation blockade treatment can render susceptibility of DC and T cells to ADCC killing by NK cells.  
By using peri-transplant CTLA4-Ig + anti-CD154 + anti OX40L therapy, the NK cells can mediate ADCC as the CD16 (FcγRIII) on NK cells can bind 
to the Fc region of the anti-CD154, anti OX40L antibody or CTLA-4 Ig as indicated by arrows. Thus, the NK cells can deplete both donor APC and 
recipient T cells by release of granzymes, and therefore NK cell mediated ADCC can be at least part of the explanation for the long-term graft 
survival of the skin grafts shown in the paper under review.
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Supporting this hypothesis is the finding that costimulation blockade through CD154 spe-
cific antibody is reported to be mediated by Fc-dependent depletion of activated T cells rather 
than costimulation blockade itself 10. However, for the survival of minor mismatched grafts, NK 
cells are not needed. This speculates that ADCC by NK cells will probably not be the only path-
way in operation to induce graft acceptance. Costimulation blockade, itself may just prevent T 
cell priming by APC and induce graft acceptance. However, this does not exclude the possibility 
that ADCC can play a role when the skin grafts are mismatched for MHC antigens. Possibly, a 
combination of costimulation blockade and ADCC by NK cells is exerting such pronounced 
effect on graft tolerance, when the role of NK cell is studied.
Another interesting question would be, whether antigen specific regulatory T cells can be 
generated when the process of T cell priming is inhibited by NK cell mediated killing of the 
donor APC. As regulatory T cells can actively promote long term graft acceptance, it is interest-
ing to know whether T cells with regulatory function can be generated in this model.  
Expert commentary
NK cell alloreactivity against APC, both in host-versus-graft and graft-versus-host responses, is 
important and unique for the field of transplantation. Recipient NK cells have the potential to 
kill graft-derived APC, thereby inhibiting the process of T cell priming via the direct pathway of 
allorecognition. In addition, the indirect pathway may also be triggered, when NK cells derived 
from the transplant exert cytotoxicity against the APC of the recipient. The latter is less signifi-
cant for small grafts, however, for liver grafts where large numbers of viable donor lymphocytes 
migrate into the recipient after transplantation, NK alloreactivity in the graft-versus-host direc-
tion could become important.  In support of this idea, the characteristics of liver-associated 
lymphocytes in liver perfusates are predominantly activated NK cells and CD8+ T cells 11.  In 
this case, NK cells of donor origin may interact with recipient APC, thereby inhibiting antigen 
presentation by the indirect pathway of allorecognition.
In the light of findings reported in this paper, immunosuppressive therapies that enhance 
NK cell survival and activity may facilitate the induction of tolerance to donor alloantigens by 
killing donor-derived APC after transplantation. Moreover, the data presented suggest that 
the addition of agents that enhance NK cell function may be of value. So far, current clinical 
immunosuppressive agents, such as cyclosporine, tacrolimus, mycophenolate mofetil and 
azathioprine, have little effect on NK cell function (reviewed in 12). 
In contrast to conventional thinking, it is important to note that NK cells can be “the good” or 
“the bad” in different settings after organ transplantation and as yet, the role of NK cell subtypes 
is not well understood. 
Human CD56brightCD16- NK cells (NKbright) and CD56dimCD16+ NK cells (NKdim) are reported 
to have distinct functions. The NKdim subset exhibits primarily a cytotoxic effector function, 
whereas NKbright cells can produce immunoregulatory cytokines such as IFN-γ, tumor necrosis 
factor β (TNF-β), IL-10, IL-13 and GM-CSF 8. In addition, NK cells are innate immune effector 
Functional Dichotomy of NK cells 105
cells expressing stimulatory receptors, such as NKG2D and NKp46, which recognize antigens 
on virus infected cells and tumour cells, while sparing normal cells. In immunocompromised 
transplant patients, it is essential to try and maintain these useful functions of NK cells on the 
one hand, while on the other the effects of immunosuppressive therapies on NK cell function 
should considered.
Key issues
•	 Natural	killer	cells	(NK	cells)	can	display	different	functional	activities	after	transplantation.
•	 	The	role	of	NK	cell	alloreactivity	after	solid	organ	transplantation	and	after	haematopoietic	
stem cell transplantation varies in some extent. 
•	 	In	 the	 setting	of	 costimulation	blockade,	NK	 cells	 of	 the	 recipient	 can	 kill	 donor	derived	
antigen presenting cells (APC), thereby reducing T cell priming.
•	 	Antibody-dependent	cell-mediated	cytotoxicity	(ADCC)	killing	of	APC	mediated	by	NK	cells	
may be a pathway to induce graft acceptance by costimulation blockade.
•	 	Immunosuppressive	therapies	that	enhance	NK	cell	activity	may	facilitate	the	induction	of	
transplant tolerance.
Ch
ap
te
r 6
106
REfERENCES
 1. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-
presenting cells. J Exp Med. 2006;203:1851-1858.
 2. Obara H, Nagasaki K, Hsieh CL, et al. IFN-gamma, produced by NK cells that infi ltrate liver allografts 
early after transplantation, links the innate and adaptive immune responses. Am J Transplant. 
2005;5:2094-2103.
 3. Uehara S, Chase CM, Kitchens WH, et al. NK cells can trigger allograft vasculopathy: the role of hybrid 
resistance in solid organ allografts. J Immunol. 2005;175:3424-3430.
 4. Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a perforin-
dependent mechanism. Nat Med. 2005;11:1059-1065.
 5. Ruggeri L, Capanni M, Urbani E, et al. Eff ectiveness of donor natural killer cell alloreactivity in mis-
matched hematopoietic transplants. Science. 2002;295:2097-2100.
 6. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
 7. Bajenoff  M, Breart B, Huang AY, et al. Natural killer cell behavior in lymph nodes revealed by static and 
real-time imaging. J Exp Med. 2006;203:619-631.
 8. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20:123-
137.
 9. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer 
cell recognition of missing self. Immunol Rev. 2006;214:202-218.
 10. Monk NJ, Hargreaves RE, Marsh JE, et al. Fc-dependent depletion of activated T cells occurs through 
CD40L-specifi c antibody rather than costimulation blockade. Nat Med. 2003;9:1275-1280.
 11. Jonsson JR, Hogan PG, Balderson GA, et al. Human liver transplant perfusate: an abundant source of 
donor liver-associated leukocytes. Hepatology. 1997;26:1111-1114.
 12. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS, Madsen JC. The changing role of natural killer 
cells in solid organ rejection and tolerance. Transplantation. 2006;81:811-817.
Chap ter 7
Intravenous Immunoglobulins trigger 
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mouse CD4+CD25+Foxp3+ T cells and 
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SuMMaRY
Intravenous Immunoglobulins (IVIg) therapy is effective as a treatment for T cell mediated 
immune diseases, but how IVIg suppress T cell responses is largely unknown. In this study, we 
investigated whether IVIg enhance the suppressive function of CD4+CD25+Foxp3+ regulatory 
T cells, and if so, whether IVIg could prevent allograft rejection. We demonstrate that IVIg bind to 
both human and mouse regulatory T cells. In both human and mouse, IVIg treatment enhances 
the activation of CD4+CD25+Foxp3+ regulatory T cells (Tregs), as detected by increased 
expression of surface activation markers and ZAP70 phosphorylation. Pre-incubation of human 
CD4+CD25+ T cells with IVIg enhanced their ability to suppress allogeneic T cell proliferation, 
while depletion of human CD25+ T cells resulted in a twofold reduction in IVIg mediated 
suppression of allogeneic T cell proliferation. In vivo, administration of IVIg prevented T cell 
mediated rejection of fully mismatched skin grafts in immunodeficient mice reconstituted with 
total CD4+ T cells.  Importantly, this IVIg effect was lost when CD4+CD25+ cells were depleted 
from transferred T cells, indicating that IVIg activation induces dominant allograft protection 
mediated by Tregs. Our data show that IVIg suppress allogeneic T cell responses by direct bind-
ing and activation of Tregs, high-lighting an additional immunomodulatory property of IVIg. 
Importantly, the data underline that the therapeutic potential for IVIg may be broader than the 
current application in organ transplantation.
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INTROduCTION
Intravenous Immunoglobulins (IVIg) are therapeutic preparations of human IgG purified 
from large donor plasma pools that contain a broad spectrum of natural antibodies and are 
widely used for the treatment of autoimmunity and inflammation.  The mechanisms of action 
of IVIg are multifaceted and complex, involving interactions with several components of the 
human immune system 1. Clinically, the beneficial effects of IVIg extend beyond the half-life 
of infused IgG. Therefore, its effects cannot merely be a result of a enhanced passive clear-
ance of pathogenic antibodies or competition with their binding to Fcγ receptors (FcγR), but 
probably involve changes in cellular immunity. In addition, in past decades clinical evidence 
has emerged that IVIg  are effective in the treatment of T cell mediated autoimmune diseases 
2,3, and that hyperimmune IVIg can protect against T cell mediated graft rejection after liver 
transplantation 4. In vitro, IVIg can inhibit human T cell proliferation and cytokine production 5,6, 
but the mechanisms by which IVIg attenuate T cell responses are not fully elucidated.
Regulatory T cells (Tregs) expressing the lineage marker Foxp3 are considered to be the “central 
immune regulator” of numerous immune processes 7. Due to their versatility and adaptability, 
Tregs can police the immune system and control a wide-range of immune responses 8. Tregs 
have been demonstrated to be involved in controlling autoimmunity, inflammation and 
anti-tumor responses. In addition, Tregs play a critical role in the induction and maintenance 
of transplantation tolerance in experimental animal models 9,10. The suppressive activity of 
Tregs requires prior activation through the T cell receptor (TCR), but once activated, Tregs can 
suppress in an antigen non-specific manner referred to as “bystander regulation” 11,12. Due to 
the limited number of Tregs in vivo and their need for prior activation to become suppressive, 
successful application of Tregs in prevention of allograft rejection requires ex vivo or in vivo 
stimulation and expansion 13. 
Several compounds have been identified that stimulate the expansion and/or the suppressive 
capacity of Tregs.  For example, rapamycine has been shown to stimulate the activity of Tregs 
and their survival in vitro 14-17 and in vivo in patients 18. In addition, therapeutic antibodies 
such as anti-CD4 mAb and rabbit anti-thymocyte globulin (rATG) can enhance the activation 
status and the expansion of CD4+CD25+Foxp3+ cells 19-21. Although all these compounds are 
suited for in vitro expansion and stimulation of Tregs, their use to activate Tregs in vivo may 
be accompanied by severe side effects upon administration to patients. Recently, Ephrem 
et al. reported that IVIg treatment protects against disease in an experimental autoimmune 
encephalomyelitis (EAE) model by promoting expansion and enhancing the suppressive capa-
city of murine CD4+CD25+Foxp3+ Tregs 22. Activation of Tregs in vivo by IVIg treatment may 
be an attractive option for prophylaxis of transplant rejection, since IVIg administration is safe 
and has moderate side effects. However, the mechanisms through which IVIg exert their effect 
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on Tregs, and whether IVIg treatment alone, can influence acute allograft rejection, are largely 
unknown. 
In this study, we have investigated the direct interaction of IVIg with human and mouse Tregs, 
and determined the effects of IVIg on their activation and regulatory function both in vitro 
and in vivo. Our observations provide an immunological insight into the mechanisms of IVIg 
and clarify how IVIg may control T-cell mediated immune responses in diseases involving T-cell 
hyperactivity .
MaTERIalS aNd METhOdS
IVIg preparations
Human IVIg (Intratect®) were a kind gift from Biotest Pharma (Dreieich, Germany). IVIg prepara-
tions were dialyzed against large volumes of culture medium (RPMI) at 4°C using Slide-A-lyzer® 
gamma irradiated dialysis cassettes (Pierce, Rockford, USA) to remove stabilizing agents and to 
obtain a neutral pH prior to use in vitro. In all in vitro experiments IVIg was used at a concentration 
of 10 mg/ml (0.06M), to correspond with reported serum IgG concentrations in patients treated 
with IVIg at 1-2 g/kg for autoimmune disorders 23-25. Biotinylation of IVIg was performed using 
D-biotinoyl-є-aminocaproic Acid N-hydroxysuccinimide ester (Roche Diagnostics, Indianapolis) 
according to manufacturer’s instructions. To control for the elevated protein concentration in 
the in vitro cultures, Human Serum Albumin (HSA) (Sanquin, Amsterdam, The Netherlands) was 
used as a negative control.
Mice
CBA.Ca (CBA, H2k), C57BL/10 (B10, H2b) and CBA-recombination-activating gene 1 knockout 
mice (CBA-Rag -/-, H2k; kindly provided by Dr D. Kioussis, Division of Molecular Immunology, 
National Institute for Medical Research, Mill Hill, London, UK) were obtained and housed in the 
Biomedical Services Unit, John Radcliffe Hospital (Oxford, UK). Sex matched mice between 8 
and 12 weeks of age at the time of first experimental procedure were used in all experiments.
Flowcytometry and monoclonal antibodies
In human in vitro experiments, the following monoclonal antibodies were used for flowcyto-
metry: CD4 PerCP-Cy5.5, CD25 PE-Cy7, HLA-DR PE, CD32 FITC, CD45RO PE, CD64-biotin (all from 
BD Biosciences, CA, USA), FoxP3 APC (eBiosciences, CA, USA), CD16 FITC, CD38 PE and CD69 PE 
(all from Beckman Coulter). 
The following reagents were used in mouse experiments for flowcytometry and cell isola-
tion: YTS 169 (anti-CD8, hybridoma kindly provided by Prof. H. Waldmann, Sir William Dunn 
School of Pathology, Oxford, UK), TIB120 (anti- class II), M1/70 (anti - CD11b) and RA3.6B2 
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(anti-B220) were from the American Type Culture Collection, Manassas, VA. CD4 PerCp and 
Foxp3 APC were from eBioscience. CD16/32 FITC or PE, CD16/32 blocking antibody, CD64 PE, 
CD25 PE, CD25 FITC, CD44 PE, goat anti human IgG-bio and anti-TCRβ mAb were all from BD 
Biosciences, Oxford, UK.
To detect binding of IVIg to T cells, biotinylated IVIg and strepavidin-PE (Caltag,  Burlingame), 
biotinylated goat-anti human IgG and strepavidin-PE, or rabbit F(ab’)2 anti-human IgG-FITC 
(DAKO Cytomation, Denmark) were used. 
Flow cytometry was performed using either FACSCanto or FACSscan instruments (BD Biosci-
ences).
Cell isolation
Human PBMC were obtained from fresh heparinized blood of healthy individuals. After Ficoll 
(Ficoll-Paque plus, Pharmacia, UK) density gradient separation, CD4+ T cells were purified 
by negative selection using the untouched CD4 isolation kit (Miltenyi Biotec, Germany). 
CD4+CD25+ T cells (typical purity >90%) were isolated by positive selection from CD4+ T 
cells using anti-CD25-microbeads (Miltenyi Biotec) 26. The CD4+CD25- fraction, containing 0.7 
± 0.5% CD4+Foxp3+ cells, was collected and used as a responder population. The isolations 
were performed according to manufacturer’s instructions. Spleen antigen presenting cells 
(APC) enriched by immunomagnetic depletion of T cells and NK cells from human spleen tissue 
obtained from a multi-allograft donor, were used as stimulators 5. 
Mouse CD4+ cells were isolated from splenocytes of naive CBA mice by positive selection 
using anti-mouse CD4-microbeads (Miltenyi Biotec, Germany). The purity of CD4+ T cell frac-
tion  was > 95%. CD4+CD25- T cells were obtained by enrichment of CD4+ cells using YTS 169, 
TIB120, B220 and M1/70 rat mAb to deplete CD8+, MHC class II+ cells, B cells and macrophages, 
respectively and depletion with sheep anti-rat IgG coated Dynabeads (Dynal Biotech, Norway) 
followed by depletion of CD25+ cells using anti-mouse CD25-PE and anti-PE beads (Miltenyi 
Biotec, Germany). The percentage of CD4+Foxp3+ cells in the CD4+CD25- fraction was below 
0.5 %.
Bone marrow-derived DC (BMDC) from C57BL/10 mice were generated according to a 
published method 27. DC precursor enriched BM cells were cultured with 20 ng/ml rmGM-CSF 
(PeproTech, London, UK). At day 6, DC were harvested, washed and counted prior to use.
Mixed lymphocyte reactions
In all in vitro experiments with human cells, cells were cultured in RPMI 1640 supplemented with 
penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% FCS (Hyclone, UT, USA). To determine 
to what extent IVIg inhibits human T cell proliferation and whether the inhibitory effect on T 
cells is mediated through CD4+CD25+ Tregs, we stimulated  human CD4+ T cells or the same 
population depleted of CD25+ T cells with allogeneic spleen APC in the presence of IVIg or HSA 
(10 mg/ml). Responder T cells (5 x 104) were cultured with 25 x 103 allogeneic APC per well in 
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round bottom 96 well plates (Greiner, Netherlands), in the absence or presence of IVIg or HSA. 
To determine whether IVIg directly enhance the inhibitory capacity of Tregs, 2 x 105 purified 
CD4+CD25+ T cells were cultured for 18 hours at 37 °C in the presence of IVIg or HSA. The cells 
were then washed twice to remove the excess and unbound IVIg, counted and added to 5 x 104 
CD4+CD25- T cells stimulated by 25 x 103 allogeneic APC at a CD25+ to CD25- T cell ratio of 1:1. 
After 4 days, proliferation was assessed by determination of the incorporation of 0.5 mCi [3H] 
thymidine (Radiochemical Center, UK) during the final 18 hours of the culture. Percentage of 
suppression was determined by the formula: ((CPMno_Tregs  – CPMIVIG or HSA) / CPMno_Tregs ) x 100%). 
Analysis of ZAP70 phosphorylation
To determine ZAP70 phosphorylation, 5 x 104 human CD4+ T cells were activated with alloge-
neic spleen APC (25 x 103) in the presence or absence of IVIg (10 mg/ml), while mouse spleno-
cytes were incubated in presence or absence of IVIg (10 mg/ml) or phytohemagglutinin (PHA, 
5 mg/ml; Murex, France) as positive control. Mouse splenocytes were incubated for 30 minutes, 
while human cells were incubated for 18 hours, as a timeline experiment with human T cells 
showed that ZAP70 phosphorylation induced by IVIg was the highest at the chosen time point 
(data not shown). After incubation cells were fixed immediately at 37ºC, stained for surface 
markers, permeabilized and stained with PE-labeled isotype control antibody or antiphospho- 
ζ-associated protein 70 (ZAP70) (BD Pharmingen) for 30 minutes using the BD phosflow kit 
(BD Pharmingen). Cells were washed with staining buffer before analysis by flowcytometry. For 
specific inhibition of src tyrosine kinases cells were incubated with 10 μM PP1 (4-amino-5-(4-
methylphenyl)-7-(t-butyl) pyrazole [3,4-d] pyrimidine, Calbiochem) 28.
Expression of Fc gamma receptors on mouse cells
2 x 106 CBA.Ca murine splenocytes were cultured in RPMI 1640 containing 10% FCS, 2  mM 
L-glutamine, 0.5 mM 2-mercaptoethanol (Sigma) and 100 U/mL of penicillin and streptomycin 
(Sigma) in a six-wells plate and stimulated with phytohemagglutinin (PHA, 5 mg/ml; Murex, 
France) or 1.5 x 104 bone marrow derived DC (BMDC). Cells were harvested at several time points 
(day 1, day 3 and day 5) and expression of Fc gamma receptors determined by flow cytometry. 
Cell adoptive transfer, skin transplantation and in vivo treatment protocol
CBA-Rag -/- mice were reconstituted intravenously with 1 x 105 total CD4+ or CD4+CD25- T 
cells from unmanipulated CBA/Ca mice and transplanted one day later with a full-thickness 
C57BL/10 skin graft. Twenty-five mg of undialyzed IVIg was administered i.v. through the tail 
vein on day 1, 3, 7, 10 and 14. Human Serum Albumin (HSA) i.v. was used as a negative control. 
Human IgG concentrations in serum of mice treated with IVIg were measured by an in-house 
ELISA using goat anti human IgG – HRP (Sigma- Aldrich, St. Louis, MO).
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Statistical analysis
In each in vitro experiment, proliferation and cytokine production was tested in triplicate from 
which means were calculated. In the results, means with SD from independent experiments 
are depicted. Statistical analyses were performed by the wilcoxon test for paired data using 
SPSS version 10.1 (SPSS, Chicago, IL). In vivo graft survival analyses were performed using the 
log-rank test (GraphPad Prism). A P-value < 0.05 was considered as statistically significant 
RESulTS
IVIg enhance the suppressive capacity of human CD4+CD25+ T cells 
We have previously shown that IVIg inhibit human T-cell proliferation and cytokine production 
after allogeneic stimulation as effectively as calcineurin inhibitors 5. To determine whether this 
inhibitory effect is mediated through regulatory CD4+CD25+ T cells, we used as responders 
in an MLR, either total CD4+ T cells or the same population depleted of naturally occurring 
Tregs. IVIg inhibited the proliferation of total CD4+ T cells by 68 ± 9 % (p = 0.03, N=6), whereas 
in contrast, the proliferation of CD4+CD25- effector T cells was not significantly reduced in the 
presence of IVIg (p=0.22, N = 6, inhibition by 16 ± 5 % (Figure 1A). To dissect whether IVIg 
exert their inhibitory effect directly via Tregs, we cultured purified CD4+CD25+ T cells for 18 
hours in presence of IVIg or HSA. Tregs were then washed to remove the unbound IVIg and 
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Figure 1: IVIg enhance the suppressive capacity of human CD4+CD25+ T cells 
A. Human CD4+ T cells or CD4+CD25- effector T cells (5 x 104 per well) were stimulated with allogeneic spleen antigen presenting cells (depleted 
from T and NK cells; 25 x 103 per well) in presence or absence of IVIg or HSA (10 mg/ml). After 4 days, T cell proliferation was measured using [3H] 
thymidine incorporation (* p < 0.05, N = 6).
B. 2 x 105 purified CD4+CD25+ Tregs were cultured for 18 hours in presence of IVIg or HSA (10 mg/ml). The day after, pre-treated CD4+CD25+ 
Tregs were extensively washed and added to 5 x 104 autologous CD4+CD25- T cells stimulated with 25 x 103 allogeneic spleen APC per well at a 
Tregs : Teff ratio of 1:1. After 4 days, proliferation was assessed using [3H] thymidine incorporation. The suppression by Tregs was determined by 
the formula: ((CPMno_Tregs – CPMIVIG or HSA ) / CPMno_Tregs ) x 100%). (* p < 0.05, N = 7)
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added to CD4+CD25- T cells stimulated by allogeneic APC. As shown in Figure 1B, the sup-
pressive effect of CD4+CD25+ T cells pre-treated with IVIg (IVIg-Tregs) on the proliferation of 
CD4+CD25- responders was significantly enhanced compared to the suppressive effect of 
CD4+CD25+ T cells pre-cultured with HSA (HSA-Tregs). This enhanced suppression applied to 
Tregs from all the donors tested (inhibition by IVIg-Tregs: 59 ± 13% versus HSA-Tregs: 35 ± 17% 
at CD25+:CD25- T cell ratio of 1:1 (p<0.05, N = 7) (Figure 1B). 
IVIg bind to and activate human CD4+CD25high Foxp3+ regulatory T cells
In the light of the observation that IVIg enhances the suppressive capacity of naturally occurring 
Tregs, we asked whether IVIg binds to and activates human Tregs. Purified human total CD4+ 
T cells were incubated for 18 hours with IVIg or HSA, either without stimulation or stimulated 
with allogeneic spleen APC. Rabbit F(ab’)2 anti-human IgG-FITC was used to detect IVIg bind-
ing. As shown in Figure 2A, IVIg bound to human CD4+CD25high Foxp3+ regulatory T cells. This 
binding occurred regardless whether the cells were stimulated by APC or not (unstimulated: 83 
± 13 %, and stimulated by APC: 83 ± 4 % IVIg+ CD4+ Foxp3+ T cells, N = 3). Human IgG bound 
also to conventional CD4+Foxp3- T cells. However, IVIg binding to Tregs was higher (mean 
fluorescence intensity; MFI = 7063) than that to conventional T cells (MFI = 3197) (Figure 2B). 
This has been reported earlier for mouse T cells 22. 
After 18 hours of culture, we determined the surface expression of activation markers HLA-
DR, CD69 and CD38 on CD4+CD25high Foxp3+ Tregs, both in unstimulated and by allogeneic 
APC stimulated conditions. Comparing the conditions with and without stimulation by allo-
geneic APC, we detected  activation of Tregs induced by allogeneic APC. However, addition of 
IVIg to allogeneically stimulated T cells enhanced  expression of HLA-DR, CD69 and CD38 on 
CD4+CD25high Foxp3+ Tregs on top of the baseline allogeneic activation. (Figure 2C)
In contrast, no effect of IVIg on Tregs activation was observed in the absence of APC, sug-
gesting an important role of APC in activation of Tregs by IVIg. CD45RO expression on human 
CD4+CD25+Foxp3+ T cells remained stable in all conditions. In addition, the CD4+CD25high 
Foxp3+ T cells to which IVIg was bound had a higher expression of the activation markers than 
the IVIg-negative CD4+CD25high Foxp3+ population, suggesting preferential activation as a 
direct consequence of IVIg binding (Figure 2D). 
Upon TCR ligation of CD4+ T cells, the intracellular domain of CD4 interacts with the src tyro-
sine kinase p56lck leading to activation and phosphorylation of Tyr319 within the linker region 
of ZAP70 29. This in turn leads to activation of ZAP70 and results in downstream activation of 
the T cell 20. Thus, the level of ZAP70 Tyr319 phosphorylation provides an independent assess-
ment of the activation status of T cells. As shown in Figure 2E, in the presence of allogeneic 
stimulation, IVIg treatment resulted in enhanced Tyr319 phosphorylation of ZAP70 in human 
CD4+CD25+ T cells relative to controls. Moreover, inhibition of lck tyrosine kinase activity by 
the src tyrosine kinase-specific inhibitor PP1 during incubation with IVIg prevented the phos-
phorylation of Tyr319 of ZAP70 in CD4+CD25+ cells in the presence of IVIg (Figure 2E), verifying 
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Figure 2: IVIg bind to and activate human CD4+CD25+ FoxP3+ regulatory T cells
A. Purified human total CD4+ T cells (5 x 104 per well) were incubated for 18 hours with IVIg or HSA, either without stimulation or stimulated 
with allogeneic spleen APC (25 x 103 per well). The day after, the binding of IVIg to and the activation status of human CD4+CD25+Foxp3+ T cells 
were determined by flowcytometry.
B. Rabbit F(ab’)2 anti-human IgG-FITC was used to detect IVIg binding. 84 ± 4% of CD4+CD25+Foxp3+ T cells stimulated by spleen APC have 
bound IVIg on their surface. As antibodies can adhere non-specifically when cells are activated, we used HSA-Treg as negative control. FACS plots 
of one representative experiment out of 3 experiments are shown. 
Rabbit F(ab’)2 anti-human IgG-FITC was used to detect IVIg binding on CD4+Foxp3+ cells (top plot) and on conventional CD4+Foxp3- T cells 
(bottom plot). Binding of IVIg was analyzed based on the mean fluorescence intensity (MFI).
that this IVIg dependent activation is mediated through p56lck, as the inhibition of p56lck 
using the inhibitor PP1 abolished the increase on ZAP70 phosphorylation. Together, these data 
show that binding of IVIg to human CD4+CD25high Foxp3+ regulatory T cells in the presence 
of APC leads to intracellular ZAP70-signaling, enhanced expression of activation markers and 
increased suppressive capacity. 
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IVIg bind to and activate mouse CD4+CD25high Foxp3+ regulatory T cells
To establish whether human IVIg can bind to mouse Tregs, IVIg were injected intravenously in 
CBA.Ca mice. Twenty-four hours later binding of human IgG to mouse spleen CD4+Foxp3+ and 
CD4+Foxp3- T cells was determined. IVIg preferentially bound to a subpopulation of mouse 
CD4+Foxp3+ T cells (16 ± 2%) (N = 4), while binding to CD4+Foxp3- T cells was minimal (Figure 
3A). This finding was confirmed using biotinylated IVIg (data not shown). In addition, as shown 
in Figure 3B, an increased level of IVIg-binding was observed on CD4+Foxp3+ cells that were 
also positive for CD44, a marker of antigen experience 30, suggesting that IVIg binds preferen-
tially to antigen experienced cells. (Figure 3B)
To investigate whether IVIg treatment could induce phosphorylation of ZAP70 in mouse 
CD4+CD25+ cells, mouse splenocytes were incubated for 30 minutes with or without IVIg or 
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Figure 2: IVIg bind to and activate human CD4+CD25+ FoxP3+ regulatory T cells
C. CD4+ T cells were incubated with IVIg or HSA without APC (  white bars) or stimulated with allogeneic spleen APC without (= CTRL + APC) or 
with IVIg or HSA (with APC, ■ black bars) for 18 hours in presence of IVIg or HSA. After incubation, the expression of the activation markers HLA-
DR, CD69 and CD38 on CD4+CD25+Foxp3+ T cells was determined by flowcytometry. After incubation with IVIg in the presence of allogeneic 
APC, higher percentages of CD4+CD25+Foxp3+ T cells expressed HLA-DR, CD69 and CD38, while CD45RO expression was comparable to the 
untreated and HSA treated conditions. The enhanced expression of activation markers in the presence of IVIg occurred only when stimulated by 
allogeneic APC. (* p< 0.05, N =3)
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Figure 2: IVIg bind to and activate human CD4+CD25+ FoxP3+ regulatory T cells
D. The CD4+CD25+Foxp3+ T cells that bound IVIg showed enhanced expression of the activation markers HLA-DR, CD69 and CD38 compared 
to CD4+CD25+Foxp3+ T cells that did not bind IVIg. This while the expression of CD45RO did not differ between he two populations. Mean 
fluorescence intensity (MFI) is depicted in the plots. Experiments are representative of 1 out of 3 experiments.
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HSA and the level of ZAP70 phosphorylation determined by FACS analysis. The presence of 
IVIg resulted in a significant up-regulation in phosphorylated ZAP70 expression (IVIg: 36 ± 8 % 
versus no treatment 18 ± 9 % versus HSA: 23 ± 7 %; p < 0.05, N = 6). PHA (5 ng/ml) was used as a 
positive control. Similar to human cells, phosphorylation of ZAP70 was inhibited by specific lck 
tyrosine kinase inhibition (Figure 3 C).
IVIg bind to mouse CD4+Foxp3+ T cells: exploration of the mechanism of binding
Several reports have suggested that that Fc receptors may be present on activated mouse 
T lymphocytes 31-34, but their functional significance is unclear. Santana et al. reported that 
aggregated human IgG binds to mouse thymocytes and T cells through receptors for the Fc 
region 35, which prompted us to ask whether CBA CD4+Foxp3+ T cells express Fc receptors, 
which might bind human IgG. We explored the expression of FcγR I, II and III on resting and on 
mitogenically and allogeneically activated CD4+Foxp3+ cells at different time points. Mouse 
FcγR II (CD32) and III (CD16) are approximately 90% homologous 36, therefore, we used a rat 
monoclonal antibody which reacts with an epitope shared by mouse CD16 and CD32. 
E
Fig. 2
Without PP1
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Figure 2: IVIg bind to and activate human CD4+CD25+ 
E. After CD4+ T cells were incubated with allogeneic spleen APC for 18 hours in presence or absence of IVIg (dotted line = control, black line = 
IVIg), ZAP70 phosphorylation in CD4+CD25+ Tregs was determined. Foxp3 staining could not be combined with the phosphorylated ZAP70 
staining (data not shown). We detected an increased phosphorylated ZAP70 expression in CD4+CD25+ cells cultured in presence of IVIg. For 
specific lck tyrosine kinase inhibition, 10 μM PP1 was added, and phosphorylated ZAP70 expression in CD4+CD25+ cells was determined.  The 
histograms are representative of 1 out of 3 experiments.
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Stimulation of splenocytes with PHA resulted in a dramatic increase in the proportion of 
TCRβ+CD4+Foxp3+ cells that expressed FcγR II/III.  This up-regulation was rapid (37 ± 5% at 
day +1,p < 0.01 compared to day 0, N = 4) but most significantly, was much less marked on 
Foxp3- cells where expression was lower than CD4+Foxp3+ cells at all time points (Figure 4A). 
More importantly, allogeneic stimulation with bone marrow-derived dendritic cells (BMDC) 
also resulted in a striking up-regulation of FcγR II/III expression on Foxp3+ T cells, but not on 
Foxp3- T cells (Figure 4B).  No expression of FcγR I (CD64) was detected on CD4+Foxp3+ T cells 
(data not shown). 
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Figure 3: IVIg bind to and activate mouse CD4+CD25high Foxp3+ regulatory T cells
A. IVIg (25 mg) was injected intravenously into naïve WT CBA.Ca mice. The day after, the spleen was harvested, single cells were prepared and 
used in flowcytometry analysis. Rabbit F(ab’)2 anti-human IgG-FITC was used to detect IVIg binding to mouse T cells. Splenocytes from untreated 
naïve WT CBA.Ca mice were used as control. The left panel shows IVIg-binding to CD4+Foxp3+ cells and the right panel to CD4+Foxp3- cells. In 
this experiment IVIg bound to 24.3% of the mouse spleen CD4+ CD25+Foxp3+ T cells 24 hours after intravenous administration, while binding 
to CD4+Foxp3- cells was minimal. The binding did not increase when it was measured after 48 hours (data not shown)
B. To determine the activation status of CD4+Foxp3+ cells in mice that were treated with IVIg, we determined CD44 expression. The plots are 
representative of 1 of 4 experiments.
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To determine whether the binding of IVIg to mouse CD4+Foxp3+ T cells is mediated through 
FcγR II/III, we studied the binding of IVIg after in vivo injection and after in vitro activation of T 
cells.  Twenty-four hours after injection into naïve CBA.Ca mice, IVIg binding to CD16/32positive 
CD4+Foxp3+ T cells could be detected, but interestingly, the vast majority of IVIg was detected 
on the surface of CD16/32negative Foxp3+ cells (Figure 4C). Presumably, it is because the natural 
occurring Foxp3+ were not activated in these mice, and only 2% to 3% of the CD4+Foxp3+ cells 
express FcγR II/III. To verify whether the binding to activated CD4+Foxp3+ T cells is  mediated by 
FcγR II/III, we activated CD4+ T cells with PHA and blocked FcγR II/III with an FcγR II/III-specific 
antibody before addition of IVIg in vitro. Indeed, binding of IVIg to CD16/32+CD4+Foxp3+ T 
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Figure 3: IVIg bind to and activate mouse CD4+CD25high Foxp3+ regulatory T cells
C. As the phosphorylation of ZAP70 is a transient event and difficult to determine in T cells from mice after intravenous administration of IVIg, we 
cultured naïve CBA.ca splenocytes in presence or absence of IVIg or HSA (10 mg/ml) for 30 minutes at 37º C, after which ZAP70 phosphorylation 
in CD4+CD25+ Tregs was determined. The isotype control is depicted for control Treg, but was similar for HSA- and IVIg-Treg. PHA (5 ng/ml) was 
used as a positive control. Histograms shown are representative of 6 experiments. By specific inhibition of lck tyrosine kinase with 10 μM PP1 
during the 30 minutes cultures, phosphorylation of ZAP70 was inhibited. 
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Figure 4: IVIg bind to mouse CD4+Foxp3+ T cells: exploration of the mechanism of binding
A. WT CBA.Ca splenocytes were stimulated with PHA (5 ng/ml) and expression of FcγR II/III (CD32/16) was determined on CD4+TCRβ+Foxp3+ 
cells (left panel; black bars) and CD4+TCRβ+Foxp3- cells (right panel; grey bars)  before culture and at day 1, 3 and 5 of culture. (** p < 0.01 in 
comparison to day 0, N = 4)
B. WT CBA.Ca splenocytes were stimulated with B10 BMDC at the ratio of 1 : 1 and expression of FcγR II/III was determined on CD4+TCRβ+Foxp3+ 
cells (left panel; black bars) and CD4+TCRβ+Foxp3- cells (right panel; grey bars)  before culture and at day 1, 3 and 5 of culture. (** p < 0.01, * 
p < 0.05 compared to day 0, N = 3)
C. 25 mg of IVIg was injected intravenously in naïve WT CBA.Ca mice. The day after, binding of IVIg to spleen CD4+Foxp3+ CD16/32+ T cells and 
CD4+Foxp3+ CD16/32- T cells was determined. Representative plots from 1 out of 3 experiments.
D. To investigate whether FcγR II/III mediate binding of IVIg to activated Tregs, we activated CBA.Ca splenocytes with PHA (5 ng/ml). After 6 hours 
IVIg (1 mg/ml) were added and 30 minutes thereafter the activated cells were extensively washed and stained for IVIg binding using biotinylated 
goat anti human IgG and strepavidin-PE (left plot). To perform blockade of FcγR II/III, CD32/16 blocking antibody (2,5 μg in 50 μl) was added 30 
minutes before IVIg was added (right plot). Depicted are FACS-plots or one representative experiment out of 3.
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cells was prevented by the blocking antibody, while IVIg binding to CD16/32-CD4+Foxp3+ 
T cells remained unaltered (Figure 4D). Taken together, these data indicate that IVIg binds to 
mouse CD4+Foxp3+ T cells via both FcγR II/III dependent and independent pathways.
IVIg treatment promotes fully MHC-mismatched skin allograft acceptance 
In order to determine whether IVIg mediated binding and activation of naturally occurring 
regulatory cells has a functional consequence in vivo, CBA-Rag -/- mice were reconstituted 
on day -1 with 1 x 105 CBA total CD4+ T cells from wild type CBA.Ca (H2k) mice, or the same 
population depleted of CD25+ cells, and transplanted one day later with allogeneic full thick-
ness C57BL/10 (H2b) skin allografts. IVIg (25 mg) was administered i.v. on days 1, 3, 7, 10 and 14 
after transplantation. Control animals were treated with equal doses of HSA (Figure 5A). Serum 
samples collected at day 15 showed that human immunoglobulin concentrations in serum 
increased from 4 ± 2 mg/ml on day 7 to a peak level of 11 ± 3 mg/ml on day 15 (N = 5), which 
is comparable to those in patients treated with IVIg 24. Mice reconstituted with total CD4+ T 
cells that received no further treatment or were treated with HSA, rejected their grafts acutely 
(median survival times of 14 and 16 days respectively). However, in clear contrast, mice recon-
stituted with the same population of CD4+ T cells and treated with IVIg all accepted their skin 
grafts long-term (MST >100 days) and showed no signs of tissue necrosis (Figure 5A, p<0.01). 
Importantly, the same IVIg regimen had no effect on graft outcome in mice reconstituted 
with CD4+ T cells depleted of naturally occurring Tregs. Indeed, these mice rejected their grafts 
at exactly the same time as reconstituted mice given no further treatment (Figure 5B). These 
data suggest that that IVIg exerts an inhibitory effect on T cell mediated graft rejection by 
enhancing the suppressive capacity of CD4+CD25+ regulatory T cells.
dISCuSSION
IVIg treatment is increasingly being used for the control of T cell mediated autoimmunity 
and inflammation and more recently, also in transplantation. Whilst its application in clinical 
transplantation has been limited largely to the rapid removal of antibodies in highly sensitised 
patients 37-39, IVIg may also have significant effects on T cell mediated graft rejection 4,40. In the 
current study, we demonstrate that IVIg is effective in prevention of CD4+ T cell-mediated graft 
rejection in a fully MHC mismatched skin transplant model by triggering functional activation 
of CD4+CD25+Foxp3+ regulatory T cells. Interestingly, through direct binding of IgG present in 
IVIg preparation to Tregs, IVIg activate not only mouse, but also human Tregs, thereby enhancing 
their suppressive function. Especially, the Tregs that bind IVIg to their surface, show increased 
expression of activation markers. Our findings extend recent data from other groups showing 
IVIg mediated activation of Tregs 22,41, by demonstrating that IVIg induce functional activation of 
Tregs via direct binding to their surface and triggering the src kinase ZAP70 signaling pathway. 
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Binding of IVIg to mouse Tregs was partly mediated by FcγR, but the majority was bound in 
a FcγR independent fashion. We detected expression of FcγR II and III on mouse T cells which 
increased upon their activation, but found no expression of Fc receptors on activated human T 
cells (data not shown). Therefore, binding of IVIg to human Tregs seems to be FcγR independent. 
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Figure 5: IVIg treatment promotes acceptance of fully MHC-mismatched skin allografts 
A/B. CBA-Rag -/- mice were reconstituted intravenously with 1 x 105 total CD4+ (A) or CD4+CD25- T cells (B) harvested from naive CBA.Ca spleen. 
One day later a full thickness tail skin graft of C57BL/10 mice was transplanted on the flanks of the reconstituted mice. Twenty-five mg of IVIg 
was administered i.v. on day 1,3,7,10 and 14 after transplantation. Human Serum Albumin (HSA) was administered in the same dose to control 
mice. Skin graft survival in mice reconstituted with total CD4+ T cells: MST in mice treated with IVIg >100 vs HSA 16 days, p<0.01, N = 9); in mice 
reconstituted with  CD4+CD25- T-cells : MST in IVIg-treated and non-treated mice were both 17 days (p = NS , N = 8).
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Several studies have shown that IVIg contain natural antibodies that recognize different surface 
molecules on T cells, such as TCRβ, CD4 and CD95 42-44. Possibly, binding of IgG to human Tregs 
is mediated via its F(ab)2 region, which recognises surface molecules, such as TCR or CD4 on 
Tregs. Still, the binding of the Fc region of IgG to an unknown Fc receptor or a glycoprotein-
recognizing molecule on Tregs is a possibility, that can not be excluded. Moreover, we showed 
that IVIg treatment leads to src-kinase-mediated ZAP70 phosphorylation of in both mouse and 
human CD4+CD25+ T cells, which supports the hypothesis that IVIg may trigger activation of 
Tregs via TCR or other ITAM motif bearing activating receptors, like (unknown) activating Fc 
receptors,  on Tregs. 
Recently, two major histocompatibility complex class II T cell epitopes in the Fc fragment of IgG 
have been identified, which are capable of activating natural regulatory T cells 45. Considering 
that these two epitopes are present in IVIg preparations, activation of Tregs by these epitopes 
is a possible alternative explanation for activation of Tregs by IVIg. However, since we observed 
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Figure 5: IVIg treatment promotes acceptance of fully MHC-mismatched skin allografts 
A/B. CBA-Rag -/- mice were reconstituted intravenously with 1 x 105 total CD4+ (A) or CD4+CD25- T cells (B) harvested from naive CBA.Ca spleen. 
One day later a full thickness tail skin graft of C57BL/10 mice was transplanted on the flanks of the reconstituted mice. Twenty-five mg of IVIg 
was administered i.v. on day 1,3,7,10 and 14 after transplantation. Human Serum Albumin (HSA) was administered in the same dose to control 
mice. Skin graft survival in mice reconstituted with total CD4+ T cells: MST in mice treated with IVIg >100 vs HSA 16 days, p<0.01, N = 9); in mice 
reconstituted with  CD4+CD25- T-cells : MST in IVIg-treated and non-treated mice were both 17 days (p = NS , N = 8).
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that activation of Tregs was a direct consequence of IVIg binding, and that Tregs that did not 
bind IVIg were less activated than IVIg positive Tregs, we believe that MHC restricted presenta-
tion of IVIg derived epitopes to Tregs is not the only explanation for the activation of Tregs in 
the co-cultures of CD4+ T-cells with APC.
Interestingly, activation of human Tregs by IVIg occurred only in presence of allogeneic APC. 
The need of APC and the specific activation of Tregs that have bound IVIg to their surface reflect 
the complexity of Tregs activation by IVIg. We propose a model in which both binding and cross 
linking of IgG are necessary to induce Tregs activation. Probably, APC serve in this situation as 
an intermediate to crosslink the Fc regions of IgG present on the Tregs surface, thereby induc-
ing Tregs activation. Still, further studies need to dissect the functional differences between 
IVIg positive and negative Tregs.
Our data indicate that there are striking discrepancies between human and mouse cells in 
their response to IVIg treatment. Human IgG in IVIg preparations bound to not only human 
CD4+Foxp3+ T cells but also to CD4+Foxp3- T cells, while binding to mouse conventional T cells 
was negligible. Since we have preliminary evidence to suggest that IVIg bind more strongly 
to human CD4+CD25+Foxp3+ T cells than that to CD4+CD25-Foxp3- effector T cells, it seems 
likely that this preferential binding of IVIg alters the functional balance between effector and 
Tregs, leading to suppression. Moreover, the inhibitory effect of IVIg on human CD4+CD25- T 
cells (depleted for CD4+CD25+ T cells) was small, and not statistically significant, showing that 
binding of IVIg to human CD4+CD25- has only a minor suppressive effect. Second, we detected 
increased expression of FcγR II and III on activated mouse T cells, while no expression of Fc 
receptors on activated human T cells was detected. These discrepancies between human and 
mouse data underline the difficulty to interpret and correlate both. Further research is war-
ranted to unravel the mechanistic basis of the effect of IVIg on both human and mouse Tregs.
We demonstrated that IVIg protected against T cell mediated rejection of fully mismatched skin 
grafts only when total CD4+ T cells, but not CD4+CD25- T cells, were adoptively transferred. It 
is worth noting that IVIg treatment resulted in allograft survival that persisted well beyond 100 
days even though the IVIg treatment was discontinued on day 14. Thus, a short period of IVIg 
therapy appears to lead to stable and robust prolonged graft survival despite the presence 
of CD4+CD25- T cells. However, we have been unable to achieve prolongation of allogeneic 
skin allograft survival in immunologically intact wild-type mice using IVIg treatment (data not 
shown). This almost certainly reflects the large total number of alloreactive T cells, including 
CD8+ T cells, in intact mice compared to the limited numbers of CD4+ T cells in the adoptive 
transfer experiments described in the current study. This observation suggests that the poten-
tial of IVIg to prevent allograft rejection may be seen only in combination with strategies that 
induce partial T cell depletion and attenuation. Of the potential candidates that exist, depletion 
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using CAMPATH-1H 46 or modulation using humanised anti-CD3 antibodies 47 appear to be 
promising. 
Our results identify a novel pathway through which IVIg treatment induces functional activa-
tion of both mouse and human regulatory T cells. Direct binding and activation of regulatory T 
cells is one of the mechanisms in the immunomodulatory repertoire of IVIg, which allows rapid 
inhibition of allogeneic responses, and therefore can be a valuable tool after organ transplanta-
tion. The identified pathway by which antibodies influence the function of the “central immune 
regulator”, the Tregs, may also be an important physiological phenomenon, and may form a 
basis for production of synthetic or biological alternatives that will enable us to selectively 
target pathogenic immune activity.
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SuMMaRY
Intravenous Immunoglobulins (IVIg) are therapeutically used in a variety of immune-mediated 
diseases. The beneficial effects of IVIg in autoantibody-mediated diseases can be explained 
by neutralization, accelerated clearance, and prevention of Fcγ receptor binding of auto-
antibodies. However, the means by which IVIg exert therapeutic effects in disorders medi-
ated by cellular immunity has remained an enigma. Clinical improvements followed by IVIg 
treatment often extend beyond the half-life of infused IgG, suggesting that IVIg modify the 
cellular immune compartment for a prolonged period. We discuss here recent advances in our 
understanding of different, mutually non-exclusive mechanisms of action of IVIg on cells of the 
innate and adaptive immune system. These mechanisms might explain the beneficial effects of 
IVIg in certain autoimmune and inflammatory diseases. 
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INTRavENOuS IMMuNOGlObulINS ThERaPY
Intravenous immunoglobulins (IVIg) for therapeutic use are polyspecific IgG preparations 
purified from plasma pools of several thousand healthy donors. IVIg preparations primarily 
contain human IgG molecules, with small amounts of IgA and IgM. The distribution of IgG 
subclasses in IVIg is comparable to that of IgG in normal serum and the half-life of infused IVIg is 
approximately three weeks. IVIg are safe preparations with no long term side effects. Although 
administration of IVIg can result in generalized reactions, such as headache, nausea and chills, 
in 1-15% of the patients, these adverse reactions are often mild and are relieved by NSAIDs or 
reducing the rate of infusion.
IVIg were initially used as a substitution for immunoglobulins otherwise lacking in patients 
with primary immune deficiencies (PIDs) and secondary immune deficiencies. However, since 
the demonstration in 1981, that IVIg ameliorate immune thrombocytopenic purpura (ITP) 1, 
IVIg are increasingly being used for the treatment of a wide range of autoimmune and systemic 
inflammatory diseases 2. In addition to antibody mediated diseases, IVIg are also effective in 
several disorders caused by derailment of cellular immunity, like Kawasaki disease, dermato-
myositis, multiple sclerosis (MS), graft versus host disease (GvHD) in recipients of allogeneic 
bone marrow transplants, and treatment of cellular rejection after organ transplantation 2-5. 
Clinically, the beneficial effects of IVIg extend beyond the half-life of infused IgG, therefore 
its effect is probably not merely due to a passive clearance or competition with pathogenic 
autoantibodies. Together, these observations evoke the possibility that IVIg therapy induces 
lasting changes in the cellular compartment of the immune system. 
The established beneficial effects of IVIg in diseases mediated by auto-antibodies can be 
explained by several mechanisms including neutralization by naturally occurring anti-idiotype 
antibodies present in IVIg, accelerated clearance (by saturation of the neonatal Fc receptor), 
and prevention of auto-antibody binding to Fcγ receptors (FcγR) on phagocytes 2. By virtue 
of a broad spectrum of antibodies, which reflect the natural antibody repertoire of the human 
population, the mechanisms of action of IVIg are multifaceted and complex. Most likely, the 
immunological effects of IVIg are not mutually exclusive, and work in synergy to contribute 
to effective therapy in various clinical settings. For a long time, the means by which IVIg exert 
their therapeutic effects in complex immune mediated disorders involving cell-cell interactions 
had remained a mystery. However, the results of several recent studies have shed light on the 
mechanistic aspects of IVIg therapy in these diseases. In this review, we discuss recent advances 
in our understanding of the effects of IVIg on the different cells of the innate and adaptive 
immune system that together explain the beneficial effects of IVIg in disorders caused by 
dysregulated cellular immunity. 
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Effects of IVIg on innate cellular immunity
Interactions with various Fcγ receptors on innate immune cells: blockade of Fcγ-receptors
Immune cells recognise the Fc part of IgG via Fcγ receptors (FcγR). FcγR are expressed on a 
variety of immune cells, and can generate intracellular activating or inhibitory signals, thereby 
modulating the function of these cells. In autoantibody-mediated pathologies, the beneficial 
effects of high-dose IVIg therapy implicate at least in part the blockade of activating FcγR by 
monomeric IgG, thereby preventing the binding of opsonised antigens and induction of effec-
tor functions, like phagocytosis and secretion of pro-inflammatory cytokines by macrophages 
6,7 and degranulation of granulocytes 8. Active suppression of inflammation: interference 
with activating Fcγ receptors. Modulation of activating FcγR expression can contribute to the 
observed sustained unresponsiveness of phagocytes to autoantibodies following IVIg therapy. 
Thus, IVIg treatment has been shown to down-regulate expression of activatory FcγRI and 
FcγRIII on human monocytes in Kawasaki’s disease patients 9, and FcγRIV on kidney-infiltrating 
macrophages in a murine nephritis model 10. In vitro, IVIg suppress expression of FcγRIIA on 
human dendritic cells (DC), thereby preventing their activation by immune complexes 11. In 
addition, by binding to FcγRIII, IVIg render murine and human macrophages refractory to IFNγ 
driven phagocytosis and inflammation. The mechanism includes suppression of the expres-
sion of the Interferon-γ (IFN-γ) receptor 2 subunit 12. This suggests that engagement of the 
activatory FcγRIII can paradoxically trigger an inhibitory cellular program. The notion that non-
conventional inhibitory signals can be generated by ligation of activatory FcγR has recently 
gathered support in several studies, although the mechanistic basis is still unclear (reviewed 
in: 13).
Active suppression of inflammation: modulation of expression of inhibitory Fcγ receptor IIB 
In humans, two types of FcγRII exist: the activatory FcγRIIA and the inhibitory FcγRIIB, the latter 
contains an intracellular ITIM motif, while in mice only the inhibitory variant is present. Evidence 
is accumulating in favour of an important role of the inhibitory FcγRIIB in the anti-inflammatory 
properties of IVIg in animal models. IVIg treatment induces FcγRIIB expression on murine 
effector macrophages in spleen 14 and kidney 10, and FcγRIIB blocking antibody abrogates the 
protective effect of IVIg in animal models 14. In addition, as shown in experimental ITP, arthritis 
or nephritis, mice that are deficient for FcγRIIB do not respond to IVIg treatment 10,14,15. The 
mechanisms by which IVIg alter the balance in expression of activating and inhibitory FcγR on 
murine cells are at present unclear. One possibility might be by neutralization of complement 
factor C5a 16. C5a induces FcγRIII on murine macrophages, while inhibiting FcγRIIB expression 
17. IVIg are able to inhibit these effects of C5a on FcγR expression 18. Another way might be 
via a two-step mechanism, in which IVIg interact with an unknown receptor on “regulatory 
macrophages” in the marginal zone of the spleen, which up-regulates the expression of FcγRIIB 
on “effector macrophages” so resulting in their inactivation (as discussed in the macrophages 
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section)15. However, whether modulation of FcγRIIB expression contributes to the beneficial 
effects of IVIg therapy in humans is questionable, since IVIg do not alter FcγRIIB expression 
on human DC in vitro 11, and IVIg treatment does not change the level of FcγRIIB transcripts in 
human monocytes 9.
Interaction with FcRn on innate immune cells
The role of neonatal Fc receptors (FcRn) in accelerating the clearance of pathogenic auto-
antibodies upon IVIg treatment has been thoroughly investigated. FcRn is expressed in the 
endosomal compartment of intestinal epithelium, vascular endothelium and macrophages. It 
regulates serum IgG levels by binding pinocytosed IgG in the endosomes and recycling it to 
the cell surface, thereby rescuing it from degradation in lysosomes. High dose IVIg therapy 
leads to saturation of this receptor by IgG, resulting in enhanced clearance of pathogenic auto-
antibodies (reviewed in: 13). However, this receptor is also expressed on the surface of human 
monocytes and macrophages 19. It would be interesting to investigate whether binding of IVIg 
to FcRn on these cells influences their function.
Interaction of IVIg with dendritic cells
Dendritic Cells (DC) are involved at several levels in the pathogenesis of autoimmune diseases, 
inflammatory disorders, and allograft rejection. High dose IVIg (at least 10 mg/ml) inhibit the dif-
ferentiation and maturation of human DC, the up-regulation of co-stimulatory molecules CD80 
and CD86, that are critical in DC-T cell crosstalk, and the ability to uptake autoantigens such as 
nucleosomes. Moreover, IVIg abrogate the capacity of mature DC to secrete pro-inflammatory 
cytokine IL-12 upon activation, while enhancing the production of anti-inflammatory cytokine 
IL-10, and suppress DC-mediated activation and proliferation of auto- and allo-reactive T cells 
20-23. Both Fc- and F(ab’)2 fragments of IVIg are able to mediate the suppression of DC, thus 
suggesting the involvement of FcγR and non-Fc-receptor mediated signalling events in IVIg 
mediated modulation of DC function 20. Moreover, IVIg differentially modulate the antigen 
presenting molecules on DC. While the expression of MHC class II is down regulated upon 
IVIg treatment of DC 20, the expression of CD1d and activation of CD1d-restricted NKT cells 
are enhanced 24. In experimental models, IVIg suppress DC function in an autoimmune giant 
cell myocarditis model 25, and DC treated with IVIg ex vivo ameliorate ongoing autoimmune 
disease in vivo upon adoptive transfer, indicating that IVIg induce so-called “regulatory” activity 
in DC 26.
Interaction of IVIg with dendritic cells: primary immune deficiencies
Patients with primary immune deficiencies (PIDs), like common variable immunodeficiency 
(CVID) and X-linked agammaglobulinemia (XLA), are characterized by deficiency of circulat-
ing antibodies and recurrent infections. In addition, these patients also display defective 
functioning of the cellular immune compartment such as DC, macrophages and T cells 27-29. 
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To prevent recurrent infections, IVIg are used as a replacement therapy in these patients. The 
effect of substitution of IgG with broad specificities in patients with IgG deficiency is evident in 
protection against infections. However, we found that IVIg replacement therapy is not merely 
a substitution; rather, it can also rectify defective functioning of the cellular compartment. In 
vitro, reconstitution of patients’ plasma with IVIg corresponding to the concentration reached 
in patients immediately following infusion (replacement dose; 5 mg/ml), could partially restore 
some of the defective expressions of markers on their DC 27,28. This process is mediated at least 
in part by self-reactive anti-CD40 Abs within IVIg, and is accompanied by an increased IL-10 and 
decreased IL-12 production. This effect of IVIg on DC is mediated by the activation of the CREB-1 
pathway that is implicated in the secretion of IL-10 by DC 28. Therefore, the recovery of “regula-
tory” DC functions might explain the remission from Th1 immunopathologies in patients with 
PIDs upon receiving IVIg. Concisely, physiological concentrations of IgG attained in patients 
after IVIg replacement therapy can stimulate maturation of impaired DC from patients with 
PIDs, while supra-physiological concentrations reached upon high dose IVIg therapy of patients 
with auto-immune diseases, but normal plasma IgG concentrations, can inhibit maturation and 
function of healthy DC. 
Interaction of IVIg with monocytes and macrophages
IVIg treatment suppresses the activation of monocytes and macrophages by altering transcrip-
tion of various inflammatory genes 9, and lowers circulating levels of monocyte/macrophage 
inflammatory cytokines TNF-α and IL-1β 30. Conversely, IVIg trigger monocyte production of 
IL-1 receptor antagonist (IL-1ra), a potent anti-inflammatory cytokine that counteracts IL-1. 
However, in mice this mechanism seems not to contribute to the beneficial effect of IVIg 
treatment in experimental ITP 31. IVIg are able to transiently block the function of FcγR on 
splenic macrophages as demonstrated by a decrease in clearance of anti-D-coated autologous 
erythrocytes in patients 6. In addition, peripheral blood monocytes from IVIg treated patients 
with ITP exhibit a decreased ability to form rosettes with IgG coated erythrocytes, and the 
administration of Fc fragments of IVIg to patients with ITP exhibit similar effects to those of IVIg 
7. As mentioned earlier, IVIg increase expression of FcγRIIB on the surface of “effector” macro-
phages in mice 10,14,15,32,33. However, the IVIg mediated beneficial effect was not observed in 
mice lacking colony-stimulating factor (CSF)-1 dependent macrophages 15. Thus, it has been 
suggested that CSF-1–dependent “regulatory” macrophages in the marginal zone of the spleen 
regulate IVIg mediated therapeutic effects by enhancing the expression of FcγRIIB on the 
surface of “effector” macrophages 33,34. However, this hypothesis is inconsistent with a recent 
report showing that overexpression of FcγRIIB on spleen macrophages does not influence the 
pathogenesis of autoimmune diseases in mice 35. The effects of IVIg on FcγRIIB expression on 
human tissue macrophages have not been studied, but IVIg treatment does not alter FcγRIIB 
mRNA expression in circulating human monocytes 9. Therefore, the role of FcγRIIB in the effects 
of IVIg treatment, especially in humans, is still unclear.
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Effects of IVIg on granulocytes
Neutrophil activation by immune complexes is antagonized by monomeric IgG present in IVIg 
by blocking activating FcγR 8. Under inflammatory conditions, high doses of IVIg can also induce 
human neutrophil and eosinophil death, by virtue of antibodies against the sialic acid-binding 
Ig-like lectin 9 (Siglec-9) and Siglec-8, respectively, present in IVIg 36,37. In addition, by inhibiting 
neutrophil adhesion to endothelium IVIg reduce neutrophil recruitment to inflamed areas in 
a mouse model of sickle cell disease. The molecular mechanism of action of IVIg in this model 
has still to be elucidated 38. Conversely, anti-neutrophil cytoplasmic antibodies (ANCA) and IgG-
dimers present in IVIg can enhance human neutrophil activation and thereby contribute to the 
adverse effects of IVIg therapy in some patients 39,40.
Effects of IVIg on natural killer cells
Contradictory observations have been published on the effect of IVIg on peripheral blood 
natural killer cells (NK cells). First, in women with recurrent spontaneous abortions accompa-
nied with elevated NK cell levels, treatment with IVIg is associated with a favourable pregnancy 
outcome as IVIg suppress the percentage of NK cells in peripheral blood and reduce their 
functional activity 41-43. On the other hand, beneficial effects of IVIg treatment in patients 
with Kawasaki disease and seizure disorders are accompanied by increased NK cell activity in 
peripheral blood 44. In addition, IVIg stimulate the production of IL-12 by mononuclear cells, 
which leads to increased anti-tumor activity of NK cells, thereby reducing tumor spread in mice 
45. However, differences between NK-cell subtypes and the site at which the NK cells exert their 
function might explain the apparent contradictions between these studies. The enhanced 
NK-cell activity in blood of Kawasaki patients might in fact reflect reduced recruitment to the 
site of infection 44. It is also important to note that NK cells are capable of interacting with 
other innate immune cells. We have reported that multimers present in IVIg enhance antibody 
dependent cell-mediated cytotoxicity (ADCC) of DC by NK cells. Thus, by promoting the interac-
tion between NK cells and DC, IVIg might reduce the antigen-presenting pool and inhibit T-cell 
priming induced by DC 46. 
Effects of IVIg on adaptive cellular immunity
Effects of IVIg on T-cell subsets
IVIg inhibit human T cell proliferation and cytokine production after mitogenic and allogeneic 
stimulation in vitro as effectively as calcineurin inhibitors 22,47. The mode of action by which IVIg 
inhibits T-cell activation is so far not completely elucidated and likely involves multiple path-
ways. Inhibition might occur by natural autoantibodies against TCR, CD4 and MHC class I that 
are present in IVIg preparations 2. The inhibitory effect of IVIg on T-cell activation is partly due 
to suppression of antigen presenting cells (as discussed above), but is certainly also mediated 
by a direct interaction of IVIg with T cells. IVIg suppress proliferation and cytokine production 
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of purified T cells 47,48 by inhibition of IL-2 production by T cells at a post-transcriptional level 
47 and induction of lymphocyte apoptosis via Fas (CD95) and activation of caspases 49. Pre-
treatment of activated T cells with IVIg has been reported to attenuate neurotoxicity of human 
T cells, possibly through an effect on LFA-1 expression, and by lowering the level of Fas and FasL 
expression on T cells 50. 
In rat models, IVIg have been shown to be protective against two distinct T cell mediated 
autoimmune diseases, i.e. uveoretinitis and encephalomyelitis 51-53. Interestingly, IVIg can 
directly bind to activated, but not to resting rat T cells, thus suggesting FcγR independent 
interaction of IVIg with T cells 53. In addition, IVIg treatment protects against GVHD in rats, which 
was associated with decreased proliferation of lymphocytes, reduced production of IFN-γ and 
enhancement of apoptosis of activated T cells 54. Reduced proliferative responses of T cells might 
also explain the beneficial effect in lupus like syndrome and atherosclerosis in mice 55,56. Yet IVIg 
treatment is not effective in T cell-mediated concanavalin A-induced hepatitis in mice  57.
Although the suppressive effects of IVIg on T cells are significant, how IVIg affect the function 
of distinct T-cell subsets is unclear. Interestingly, IVIg have been shown to expand and enhance 
the functions of human and murine Foxp3+ regulatory T cells (Tregs) both in vitro and in vivo 
58-61. Thus, beneficial effects of IVIg in patients are associated with an increase in Tregs both 
functionally and numerically 59,60, while IVIg failed to protect against encephalomyelitis in mice 
that were depleted of the Tregs population 58. The mechanisms underlying the IVIg mediated 
expansion, and enhanced suppressive properties of Tregs remain unclear and are in need of 
further investigation. Interestingly, both CD4+CD25+ Treg and CD4+CD25- non-Treg bind IVIg, 
but Tregs better that non-Treg 58. We speculate that most of the direct effects of IVIg on T cells 
published before are mediated by activation of Tregs. It is at present unknown to which surface 
molecules on Tregs IgG binds. It is tempting to speculate that self reactive natural autoantibod-
ies present in IVIg preparations may play an important role.
Interaction of IVIg with B cells
The therapeutic effects of IVIg in several antibody-mediated diseases are not merely due to 
passive effects, such as neutralization and FcγR blockade. They also include suppression of the 
expansion of autoreactive B lymphocytes through signalling via FcγRIIB, idiotypes mediated 
inhibition of B-cell receptors, and neutralization of cytokines such as the B-cell survival factors 
BAFF and APRIL 49,62-67. Binding of the anti-idiotypic antibodies to the surface IgG or IgM of B 
cells can transmit negative signals and result in down modulation of pathogenic auto-antibody 
production 2. In addition, IVIg can induce the secretion of IgG reacting against various self- 
and non-self antigens from a unique subset of human B lymphocytes. These de novo induced 
antibodies might further help in controlling reactivities of pathogenic autoantibodies either 
by idiotype-mediated mechanisms or by sequestering autoantigens 67. Analogous to these in 
vitro findings, IVIg therapy in women with recurrent spontaneous abortion is accompanied by 
decrease in the peripheral blood B cell numbers 41. 
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ThE IMMuNOMOdulaTORY EffECTS Of IvIG IN vIvO: RESulTS fROM 
ClINICal ExPERIENCE
IVIg have major clinical impact in the treatment of various diseases caused by hyperactivity 
of the cellular arm of the immune system. Both in autoimmune diseases and transplantation, 
considerable progress has been made in recent years in elucidation of the effects of IVIg on 
cellular immunity in experimental animal models, but these models might not always repro-
duce the complexity of the diseases in the human situation. Limited data are available on the 
mechanistic effects of IVIg treatment on cellular immunity in patients.
IVIg in immune thrombocytopenic purpura (ITP) 
The precise mechanisms of action of IVIg in patients with ITP remain controversial, and include 
at least inhibition of platelet phagocytosis by FcγR blockade (as discussed in the monocytes 
section above). Treatment with IVIg also results in a rapid, but transient increase of anti-inflam-
matory cytokines 68, which are thought to further reduce the phagocytic activity of the reticulo-
endothelial system. Stable remission and good prognosis after IVIg therapy has been reported 
to be associated with a Th0 or Th2 cytokine pattern, whereas sustained high expression of IFN-γ 
reflects poor prognosis for ITP 69. A strong association between FcγRIIB polymorphisms and 
development of chronic disease in children with acute ITP suggests involvement of this recep-
tor in ITP pathogenesis in humans 70. However, the importance of inhibitory FcγRIIB receptor 
or inhibition of IFN-γ signalling in mediating the therapeutic effects of IVIg, as suggested by 
animal studies, remains to be determined in patients.
IVIg in Kawasaki Disease 
Serum levels of pro-inflammatory cytokines are elevated in patients with Kawasaki disease, 
which stimulate de novo production of acute phase proteins causing thrombocytosis and fever 
in response to tissue injury. Following IVIg therapy, the expression of adhesion molecule CD11b 
on neutrophils, and of inflammatory cytokines and chemokines including IL-6, G-CSF and 
C-reactive protein, are significantly decreased 31,71,72, while IL1Ra is increased. More recently, 
gene array analysis has revealed that IVIg down regulate transcripts of activating FcγRI and 
FcγRIII receptors and the chemokine receptor CCR2 in monocytes. In addition the production 
of monocyte derived inflammatory proteins adrenomedullin, S100 A8, A9 and A12 were sup-
pressed 9. Interestingly, FCGR2B transcripts were not increased following IVIg therapy, although 
the staining intensity for CD32 was unchanged 9. These results suggest that IVIg in patients 
can balance the expression of activating and inhibitory FcγR but, unlike mouse models, this 
modulation might not involve up-regulation of FcγRIIB. 
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IVIg in Guillain-Barré syndrome
Cellular interactions mediated through the release of cytokines play a role in the pathogenesis 
of GBS. The majority of the patients with GBS show elevated serum levels of TNF and IL-1β, 
inflammatory cytokines that can induce demyelination of peripheral nerves. Following IVIg 
therapy, these cytokines decline significantly 73,74. Further, a recent study has demonstrated 
that the number of Tregs in acute stage GBS patients is significantly decreased and attains the 
level of  healthy controls in stable patients following IVIg therapy 60. In addition, soluble TNF 
receptor II is increased in the serum of patients following IVIg therapy, which may inhibit the 
demyelinating effect of TNF in the peripheral nerves 74.
IVIg in transplantation
Following allogeneic hematopoietic stem cell transplantation, a potential beneficial effect of 
IVIg in preventing GVHD has been reported, but it requires a high dose of IVIg 75. The beneficial 
effects of IVIg in GVHD were not confirmed in other studies, but there were differences in dos-
ing strategy in various studies 4. The utility of targeted trough levels for IVIg dosing in GVHD is 
a potential area of investigation.
To shorten the waiting time for solid organ transplantation and to improve graft survival, 
sensitized patients with high titers of donor-specific anti-HLA antibodies are treated with IVIg, 
often in combination with plasmapheresis, anti-lymphocyte antibody or immunoadsorption 
techniques. In addition, IVIg are used to facilitate transplantation of ABO incompatible organs. 
After organ transplantation, IVIg have been used successfully for treatment of antibody medi-
ated rejection 76. In renal transplant patients, IVIg are effective as treatment of steroid resistant 
cell mediated rejection 3,5. In addition, prophylactic administration of hyperimmune anti-HBV 
surface antigen specific IVIg (anti-HBs IVIg) in hepatitis B-infected liver transplant patients 
protects against acute rejection 23,77. 
Together, IVIg could be a powerful treatment for controlling the acute rejection process after 
organ transplantation. However, clinical trials are needed to determine whether IVIg adminis-
tration allows reduction or discontinuation of the maintenance immunosuppressive treatment 
(e.g. cyclosporine) in order to reduce the long term side effects after transplantation. 
Future perspectives
Antibodies are the “first line defence” mechanism of our immune system, with a broad reper-
toire of activities, and exert a wide range of effector functions. Therapeutically administered 
antibodies in the form of IVIg, as a physiological means to modulate the immune system, have 
proven over the years to be effective. IVIg targets the cellular immune compartment at multiple 
levels, including innate and adaptive immune cells (Figure 1). Although increasing numbers of 
animal models have provided us with new insights, the reported mechanisms of action of IVIg 
are either not confirmed in patients or have shown discrepancies. Future studies in humans 
must focus on immune cells at the site of inflammation or in lymphoid tissues. Due to the 
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high costs and the upcoming shortage of IVIg as a consequence of shortage in donated blood 
plasma, it is important to identify the active components in IVIg in various diseases. Although 
IgG dimers and sialylated IgG have shown promising results in experimental models, their 
efficacy in patients needs to be established. Purification of the anti-inflammatory compound 
or production of synthetic or biological alternatives of IVIg will enable us to selectively target 
pathogenic immune activity.  
Figure 1: A schematic representation of the proposed mechanisms of action of Intravenous Immunoglobulin (IVIg) on cellular immunity. 
IVIg target the cellular immune compartment at multiple levels, including innate and adaptive immune cells. IVIg interact with DC, macrophages 
(MǾ) and granulocytes mainly via activating and inhibitory Fcγ receptors. Monomeric IgG in IVIg preparations can block the interaction of 
immune complexes with activating Fcγ receptors, thereby inhibiting endocytosis and phagocytosis by DC and macrophages, and activation of 
granulocytes. IgG dimers in IVIg preparations binding to activating Fcγ receptors on macrophages induce the expression of the inhibitory FcγRIIB 
and suppress expression of IFNγR2, thereby inhibiting macrophages functions. In addition, IgG dimers promote ADCC of DC by NK cells, resulting 
in reduced T-cell activation. IgG dimers suppress macrophage and B-cell functions by ligating FcγRIIB. In addition, F(ab’)2-mediated effects of 
natural antibodies present in IVIg have been described for DC activation (mainly via CD40), granulocytes (induction of apoptosis via Siglec) and B 
cells (idiotype-mediated inhibition of B-cell receptors). Interactions between IVIg and Tregs via yet unknown mechanisms lead to expansion and 
increased suppressive function of Tregs. 
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Summary and discussion
Introduction
Over de last four decades, liver transplantation has evolved from an experimental therapy for a 
limited number of selected patients to the treatment of choice of patients with end stage liver 
diseases. This remarkable success is in part attributable to the development of immunosup-
pressive drug therapy. The introduction of calcineurin inhibitors and other immunosuppressive 
agents has led to a dramatic reduction in the incidence and the severity of acute rejection, 
and consequently to a significantly improved graft and patient survival during the first post-
operative years. Still, the long term outcome of liver transplantation has not improved in 
similar degree 1,2. Today, the main obstacles to successful long term patient survival are the 
high incidence of cancer, infection, renal failure, and cardiovascular diseases, due to life long 
use of immunosuppressive drugs 3-8. Currently, the main challenge of transplant physicians 
is to improve the long term outcomes after liver transplantation by optimising the current 
immunosuppressive regimen and dosing strategy in order to reduce toxicity, or by exploring 
therapeutic potentials of new immunosuppressive drugs with moderate side effects 2.
Aim of this dissertation
The overall aim of this dissertation was to explore ways of reducing long term side effects 
of immunosuppressive drugs in liver transplant recipients by either optimising the current 
dosing strategy of cyclosporine, and to investigate the therapeutic potential of alternative 
immunosuppressive drugs, in particular intravenous immunoglobulins (IVIg). Our final goal 
is to develop a less toxic immunosuppressive protocol to be used as therapy to prevent liver 
allograft rejection. The basic concept behind our approach is based upon the clinical observa-
tion that liver transplant patients treated with anti-HBs IVIg, a form of hyperimmune IVIg, as 
prophylaxis, had a two-until three-fold lower risk of rejection (chapter 3) 9-11. Based on this 
finding, we investigated the effect of IVIg on different cell types mediating innate and adap-
tive immunity, searching for the explanation for the beneficial effects of IVIg in hampering the 
process of cell mediated rejection. Better understanding of the effects of IVIg on the cellular 
immune response, may help us to identify the therapeutic potential of IVIg in preventing trans-
plant rejection, which can form a basis to develop a less toxic immunosuppressive regimen 
after liver transplantation. 
Main findings
Benefits and drawbacks of cyclosporine dosing based on C2 levels 
In chapter 2, we investigated the effect of cyclosporine dose reduction based on cyclosporine 
whole blood concentration two hours after administration (C2 levels) on renal function in 
long term liver transplant recipients. Cyclosporine C2 levels were measured in 60 stable liver 
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transplant recipients more than 1 year after transplantation, and dose reduction was performed 
if C2 levels exceeded the recommended target range of 600 ng/ml ± 20 % 
12. In twenty three 
patients (38%), C2 levels were above the upper limit of the target range, whereas C2 levels were 
within the target range in 27% of the patients. In twenty of the 23 patients with high C2 levels, 
the cyclosporine dose was reduced. Although cyclosporine target levels were reached rapidly in 
these patients, at 6 months follow up, no improvement of renal function, lipid levels or systolic 
blood pressure was observed. However, after cyclosporine dose reduction, one patient expe-
rienced an episode of acute cellular rejection, in 2 patients primary biliary cirrhosis recurred, 
and one patient had a recurrence of autoimmune hepatitis. We concluded that according to 
current recommendations 12,13, cyclosporine overexposure is common among long term liver 
transplant patients. However, cyclosporine dose reduction based on recommended C2 levels 
did not result in an improvement in renal function, and was accompanied with a risk of immune 
activation, especially in patients on cyclosporine monotherapy.
The therapeutic potential of anti – HBs IVIg
In order to explore the therapeutic potential of other immunosuppressive drugs with fewer 
side effects, chapter 3 became the cornerstone of this thesis, as it forms the basis for a concept 
to investigate the immunomodulatory effects of anti-viral, and non-specific IVIg on the cel-
lular rejection response. In this chapter, the efficacy of anti-viral intravenous immunoglobulins 
(anti-HBs IVIg and anti-CMV IVIg) 10,11 in preventing acute rejection after liver transplantation 
was assessed in a retrospective analysis, and the effects of anti-HBs IVIg was correlated to their 
effects on immune cells in vitro. We observed that HBsAg positive liver transplant patients (n 
= 40), who were treated with anti-HBs IVIg as prophylaxis to prevent HBV re-infection of the 
graft, had a significant lower incidence of acute rejection compared to recipients without viral 
hepatitis (n = 147) (12% versus 34%; p = 0.012). The low rejection rate was not due to a pos-
sible immune compromised status of HBsAg positive patients before transplantation, as the 
incidence of rejection in HCV positive recipients (n = 29) was similar to that in the control group. 
Treatment with anti-CMV IVIg (n = 18), which resulted in lower anti-CMV IVIg concentrations 
in serum compared to anti-HBs IVIg-treatment, did not protect against rejection. In vitro, anti-
HBs IVIg suppressed functional maturation and cytokine production by human blood-derived 
dendritic cells (DC) at concentrations similar to the serum concentrations reached during anti-
HBs IVIg treatment of liver graft recipients. In addition, anti-HBs IVIg inhibited allo-antigen and 
lectin stimulated proliferation of peripheral T cells. We concluded that anti-HBs IVIg protects 
against acute rejection after liver transplantation, probably by functional inhibition of the two 
principal immune cells involved in allograft rejection, DC and T cells. The mechanism by which 
IVIg suppress DC and T-cell function was so far unidentified. In the next chapters, we investi-
gated in depth the immunomodulatory effect of IVIg on immune cells of, both from innate and 
adaptive origin 14, which play altogether a pivotal role in the cellular rejection process.
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The immunomodulatory mechanisms of action of IVIg
Comparison to calcineurin inhibitors
In chapter 4, we compared the suppressive effects of IVIg and the calcineurin inhibitors (CNI), 
Cyclosporin (CsA) and Tacrolimus (TAC), on human blood derived T cells and DC. This is the 
first study to compare the immune suppressive activities of IVIg to that of CNI, which are 
the first treatment of choice in current immunosuppressive regimens 5,8. CNI are extremely 
potent inhibitors of T-cell proliferation and cytokine production. Whether CNI also inhibit DC 
function was less clear 15. We observed that IVIg and CNI were equally effective in inhibiting 
proliferation and IFN-γ production of T cells after polyclonal or allogeneic stimulation. CD8+ 
T cells were preferentially affected by both IVIg and CNI. Like CNI, addition of IVIg at later time 
points after T-cell activation suppressed mitotic progression of responding T cells. Furthermore, 
IVIg treated DC were suppressed in their capacity to stimulate allogeneic T-cell proliferation 
by 73 ± 12%, whereas DC function was not affected by CNI. The decreased allogeneic T-cell 
stimulatory capacity of IVIg treated DC correlated to induction of DC apoptosis, and decreased 
up-regulation of CD40 and CD80. The direct inhibitory effect of IVIg on T cell proliferation was 
at least partly due to induction of apoptosis in T cells. From these observations, we concluded 
that IVIg have strong suppressive effects on both human T cells and DC, while CNI only inhibit 
T cells. Therefore, by simultaneous targeting both T cells and DC, we assume that IVIg will be 
superior in the control of acute rejection and GVHD in comparison to CNI. Since long term IVIg 
treatment has no significant side effects 16,17, inclusion of IVIg in immunosuppressive therapy 
after transplantation may enable dose reduction of CNI, and thereby contribute to a lower rate 
of complications. The exact mechanisms of action of the inhibitory effects of IVIg on DC and T 
cells were further investigated in chapter 5 and 7.
Effects of IVIg on dendritic cell function: ADCC by NK cells
IVIg can modulate the function of various immune cells, including suppressing the capacity 
of DC to stimulate T cells. In chapter 5, we focused on the mechanism by which IVIg affect DC 
function 18,19. We found that the decreased T-cell stimulatory capacity of IVIg treated DC was 
associated with induction of cell death in mature DC. Interestingly, IVIg treatment itself did not 
induce DC death directly, as the increased death of IVIg treated DC only occurred when cultured 
together with other immune cells, i.e. NK cells. Cross-talk between DC and NK cells can result 
in lysis, inhibition or maturation of DC by NK cells, and reciprocally, DC can activate or inhibit 
NK-cell functions. The final outcome of DC-NK cell interaction depends on the conditions in 
which both cell types encounter each other 20-23, and will subsequently determine the develop-
ment of the following adaptive immune response. We showed that DC matured in presence 
of IVIg (IVIg-DC) activated NK cells, and increased their IFN-γ production and degranulation. 
The activated NK cells induced apoptosis of the majority of IVIg-DC. In consequence, only in 
the presence of NK cells, IVIg-DC were 4-fold impaired in their T-cell priming capacity. This was 
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due to NK-cell mediated Antibody Dependent Cellular Cytotoxicity (ADCC) to IVIg-DC. By bind-
ing to the DC surface, IVIg facilitate recognition of mature DC by NK cells via FcγRIII, resulting 
in activation of the NK cells. These NK cells acquire the capacity to kill the IVIg-DC by ADCC, 
thereby reducing in numbers the total stimulatory pool of mature DC. Interestingly, multimers, 
but not monomers of human monoclonal IgG, could replicates these effects of IVIg, suggesting 
that IgG multimers and/or dimers in IVIg preparations are the active components that induce 
NK-cell activation and DC lysis. Furthermore, IVIg-DC down regulated the expression of NKp30 
and KIR receptors, and induced the generation of CD56brightCD16-CCR7+ lymph node type NK 
cells. These results identify a novel pathway, in which IVIg induce ADCC of mature DC by NK 
cells, which downsizes the antigen presenting pool, and inhibits T-cell priming 24. This model 
has also physiological relevance, in that it predicts that immunoglobulin-antigen immune com-
plexes may contribute to the termination of T-cell responses during for example clearance of 
infections. As immune complexes emerge when antigen-specific antibodies have been formed, 
physiological immune complexes as well as immune complexes in IVIg preparations may be the 
essential element that contributes to the termination or “cooling down” of the immune system 
after prolonged activation 25-27. ADCC, identified as the pathway by which IVIg exert one of 
their immunomodulatory capacities, is probably not restricted to DC killing. Any cell type that 
expresses Fcγ receptors 28,29, that are able to bind IgG complexes, can be identified as “target 
cells”, and is therefore susceptible to ADCC by NK cells. On the other hand, in anti-rejection 
protocol in which therapeutic antibodies such as anti-CD4 mAb, rabbit anti-thymocyte globulin 
(rATG) or co-stimulation blockade are used 30-33, NK cells may cause destruction of antibody 
coated target cells through antibody-dependent cell-mediated cytotoxicity. In chapter 6, we 
elaborate further on this hypothesis.
The changing role of Natural Killer cells in transplantation
Natural killer cells (NK cells) have the potential to display different functional activities after 
transplantation. The traditional view is that NK cells are predominantly pro-inflammatory and 
although they are not sufficient to reject a solid allograft directly, they may contribute to early 
chemokine and cytokine production after transplantation, and thereby supporting the rejec-
tion response 34-36. In contrast, NK cells have been implicated as playing a role in the induction 
of tolerance to organ allografts 24,37, while in hematopoietic stem cell transplantation (HSCT) 
the presence of NK cell alloreactivity in the graft-versus-host direction has been associated with 
a reduced incidence of leukemia relapse without causing graft-versus-host disease (GVHD) 38,39. 
In chapter 6, we reviewed a manuscript  24, in which a novel role for NK cells in the setting of 
co-stimulation blockade was identified. Alloreactive NK cells of recipient origin were found to 
have the capacity to kill donor derived antigen presenting cells (APC), thereby reducing T cell 
priming and promoting long term skin graft acceptance in mice with co-stimulation block-
ade therapy. Depletion of NK cells from the recipient mice using a depleting anti-NK1.1 mAb 
rendered the triple costimulation blockade treatment completely ineffective at preventing the 
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rejection response. We went further and tried to provide an answer for the intriguing question: 
How do NK cells influence the efficacy of triple costimulation blockade? We proposed a model 
in which the cells to which the co-stimulation blockade antibodies have bound are rendered 
susceptible to ADCC killing by NK cells. NK cells express Fcγ receptor III (CD16), which recognizes 
IgG1 and IgG3 subclasses 40. Each component of the triple co-stimulation blockade treatment, 
anti-CD154, CTLA-4Ig and anti-OX40L can bind with either T cells or APC 41. Their Fc region can 
be recognized by Fcγ receptor III on the NK cell, which can lead to ADCC of both donor APC 
and recipient T cells. In addition, another pathway of alloreactive killing may also be triggered, 
when NK cells derived from the transplant exert cytotoxicity against the APC of the recipient. 
The latter is less significant for small grafts, however, for liver grafts where large numbers of 
viable donor lymphocytes migrate into the recipient after transplantation, NK alloreactivity in 
the graft-versus-host direction could become important 38,39,42,43.
NK cells are innate immune effector cells expressing stimulatory receptors,  which recognize 
antigens on virus infected cells and tumour cells, while sparing normal cells 44. In immuno-
compromised transplant patients, it is essential to try maintaining these useful functions of 
NK cells. Therefore, the effects of immunosuppressive therapies on NK cell function should be 
considered.
Effects of IVIg on regulatory T cells
In the past decades clinical evidence has emerged that IVIg are effective in the treatment of 
T cell mediated autoimmune diseases 16,45,46, and that hyperimmune IVIg can protect against 
T cell mediated graft rejection after liver transplantation 9. In vitro, IVIg can inhibit human T 
cell proliferation and cytokine production as mentioned in chapters 3 and 4 47,48. Chapter 7 
focus on the mechanisms by which IVIg attenuate T cell responses. We investigated whether 
IVIg might enhance the suppressive function of CD4+CD25+Foxp3+ regulatory T cells, and 
if so, whether IVIg could prevent allograft rejection. Regulatory T cells (Tregs), expressing 
the lineage marker Foxp3, are considered to be the “central immune regulator” of numerous 
immune processes, including transplant rejection 49. Importantly, Tregs play a critical role in 
induction and maintenance of transplantation tolerance in experimental animal models 50-52. 
Several compounds have been identified that stimulate the expansion and/or the suppressive 
capacity of Tregs. For example, rapamycin has shown to stimulate Tregs activity and survival in 
vitro 53-57 and in vivo in patients 57. In addition, therapeutic antibodies such as anti-CD4 mAb 
and rabbit anti-thymocyte globulin (rATG) can enhance the activation status and the expan-
sion of CD4+CD25+Foxp3+ cells 32,58-60. Although all these compounds are suited for in vitro 
expansion and stimulation of Tregs, their use to activate Tregs in vivo will be accompanied by 
severe side effects upon administration to patients. Therefore, activation of Tregs in vivo by 
IVIg treatment may be an attractive option for prophylaxis of transplant rejection, since IVIg 
administration is safe and has moderate side effects. 
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We demonstrated that IVIg bind to both human and mouse regulatory T cells. As IVIg 
contain natural antibodies that recognize different surface molecules such as TCR-β, CD3 and 
CD4 on cells of the immune system 61,62, binding of IgG to human Tregs may be  mediated 
via its variable F(ab)2 region, which recognise surface molecules on Tregs. Still, the binding 
of the Fc region of IgG to an unknown Fc receptor on Tregs is a possibility 63-66. In addition, 
in both human and mouse, IVIg treatment enhanced the activation of CD4+CD25+Foxp3+ 
regulatory T cells, as detected by increased expression of surface activation markers and ZAP70 
phosphorylation. Pre-incubation of human CD4+CD25+ T cells with IVIg enhanced their ability 
to suppress allogeneic T cell proliferation, while depletion of human CD25+ T cells resulted in 
a twofold reduction in IVIg mediated suppression of allogeneic T cell proliferation. Interest-
ingly, both direct binding of IVIg to Tregs and the presence of APC were necessary to induce 
Tregs activation. Probably, APC may serve in this situation as an intermediate to crosslink the 
Fc regions of IgG present on the Tregs surface, and thereby induce Tregs activation. In vivo, 
administration of IVIg prevented T cell mediated rejection of fully mismatched skin grafts in 
immunodeficient mice reconstituted with total CD4+ T cells. Significantly, this IVIg effect was 
lost when CD4+CD25+ cells were depleted from T-cells which were transferred to the mice, sug-
gesting that IVIg mediate their effect through Tregs. IVIg was able to induce allograft survival 
that persisted well beyond 100 days even though the IVIg treatment was discontinued after 
day 14. Unfortunately, we have been unable to achieve prolongation of skin allograft survival 
in immunologically intact wild-type mice using IVIg treatment. This is probably due to the large 
total number of alloreactive T cells in intact recipients compared with that in the adoptive 
transfer experiments described in our study. This observation suggests that the full potential 
of IVIg to modulate adaptive T cell responses may be seen only in combination with strategies 
that induce partial T cell depletion and attenuation. Of the potential candidates that exist, 
depletion using CAMPATH-1H 67 or modulation using humanised anti-CD3 antibodies 68 appear 
to be promising. In this chapter, we demonstrated that through direct binding and activation of 
regulatory T cells, IVIg can mediate suppression of allogeneic T cell responses, highlighting an 
additional, important property of these compounds. Importantly, the data underline that the 
therapeutic potential for IVIg may be broader than today’s application in organ transplantation 
considers.
Modulation of the cellular immune system by IVIg
In chapter 8, we discuss recent advances in our understanding of different, mutually non-
exclusive mechanisms of action of IVIg on cells of innate and adaptive immunity. The means by 
which IVIg exert therapeutic effects in disorders mediated by cellular immunity has remained 
an enigma. Clinical improvements followed by IVIg treatment often extend beyond the half-life 
of infused IgG, suggesting that IVIg modify the cellular immune compartment for a prolonged 
period. 
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Both in autoimmune diseases and transplantation, considerable progress has been made 
in recent years in elucidation of the effects of IVIg on cellular immunity in experimental animal 
models, but these models might not always reproduce the complexity of the diseases in the 
human situation. Limited data are available on the mechanistic effects of IVIg treatment on 
cellular immunity in patients. 
In the light of organ transplantation, it is of importance to study the effects of IVIg on the 
indirect pathway of allorecognition as donor derived APC are probably deceased long after 
transplantation 69,70. The indirect pathway in which the recipients’ T cells recognise the donor 
antigen displayed by the MHC of recipients' APC will therefore become more prominent late 
after transplantation. In this thesis, we focus on the effect of IVIg on the direct pathway of 
allorecognition. How IVIg alter the process of antigen processing and antigen presentation by 
recipients’ APC, and how IVIg modify recipient’ APC-T cell interaction, remain important ques-
tions to be answered by future studies.
Antibodies have a broad repertoire of activities and exert a wide range of effector functions. 
Therapeutically administered antibodies in the form of IVIg, as a physiological means to 
modulate the immune system, have proven over the years to be effective in various immune 
mediated diseases 16,17,26,71-73. IVIg target the cellular immune compartment at multiple levels, 
including innate and adaptive immune cells. Although increasing numbers of animal models 
have provided new insights, the reported mechanisms of action of IVIg are either not confirmed 
in patients or there are discrepancies between human and animal data. 
Potential active components in IVIg
Due to the high costs and the upcoming shortage of IVIg as a consequence of shortage in 
donated blood plasma, it is important to identify the active components in IVIg in various 
diseases. IgG dimers and sialylated IgG are promising candidates with encouraging results in 
experimental models 26,74. 
Due to the large donor pool and different manipulations during the purification process of 
IVIg, complexes of anti-idiotype antibodies with complementary idiotypes can be formed 25. 
Since dimers and aggregates in IVIg preparations can induce severe side effects, several precau-
tions are taken during the production process to keep the content of multimers in IVIg prepara-
tions minimal 75. Immune complexes are generally regarded as pro-inflammatory compounds, 
still, evidence is emerging that they can also mediate suppression of immune responses 76,77. 
IgG dimers can be one of the active anti-inflammatory components in IVIg, which are not pres-
ent in the immune repertoire of a single individual, but are formed in plasma pools due to 
idiotype-anti-idiotype complex formation between IgG molecules from different individuals 
25,78,79. However, it is less likely that IgG dimer is the only component of IVIg that is responsible 
for the immunomodulatory effects. Moreover, some effects on DC in vitro can be recapitulated 
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by F(ab)’ fragments and are probably related to natural antibodies against cytokines present 
in IVIg 80.
Accumulating evidences suggest that the immune system is able to make distinctions 
between different antibody glycoforms. Interactions between human IgG and Fc receptors 
depend on the sugar structures on both the IgG as on the receptor 81. G0 glycoforms (no 
galactoses and no sialic acids) correspond to the pro-inflammatory effects of IgG 74. In two 
animal models, Kaneko et al. illustrated that sialylated S2 glycoforms are responsible for the 
anti-inflammatory effects of IVIg 82. The precise sialylation pattern that is responsible for the 
anti-inflammatory activity of IVIg in experimental models is the 2,6-linkage of sialic acid to 
galactose on the glycan found at Asn297 in the CH2 region of human IgG 83. Since sialylation 
at this residue reduced FcγR binding, it was proposed that this 2,6-sialylated IgG binds to a 
currently unidentified sialic acid-specific receptor on macrophages in the marginal zone of 
the spleen. These marginal zone macrophages in turn enhance the expression of FcγRIIB on 
conventional macrophages by an unknown mechanism. Whether the effects of IVIg on human 
immune cells are mediated by this minor sialylated component of IVIg (1-2 %) is at present 
unknown. 
Overall, the efficacy of IgG dimers and sialylated IgG in patients needs to be established in 
future research. Purification of the anti-inflammatory compound or production of synthetic or 
biological alternatives of IVIg will enable us to selectively target pathogenic immune activity 
in future. 
Liver transplantation and IVIg
The liver is an intriguing organ. Spontaneous acceptance of liver allografts occurs in several spe-
cies. However, tolerance is rare in human transplant patients even though liver graft rejection is 
relatively easily reversed 84-87. Histological features of acute rejection in liver transplantation are 
similar to those in other organs. Nevertheless, mechanisms of rejection of liver transplants may 
differ in degrees and cellular involvement. Liver-specific cell populations, such as Kupffer cells, 
liver sinusoidal epithelial cells, and hepatic stellate cells, may contribute to liver tolerogenicity. 
Other mechanisms, such as microchimerism, soluble MHC molecules, and regulatory T cells, 
may also participate in inducing tolerance 88. Understanding the mechanisms of liver transplant 
rejection and tolerance, and the availability of better immune monitoring could help develop 
strategies to recognize tolerance and reduce rejection.
In the setting of liver transplantation, physicians still face the challenge to improve the 
long term outcomes after transplantation by either optimising current immunosuppressive 
regimens or exploring therapeutic potentials of immunosuppressive drugs. In this thesis, we 
investigated the effects of IVIg on the different cells of the innate and adaptive immune system, 
which altogether play a pivotal role in the cellular rejection response. Based on the reported 
findings from our group and others, we consider IVIg as a promising candidate for prevention 
and attenuation of the acute cellular rejection process after liver transplantation. 
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It is important to note that IVIg treatment will probably not be able to create “true allograft 
tolerance”, defined as acceptance of donor allograft despite cessation of immunosuppressive 
therapy, while retaining the ability to reject third party allografts 33. As IVIg contain a broad 
spectrum of antibodies and can exert various immunomodulatory properties, most of the 
identified immunomodulatory mechanisms appear to be antigen non-specific, and therefore 
do not specifically target or modulate alloreactive T cells. However, IVIg is still a compound that 
can induce strong suppression of alloreactive responses at multiple levels, while having moder-
ate side effects. Therefore, IVIg should be considered as a serious candidate to be included in 
future immunosuppressive regimens. First, clinical trials are needed to determine optimal dos-
ing strategy, and to assess whether IVIg administration allows reduction or discontinuation of 
the maintenance immunosuppressive treatment in order to reduce the long term side effects 
after liver transplantation. 
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CONCluSIONS
Chapter 2: Cyclosporine dose reduction based on recommended C2 levels does not result in an 
improvement in renal function in stable liver transplant patients, and is accompanied with the 
risk of immune activation, especially in patients on cyclosporine monotherapy.
Chapter 3: Anti-HBs IVIg protects against acute rejection after liver transplantation, probably by 
functional inhibition of the two principal celtypes involved in allograft rejection, i.e. dendritic 
cells and T cells.
Chapter 4: Since IVIg can simultaneously target both human T cells and DC, while calcineurin 
inhibitors only inhibit T cells, inclusion of IVIg in future immunosuppressive therapy after 
transplantation may enable dose reduction of calcineurin inhibitors, and thereby contribute to 
a lower rate of complications. 
Chapter 5: By influencing the bi-directional interaction between DC and NK cells, IVIg induce 
ADCC of mature DC by NK cells, and thereby hamper the ability of the innate immunity to trig-
ger proper T-cell activation.
Chapter 6: Antibody-dependent cell-mediated cytotoxicity (ADCC) killing of APC mediated by 
NK cells may be a pathway by which costimulation blockade induces graft acceptance in a skin 
transplant model.
Chapter 7: Through immediate binding and activation of regulatory T cells, IVIg can mediate 
suppression of allogeneic T cell responses, high-lighting an additional, important therapeutic 
potential of IVIg in organ transplantation.
Chapter 8: With the novel immunomodulatory mechanisms of IVIg identified and the upcom-
ing shortage of IVIg, it is important to identify the active components in IVIg in various diseases.
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fuTuRE dIRECTIONS
Mechanisms of action
•	 	Identify	the	active	components	in	IVIg	preparations.	IgG	dimers	and	sialylated	IgG	are	prom-
ising candidates.
•	 	IVIg	treatment	is	accompanied	by	increased	NK	cell	activity	and	cytokine	production	in vitro 
and in vivo in peripheral blood of treated patients. NK cells are innate immune effector cells 
expressing receptors,  which recognize antigens on virus infected cells and tumour cells, 
while sparing normal cells. We would like to study the potential anti-tumor and anti-viral 
effects of IVIg, first in vitro, and later in liver transplant patients.
•	 	Study	 the	 immunomodulatory	 effects	 of	 IVIg	 on	 liver-specific	 cell	 populations,	 such	 as	
Kupffer cells, liver sinusoidal epithelial cells, and hepatic stellate cells.
•	 	Study	the	effect	of	IVIg	on	the	indirect	pathway	of	donor	antigen	processing	and	presenta-
tion by recipients’ APC.
Ex vivo immunomonitoring in patients
•	 	Investigate	the	immunomodulatory	effects	of	IVIg	ex vivo in patients receiving IVIg therapy 
or anti-HBs IVIg therapy. Focus will be on the changes in cellular immunity, cytokine profile 
and expression of inhibitory Fc receptors.
Include IVIg in the immunosuppressive protocol after liver transplantation
•	 Determine	with	clinical	trials	the	optimal	dosing	strategy	for	IVIg
•	 	Assess	whether	IVIg	administration	allows	reduction	or	discontinuation	of	the	maintenance	
immunosuppressive treatment in order to reduce the long term side effects after liver trans-
plantation.
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SaMENvaTTING EN dISCuSSIE
Introductie  
Levertransplantatie als therapie is de afgelopen veertig jaar geëvolueerd van een experimen-
tele behandeling voor een beperkt aantal patiënten naar de aangewezen behandeling voor 
patiënten met eindstadium leverfalen. Dit succes is mede te danken aan de ontwikkeling van 
immunosuppressieve geneesmiddelen, die de afweer tegen de getransplanteerde lever kun-
nen onderdrukken. De introductie van calcineurineremmers en andere immunosuppressieve 
geneesmiddelen leidde tot een sterke afname van het aantal acute afstotingen na levertrans-
plantatie. Dientengevolge is er een aanzienlijke verbetering opgetreden van de overleving in 
de eerste vijf jaar na transplantatie van zowel de getransplanteerde lever als de patiënt. De 
lange termijn overleving na levertransplantatie is ondanks deze ontwikkelingen echter niet 
verbeterd 1,2. De hoge incidentie van bijwerkingen veroorzaakt door levenslang gebruik van 
immunosuppressieve medicijnen. Bijwerkingen, zoals maligniteiten, infecties, nierfalen en 
cardiovasculaire ziekten 3-8, vormen heden de grootste belemmering voor een optimaal lange 
termijn resultaat na levertransplantatie. De grootste uitdaging voor transplantatie genees-
kundigen is dan ook het verbeteren van de lange termijn overleving na levertransplantatie 
door het huidige immunosuppressieve regime te optimaliseren met betere dosering om de 
toxiciteit te verminderen, of de therapeutische mogelijkheden van nieuwe immunosuppres-
sieve geneesmiddelen met minder bijwerkingen te onderzoeken 1.
Doel van het onderzoek
Het doel van het onderzoek zoals beschreven in dit proefschrift was om te onderzoeken hoe 
de lange termijn bijwerkingen van de huidige immunosuppressieve behandeling kan worden 
gereduceerd. Het uiteindelijke streven is om een minder toxisch immunosuppressief protocol 
te ontwikkelen als behandeling van afstoting na levertransplantatie. Hierbij werd de mogelijk-
heid onderzocht om de dosering van ciclosporine, de hoeksteen van de huidige immunosup-
pressieve behandeling, te verlagen met als doel bijwerkingen te verminderen. Tevens werden 
de therapeutische mogelijkheden van het immunosuppressieve geneesmiddel, intraveneuze 
immunoglobulinen (IVIg), onderzocht. Het idee om IVIg te gebruiken als immunosuppressief 
geneesmiddel komt voort uit een klinische observatie. Het risico op acute afstoting bleek twee 
tot driemaal verlaagd te zijn bij levertransplantatie patiënten die werden behandeld met anti-
viraal IVIg (hoofdstuk 3) 9-11. Deze patiënten werden behandeld met anti-Hepatitis B surface 
IVIg (anti-HBs IVIg) om re-infectie van het getransplanteerde orgaan door het hepatitis B virus 
te voorkomen. Op basis van deze waarneming, werden we geïnspireerd om verder de immu-
nologische effecten van IVIg op verschillende celtypen, van zowel het innate als adaptieve 
immune systeem, te onderzoeken. Hierdoor wilden wij inzicht verkrijgen in hoe IVIg het immu-
nologische proces van cellulaire afstoting kan remmen en of IVIg een nieuwe therapeutische 
benadering kan zijn om afstoting na levertransplantatie te voorkomen. 
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Belangrijkste bevindingen
Voor- en nadelen van ciclosporine dosering op basis van C2 spiegels
In hoofdstuk 2, onderzochten wij de mogelijkheden om de doseringsstrategie van ciclosporine 
te verbeteren. Hierbij werden de effecten van ciclosporine dosis reductie, op geleide van bloed 
spiegels twee uur na ciclosporine inname (C2 spiegels) op de nierfunctie van stabiele lever-
transplantatie patiënten onderzocht. Hiertoe werden de C2 spiegels gemeten in 60 stabiele 
ontvangers van een levertransplantaat (>1 jaar na levertransplantatie). De ciclosporine dosis 
werd vervolgens gereduceerd als de C2 spiegel boven het aanbevolen niveau van 600 ng/ml ± 
20% lag 12. Bij 23 patiënten (38%) werd een C2 spiegel boven de bovengrens van het aanbevo-
len niveau gemeten. In 27% van de gevallen lag C2 binnen de normaalwaarde. Twintig van de 
23 patiënten met een “te hoge” blootstelling aan ciclosporine stemden in met het verlagen van 
de ciclosporine dosis. Het aanbevolen C2 niveau werd snel bereikt met een gemiddelde ciclos-
porine dosis reductie van 25%. Echter, deze dosis reductie leidde na 6 maanden follow up niet 
tot een verbetering van het belangrijkste eindpunt; de nierfunctie, of secundaire eindpunten; 
het lipidenspectrum of de systolische bloeddruk. Met betrekking tot de immunosuppressieve 
effectiviteit kreeg één patiënt een acute afstoting en bij drie andere patiënten keerde de oor-
spronkelijke ziekte terug in het transplantaat (twee gevallen van primaire biliaire cirrose en één 
geval van autoimmune hepatitis). Wij concludeerden daarom dat, uitgaande van huidige aan-
bevelingen 12,13, een te hoge blootstelling aan ciclosporine frequent voorkomt onder stabiele 
levertransplantatie patiënten. Een dosis reductie met als doel het realiseren van de aanbevolen 
C2 spiegels, leidt echter niet tot verbetering van de nierfunctie en geeft mogelijk zelfs een risico 
op immuunactivatie.
Therapeutische mogelijkheden van anti-HBs IVIg
Hoofdstuk 3 is de hoeksteen van dit proefschrift, die als doel heeft de therapeutische mogelijk-
heden van immunosuppressieve geneesmiddelen met minder bijwerkingen te onderzoeken. 
Het fungeert als basis concept om de immunomodulatoire effecten van anti–virale, en later 
non-specifieke IVIg op de cellulaire immune response te onderzoeken. In dit hoofdstuk, werden 
de effecten van anti-virale intraveneuze immunoglobulinen anti-HBs IVIg 9,10 en anti-cytomega-
lovirus IVIg (anti-CMV IVIg) in het voorkomen van acute afstoting na levertransplantatie onder-
zocht in een retrospectieve analyse en gecorreleerd aan hun in vitro effecten op immuuncellen. 
Hepatitis B surface antigeen (HBsAg) positieve levertransplantatie patiënten (n = 40), die 
worden behandeld met anti-HBs IVIg als profylaxe om HBV-reïnfectie van het transplantaat te 
voorkomen bleken een lagere incidentie van afstoting te hebben vergeleken met patiënten 
zonder virale hepatitis (n = 147) (12% versus 34%; p = 0.012). De lagere incidentie van afstoting 
was niet toe te schrijven aan een mogelijke immuungecompromitteerde status van de HBsAg 
positieve patiënten voor transplantatie, gezien de incidentie van afstoting in de HCV positieve 
patiënten (n = 29) gelijk is aan de controle groep zonder virale hepatitis. De behandeling met 
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anti-CMV IVIg (n = 18) bood geen bescherming tegen acute afstoting. Anti-HBs IVIg remden in 
vitro de functionele maturatie en cytokine productie van humane dendritische cellen (DC) bij 
een anti-HBs IVIg concentratie vergelijkbaar met het gemeten serum concentratie in de met 
anti-HBs IVIg behandelde levertransplantatie patiënten. Tevens, remde anti-HBs IVIg de pro-
liferatie van perifere T cellen gestimuleerd door lectine of allo-antigenen. Wij concludeerden 
dat anti-HBs IVIg beschermt tegen acute afstoting na levertransplantatie, mogelijk door func-
tionele inhibitie van twee belangrijke celtypen van het immuunsysteem die betrokken zijn bij 
het afstotingsproces; DC en T cellen. Het mechanisme van DC en T cel remming door IVIg was 
voor dit proefschrift nog niet bekend. De volgende hoofdstukken beschrijven ons diepgaand 
onderzoek naar de immunomodulatoire effecten van IVIg op immuuncellen van zowel innate 
als adaptieve origine 14, die samen een cruciale rol spelen in het cellulaire afstotingsproces.
Immunomodulatoire mechanismen van IVIg
Een vergelijking met calcineurineremmers
De bruikbaarheid van non-specifieke IVIg als profylaxe voor acute afstoting en graft versus host 
disease (GVHD) na transplantatie wordt in hoofdstuk 4 beschreven. De immunomodulatoire 
effecten van IVIg en calcineurineremmers (CNI), ciclosporine (CsA) en tacrolimus (TAC), op 
humane T cellen en DC werden vergeleken. Dit is de eerste studie die de immunosuppressieve 
activiteiten van IVIg vergelijkt met die van de CNI. In het huidige immunosuppressieve regime 
zijn CNI de eerste keuze om acute afstoting na orgaan transplantatie te voorkomen 6,8. CNI rem-
men potent de proliferatie en de cytokine productie van T cellen, maar of CNI de functie van 
DC kunnen beïnvloeden is nog onduidelijk 15. In onze studie waren IVIg en CNI even effectief 
in het remmen van de proliferatie en IFN-γ productie door T cellen. Vooral de proliferatie van 
CD8+ T cellen werd geremd door zowel IVIg als CNI. Zelfs bij toevoeging van IVIg of CNI op een 
later tijdstip na T cel stimulatie, kon de proliferatie van reagerende T cellen worden geremd. 
Naast een effect op T cellen, remde IVIg ook het vermogen van DC om allogene T cellen te 
stimuleren met 73 ± 12%, terwijl behandeling met CNI de DC functie niet beïnvloedde. Het 
door IVIg geïnduceerde verminderde vermogen van DC om allogene T cellen te stimuleren 
bleek gerelateerd te zijn aan de inductie van DC apoptose en verminderde expressie van CD40 
en CD80. Door de lagere expressie van de co-stimulatoire moleculen zijn de overgebleven DC 
minder goed in staat op T cellen te activeren. Het remmend effect van IVIg op T cellen was ook 
toe te schrijven aan de inductie van apoptose van behandelde T cellen. IVIg heeft dus een sterk 
suppressief effect op zowel humane T cellen als DC, terwijl CNI alleen T cellen remmen. Omdat 
IVIg tegelijkertijd zowel DC als T cellen kunnen attaqueren, postuleren wij dat IVIg mogelijk 
beter het afstotingsproces onder bedwang kunnen houden dan CNI. Uit eerdere onderzoeken, 
weten we dat lange termijn gebruik van IVIg geen ernstige bijwerkingen heeft 16,17, derhalve 
kan toevoeging van IVIg aan de huidige immunosuppressieve behandeling mogelijk leiden tot 
dosis reductie van CNI, met als mogelijke gevolg een lagere incidentie van aan CNI gerelateerde 
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bijwerkingen. De exacte mechanismen van de remmende effecten van IVIg op DC en T cellen 
zullen verder uiteen gezet worden in de hoofdstukken 5 en 7.
Effecten van IVIg op DC functie: ADCC door NK cellen
In hoofdstuk 5 focussen wij op het remmende effect van IVIg op de DC functie om T cellen te 
stimuleren 18,19. Opmerkelijk, is het feit dat IVIg niet op een directe manier de eerder beschreven 
celdood van DC induceerde. De toename in celdood trad pas op wanneer de door IVIg behan-
delde DC werden gekweekt samen met natural killer cellen (NK cellen). NK cellen kunnen DC 
remmen door DC te lyseren, hun uitrijping te voorkomen of hun activiteit stop te zetten. Omge-
keerd kunnen DC het functioneren van NK cellen remmen of juist stimuleren. De uiteindelijke 
uitkomst van de interactie tussen DC en NK cellen is afhankelijk van de conditie waarin de beide 
celtypen elkaar treffen 20-23 en bepaalt uiteindelijk welke soort adaptieve immuunrespons 
hierna wordt gevormd. Wij hebben aangetoond dat DC die behandeld zijn met IVIg (IVIg-DC) 
NK cellen konden activeren en daarmee de IFN-γ productie en het degranulerende vermogen 
van NK cellen verhoogden. De geactiveerde NK cellen konden op hun beurt apoptose van de 
IVIg-DC bewerkstelligen. De verhoogde DC apoptose trad alleen maar op in aanwezigheid van 
NK cellen. Hierdoor waren de IVIg-DC minder goed in staat om T cellen te stimuleren. De T cel 
stimulatoire capaciteit van IVIg-DC was viermaal verlaagd vergeleken met de onbehandelde 
DC. Dit effect was toe te schrijven aan de door antilichaam geïnduceerde cellulaire cytotoxici-
teit (ADCC) geïnduceerd door NK cellen. IVIg, gebonden aan het DC celoppervlak, resulteerde 
in herkenning van de mature IVIg-DC door NK cellen via Fc gamma receptor III (FcγRIII), met als 
gevolg dat de NK cellen geactiveerd raakten. De geactiveerde NK cellen konden op hun beurt 
de IVIg-DC doden met het ADCC mechanisme. Hiermee werd het aantal mature DC in de T cel 
stimulatoire pool verlaagd. Opvallend was dat de alleen multimeren, en niet de monomeren 
van humaan IgG, dit effect induceerden. Dit suggereert dat de IgG multimeren de actieve 
componenten zijn in IVIg, die NK cel activatie en DC lysis  bewerkstelligden. Daarnaast hebben 
wij aangetoond dat IVIg-DC de expressie van NKp30 en KIR receptoren op NK cellen verlaagde 
en dat IVIg-DC de aanmaak van CD56brightCD16-CCR7+  lymfeklier type NK cellen gunstig beïn-
vloedde. Deze resultaten onderscheiden een nieuw mechanisme, waarin IVIg therapie leidt 
tot ADCC van mature DC door NK cellen. Dit heeft tot gevolg dat het aantal mature DC dat 
T cellen kunnen primen wordt verlaagd 24. Dit model is fysiologisch relevant, aangezien niet 
alleen multimeren in IVIg, maar ook immuuncomplexen van IgG en antigenen, T cel reacties 
kunnen beëindigen ten tijde van bijvoorbeeld klaring van infecties. Omdat immuuncomplexen 
worden gevormd aan het eind van het humorale immuunrespons, kunnen zowel fysiologische 
immuuncomplexen als immuuncomplexen in IVIg preparaten bijdragen tot het “afkoelen” van 
actieve immuunprocessen 25-27. ADCC, hier geïdentificeerd als het mechanisme waarmee IVIg 
haar immunomodulatoire capaciteiten beoefent, remt waarschijnlijk niet alleen DC. Waar-
schijnlijk kan elk celtype dat Fcγ receptoren tot expressie brengt 28,29 en dus IgG complexen 
kan binden op dezelfde wijze als doelwit fungeren voor ADCC gemedieerde celdoding. Tevens 
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is het belangrijk om op te merken dat therapeutische antilichamen, gebruikt in verscheidene 
protocollen tegen afstoting na orgaan transplantatie, antilichamen zoals anti-CD4 mAb, rab-
bit anti-thymocyte globulin (rATG) of costimulatie blokkade 30-33, ook ADCC van de door de 
antilichamen gebonden cellen kunnen induceren. In hoofdstuk 6, zetten wij de discussie over 
deze hypothese en de rol van NK cellen in transplantatie voort.
Rolverandering van de NK cel in transplantatie
NK cellen hebben verscheidene functionele activiteiten na transplantatie. De gebruikelijke 
opvatting is dat NK cellen voornamelijk pro-inflammatoir zijn, maar dat zij niet zelfstandig 
een transplantaat kunnen afstoten. Wel kunnen NK cellen het afstotingsproces bevorderen 
door vroege chemokine en cytokine productie na transplantatie 34,35. Uit recente publicaties, 
komt naar voren dat NK cellen ook een belangrijke rol spelen in tolerantie inductie na orgaan 
transplantatie 24,35-37. Tevens kan na hematogene stamcel transplantatie (HSCT), de NK-cel allo-
reactiviteit van donor richting ontvanger leiden tot verminderde terugkeer van leukemie 38,39. 
In hoofdstuk 6 bespraken wij een publicatie 24, die een nieuwe rol van NK cellen na het 
toepassen van costimulatie blokkade hadden vastgesteld. Co-stimulatie blokkade met, anti-
CD154, CTLA-4Ig en anti-OX40L, voorkwam dat een huidtransplantaat wordt afgestoten in een 
muizen model. Ze hadden in deze publicatie aangetoond dat alloreactieve NK cellen van de 
ontvanger de antigeen presenterende cellen (APC) van de donor kunnen doden bij gebruik 
van co-stimulatie blokkade. Door hun behandeling met anti-CD154, CTLA-4Ig en anti-OX40L 
konden zij het proces van T cel priming remmen en induceerden langdurige acceptatie van het 
huidtransplantaat. Na depletie van NK cellen met anti-NK1.1 mAb bleek de triple costimulatie 
blokkade therapie echter geheel ineffectief te zijn in het voorkomen van afstoting. Wij bespra-
ken verder hoe de NK cellen de effectiviteit van costimulatie blokkade kunnen beïnvloeden. 
Hierbij introduceerden wij de hypothese dat costimulatie blokkade antilichamen, anti-CD154, 
CTLA-4Ig and anti-OX40L, mogelijk aan hun target cellen binden en hiermee de gebonden 
cellen gevoelig maken voor ADCC killing door NK cellen. Elke component van de costimulatie 
blokkade therapie, anti-CD154, CTLA-4Ig en anti-OX40L, kan binden aan APC of T cellen 40, met 
als gevolg dat costimulatie blokkade antilichamen zowel ADCC killing van zowel donor APC 
als ontvanger T cellen door NK cellen kan induceren. Daarnaast kunnen ook donor NK cellen, 
die migreren uit het transplantaat, ontvanger APC doden. Dit geldt voornamelijk voor grote 
orgaantransplantaten zoals de lever, waarbij na transplantatie grote aantallen donor lymfocy-
ten in de ontvanger migreren. In dit geval, kan de NK-alloreactiviteit in de graft versus host 
richting relevant worden 38,39,41,42.
NK cellen zijn innate effector immuuncellen die stimulatoire receptoren tot expressie brengen. 
Hiermee herkennen ze door virus geïnfecteerde cellen en tumorcellen, terwijl normale cellen 
worden gespaard 43,44. In immuungecompromitteerde transplantatie patiënten, is het belangrijk 
om deze bruikbare functie van de NK cellen te behouden. Daarom dienen de effecten van ver-
scheidene immunosuppressieve geneesmiddelen op NK cellen verder te worden onderzocht.
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Effecten van IVIg op regulatoire T cellen
In toenemende mate wordt er gerapporteerd dat IVIg effectief is in de behandeling van, door 
T cellen gemedieerde, auto-immuunziekten 17,45,46. Tevens hebben wij waargenomen dat anti-
HBs IVIg beschermt tegen T cel gemedieerde afstoting na levertransplantatie 11. IVIg remt in 
vitro de humane T cel proliferatie en cytokine productie zoals besproken in hoofdstuk 3 en 4 
47,48. In hoofdstuk 7 ligt de focus op het mechanisme waarmee IVIg de T cel respons beïnvloedt. 
Wij onderzochten of IVIg de suppressieve functie van CD4+CD25+Foxp3+ regulatoire T cellen 
verhoogt en of IVIg de T cel gemedieerde afstoting kan voorkomen in een transplantatie model 
met muizen. Regulatoire T cellen (Tregs) brengen de lineage marker Foxp3 tot expressie en 
zijn de “centrale immuunregulator” van verscheidene immuunprocessen waaronder transplan-
taatafstoting 49. Tregs spelen een cruciale rol in de inductie en handhaving van transplantaat 
acceptatie in verschillende experimentele diermodellen 50-52. Verschillende middelen, die Tregs 
kunnen stimuleren en expanderen, zijn geïdentificeerd. Van rapamycine is bijvoorbeeld aange-
toond dat dit de overleving en de activiteit van Tregs gunstig kan beïnvloeden, zowel in vitro 
53-56, als in vivo in transplantatie patiënten 57. Daarnaast kunnen therapeutische antilichamen 
zoals anti-CD4mAb en rATG een verhoogde activatie status en een toename van het aantal 
Tregs induceren 32,58-60. Hoewel deze geneesmiddelen geschikt zijn voor in vitro expansie kan 
het gebruik van deze geneesmiddelen om Tregs  in vivo te activeren in patiënten gepaard gaan 
met serieuze bijwerkingen. Indien behandeling met IVIg leidt tot een verhoging van de sup-
pressieve functie van Tregs en daarmee T cel gemedieerde afstoting kan worden verminderd in 
hevigheid of zelfs voorkomen, dan is dit een aantrekkelijke optie, aangezien IVIg behandeling 
weinig bijwerkingen heeft.
Wij hebben aangetoond dat IVIg kon binden aan Tregs van muizen en mensen. IVIg bevat 
antilichamen die van nature voorkomen in het lichaam en deze natuurlijke antilichamen kun-
nen verschillende oppervlakte moleculen zoals TCR-β, CD3 en CD4 op immuuncellen kunnen 
herkennen 61,62. Mogelijk bindt IVIg aan Tregs via haar variabele F(ab’)2 fragment door herken-
ning van een van de oppervlakte moleculen op Tregs. Ook binding van de Fc regio van het 
IgG aan een onbekende Fc receptor op Tregs behoort tot de mogelijkheid 63-66. IVIg therapie 
leidde tot activatie van CD4+CD25+Foxp3+ Tregs in zowel experimenten met humane cellen 
als in een muizen model. Deze activatie werd geobjectiveerd door verhoogde expressie van 
activatie markers en ZAP70 fosforylatie. Voorbehandeling van humane Tregs met IVIg leidde 
tot een toename van hun suppressieve capaciteit vergeleken met onbehandelde Tregs. Dus 
IVIg oefende haar effect op T cellen uit via Tregs. Na depletie van humane CD25+ Tregs nam 
de suppressieve capaciteit van IVIg op humane T cel proliferatie met tweevoud af, dit in 
vergelijking met condities waarbij Tregs wel aanwezig zijn. Opmerkelijk is dat zowel binding 
van IgG als de aanwezigheid van APC noodzakelijk was om Tregs te activeren. Waarschijnlijk 
fungeerden de APC in deze situatie als een intermediair die de Fc regio’s van het IgG op 
het Tregs oppervlak crosslinkten waardoor de activatie van Treg werd geïnduceerd. In vivo 
beschermde de IVIg behandeling tegen T cel gemedieerde afstoting van een huidtransplantaat 
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in een muizenmodel, waarbij immuundeficiënte muizen werden gerepopuleerd met totale 
CD4+ T cellen. Opvallend is dat het beschreven IVIg effect geheel afwezig was wanneer de 
muizen werden gereconstitueerd met CD4+CD25- conventionele T cellen zonder Tregs. In 
aanwezigheid van Tregs, induceerde IVIg therapie een transplantaat overleving van langer dan 
100 dagen. Dit terwijl de behandeling alleen werd toegepast gedurende de eerste 14 dagen na 
transplantatie. Helaas konden wij met IVIg therapie geen transplantaat acceptatie induceren 
in een transplantatie model met immuun competente wild type muizen. Dit werd mogelijk 
veroorzaakt door de grote aantal alloreactieve T cellen in immuun competente muizen. Om 
de maximale therapeutische potentie van IVIg in het moduleren van T cel reacties te kunnen 
realiseren, zal IVIg therapie daarom waarschijnlijk gecombineerd moeten worden met een T cel 
depleterende strategie. Mogelijk kan IVIg therapie worden gecombineerd CAMPATH-1H 67 of 
gehumaniseerde anti-CD3 antilichamen 68. In dit hoofdstuk hebben we aangetoond dat IVIg 
T cel reacties kunnen remmen door het suppressieve effect van Tregs te verhogen via directe 
binding en activatie. Toepassingsmogelijkheden van IVIg als therapie na orgaan transplantatie 
zijn daarom mogelijk groter dan in de huidige richtlijnen is vastgelegd.
Modulatie van het cellulaire immuunsysteem door IVIg
In hoofdstuk 8 vatten we samen wij de recente ontwikkelingen in werkingsmechanismen van 
IVIg op cellen van het innate en adaptieve immuunsysteem. Hiermee proberen we de thera-
peutische effecten van IVIg op verscheidene ziekten veroorzaakt door verstoringen op cellulair 
niveau te doorgronden. Klinische verbeteringen veroorzaakt door IVIg duren veel langer voort 
dan de tijd dat IVIg na behandeling in het lichaam aanwezig is. Dit suggereert dat IVIg langdu-
rige effecten kan induceren op het cellulaire immuunrespons.
Zowel op het gebied van auto-immuunziekten en transplantatie zijn er recente bevindingen 
die de effecten van IVIg op het cellulaire immuunrespons kan verklaren in diermodellen. Echter, 
deze waarnemingen komen niet altijd overeen met werkingsmechanismen van IVIg in het 
complexe humane immuunsysteem. Tevens zijn er onvoldoende gegevens voorhanden om de 
effecten van IVIg om de cellulaire immuun response in patiënten te verklaren. 
Na orgaantransplantatie is het verder van belang om de effecten van IVIg op de indirecte 
antigeenpresentatie te onderzoeken. Het proces van indirecte antigeen presentatie is in prin-
cipe het proces waarbij de ontvanger APC het donor antigen presenteren aan de ontvanger T 
cellen 69,70. Vroeg na transplantatie kunnen donor APC, die uit het transplantaat migreren, T cel-
len van de ontvanger activeren (directe antigeenpresentatie), echter, lang na transplantatie 
zullen de donor APC waarschijnlijk niet meer aanwezig zijn. De ontvanger APC zullen dan zelf 
het proces van T cel priming induceren. Langer na transplantatie zal dit proces van antigeen 
presentatie een prominentere rol gaan innemen. Hoe IVIg dit proces van antigeenprocessing 
en presentatie door ontvanger APC beïnvloedt en hoe IVIg de DC-T cel interactie moduleert, is 
een belangrijke vraag voor verder onderzoek.
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Antilichamen vormen de frontlinie van ons afweersysteem. Ze hebben een breed repertoire 
aan activiteiten en een variëteit aan effector functies. Het therapeutisch toedienen van antili-
chamen in de vorm van IVIg om ons immuunsysteem te moduleren is over de jaren effectief 
gebleken 16,17,27,71-73. IVIg attaqueert het immuunsysteem op meerdere niveaus, waaronder het 
innate en adaptieve immuunsysteem. Hoewel veel studies in diermodellen nieuwe werkings-
mechanismen van IVIg rapporten, zijn deze mechanismen vaak niet bevestigd in patiënten en 
kennen veel tegenstrijdigheden. 
Mogelijke actieve componenten in IVIg
Het is belangrijk om de actieve componenten in IVIg preparaten te identificeren, gezien de 
hoge kosten van de behandeling en de opkomende tekorten aan plasma donoren. IgG dime-
ren en gesialyleerd IgG zijn potentiële kandidaten, maar hun effectiviteit in patiënten dient nog 
te worden onderzocht 27,74.
Door het grote donor aantal en door verscheidene bewerkingsmethoden tijdens het 
zuiveren van IVIg, worden er complexen gevormd tussen anti-idiotype antilichamen met hun 
complementaire idiotype-antilichaam 25. Dimeren en aggregaten in IVIg preparaten kunnen 
ernstige bijwerkingen induceren. De producenten van IVIg proberen om bovenstaande reden 
het percentage aggregaten laag te houden 75. Immuuncomplexen worden dan ook gezien als 
pro-inflammatoire elementen, echter, in toenemende mate zijn er aanwijzingen dat immuun-
complexen ook anti-inflammatoir kunnen werken 76,77. IgG dimeren kunnen een van de actieve 
componenten zijn van IVIg. Dimeren komen niet voor in het immuun repertoire van een 
individu, maar wordt juist gevormd door het idiotype-anti-idiotype complex formatie tussen 
IgG moleculen van verscheidene individuen 25,78,79. IgG dimeer is waarschijnlijk niet de enige 
component verantwoordelijk voor de immunomodulatoire effecten van IVIg. Sommige effecten 
van IVIg op DC kunnen in vitro ook worden bewerkstelligd door F(ab)’ fragmenten. Dit is waar-
schijnlijk gerelateerd aan natuurlijke antilichamen tegen cytokinen, die aanwezig zijn in IVIg 80.
Het immuunsysteem maakt onderscheid tussen verschillende glycosylatie vormen van een 
antilichaam. Interactie tussen een IgG en een Fc receptor is afhankelijk van suikergroepen aan 
zowel het antilichaam als aan de receptor 81. “G0 glycoforms” (no galactoses and no sialic acids) 
hangt samen met de pro-inflammatoire effecten van IgG 74. Dit terwijl “sialylated S2 glycoforms” 
gecorreleerd zijn aan de anti-inflammatoire effecten van IgG 82,83. Of de anti-inflammatoire 
effecten van IVIg gerelateerd zijn aan de gesialyleerde vorm van IgG, die 1-2% aanwezig is in 
IVIg, is onbekend. 
Effecten van IgG dimeren en gesialyleerde IgG in patiënten dienen te worden onderzocht. 
Het zuiveren van de componenten met anti-inflammatoire activiteit of productie van synthe-
tische of biologische alternatieven van IVIg kan er mogelijk voor zorgen dat pathologische 
immuunactivatie in verschillende ziekten selectief worden aangepakt.
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Levertransplantatie en IVIg
De lever is een fascinerend orgaan. Spontane acceptatie van een levertransplantaat komt voor 
bij sommige diersoorten.  Acute afstoting van de lever is bij mensen vaak goed behandelbaar, 
maar tolerantie komt weinig voor bij levertransplantatie patiënten 84-87. Het feit dat de lever 
een relatief tolerogeen orgaan is, doet ons vermoeden dat het mechanisme van afstoting 
wat genuanceerder is vergeleken met de afstotingsreactie van andere getransplanteerde 
organen zoals hart en nier. Leverspecifieke cellen, zoals Kupffer cellen, lever sinusoïdale cellen 
en stellate cellen, kunnen een belangrijke rol spelen bij het tolerogene karakter van de lever. 
Andere mechanismen zoals microchimerisme, “soluble” MHC moleculen en Tregs, kunnen ook 
bijdragen tot tolerantie inductie 88. Door de mechanismen van lever afstoting en tolerantie te 
doorgronden en door immunomonitoring na levertransplantatie tot te passen, zullen we in de 
toekomst in staat zijn strategieën te ontwikkelen om tolerantie te herkennen en afstoting te 
reduceren.
Op het gebied van transplantatie, hebben artsen nog steeds de uitdaging om de lange 
termijn uitkomsten en overleving na transplantatie te verbeteren. Men probeert dit te bereiken 
door het optimaliseren van de huidige immunosuppressieve regimes of door de therapeutische 
mogelijkheden van andere geneesmiddelen te onderzoeken. In dit proefschrift, onderzochten 
wij de effecten van IVIg op verscheidene cellen van zowel het innate als het adaptieve immuun-
systeem. In het bijzonder DC, T cellen en NK cellen spelen een cruciale rol in cellulaire afstoting. 
Op basis van onze resultaten en die van andere onderzoekers, kunnen wij concluderen dat IVIg 
een potente behandeling is om  cellulaire afstoting na levertransplantatie te voorkomen.
Het is van belang op te merken dat IVIg therapie waarschijnlijk niet zal leiden tot “echte 
transplantaat acceptatie” gedefinieerd als orgaan acceptatie na het staken van de behandeling, 
terwijl de ontvanger de potentie behoudt om een transplantaat van de derde partij af te stoten. 
IVIg kent een breed spectrum aan antilichamen en heeft verscheidene immunomodulatoire 
activiteiten. Omdat de meeste mechanismen, die geïdentificeerd zijn, antigeen-specifiek 
blijken te zijn, is het onwaarschijnlijk dat IVIg specifiek “echte transplantaat acceptatie” kan rea-
liseren door het moduleren van alloreactieve T cellen. Echter, IVIg therapie kan de alloreactieve 
immuun response sterk remmen, terwijl de behandeling meestal weinig bijwerkingen heeft. 
IVIg dient daarom als een serieuze kandidaat te worden beschouwd om te worden toegevoegd 
aan toekomstige immunosuppressieve protocollen na transplantatie. Eerst zijn klinische trials 
echter nog noodzakelijk om de optimale dosering te bepalen. Ook dient te worden onderzocht 
of IVIg therapie daadwerkelijk kan leiden tot dosisverlaging of zelfs stoppen van de huidige 
toxische immunosuppressieve geneesmiddelen en hiermee de lange termijn bijwerkingen na 
orgaantransplantatie kan verlagen.
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CONCluSIES
Hoofdstuk 2: Ciclosporine dosis reductie op basis van de aanbevolen C2 spiegels leidt niet tot 
verbetering van de nierfunctie in stabiele levertransplantatie patiënten en geeft mogelijk zelfs 
een risico op immuunactivatie, met name bij patiënten met ciclosporine monotherapie.
Hoofdstuk 3: Anti-HBs IVIg beschermt tegen acute afstoting na levertransplantatie, mogelijk 
door functionele inhibitie van twee belangrijke immune celtypen die betrokken zijn in het 
afstotingsproces; DC en T cellen.
Hoofdstuk 4: Omdat IVIg tegelijkertijd zowel DC als T cellen kan attaqueren in het afstotingspro-
ces, kan toevoeging van IVIg aan de huidige immunosuppressieve behandeling leiden tot dosis 
reductie van CNI, met als gevolg een lagere incidentie van aan CNI gerelateerde bijwerkingen.
Hoofdstuk 5: Door de interactie tussen DC en NK cellen te beïnvloeden, leidt IVIg therapie 
tot antilichaam geïnduceerde cellulaire cytotoxiciteit (ADCC) doding van mature DC door NK 
cellen. Het gevolg is dat het aantal mature DC in de T cel stimulatoire pool wordt verlaagd en 
daarmee ook het proces van T cel priming.
Hoofdstuk 6: Antilichaam geïnduceerde cellulaire cytotoxiciteit (ADCC) doding van APC door 
NK cellen kan een mechanisme zijn, waarbij costimulatie blokkade leidt tot transplantaat 
acceptatie in een transplantatie model.
Hoofdstuk 7: IVIg kan T cel responsen remmen door het suppressieve effect van Tregs te verho-
gen via directe binding en activatie, hiermee worden de toepassingsmogelijkheden van IVIg als 
therapie na orgaan transplantatie mogelijk vergroot.
Hoofdstuk 8: Het is belangrijk om de actieve componenten in IVIg preparaten te identificeren 
gezien de recent geïdentificeerde werkingsmechanismen een de opkomende tekorten aan 
plasma donoren.
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abbREvIaTIONS
ADCC Antibody Dependent Cellular Cytotoxicity;
Anti-HBs IVIg anti-HBV surface antigen-specific IVIg
APC Antigen presenting cells; 
AUC area under the curve;
BMDC bone marrow-derived dendritic cells;
C0 cyclosporine whole blood concentration before administration
C2 cyclosporine whole blood concentration two hours after administration
CFSE  Carboxyfluorescein diacetate Succinimidyl Ester;
CIDP Chronic Inflammatory Demyelinating Polyneuropathy
CNI Calcineurin inhibitors; 
CsA Cyclosporine;
CTRL-DC   DC stimulated with pro-inflammatory cytokines;
DC  Dendritic Cells;
EAE Experimental Autoimmune Encephalomyelitis;
FcγR Fc gamma receptor;
FcRn Neonatal Fc Receptor
GBS Guillain Barré syndrome 
GVHD Graft versus Host Disease; 
HBV Hepatitis B Virus
HBsAg Hepatitis B surface antigen;
HLA Human Leukocyte Antigen;
HRC  humanized monoclonal antibody against human epidermal growth factor 
receptor 2 (Herceptin)
HRC-DC DC stimulated with pro-inflammatory cytokines in presence of 10 mg/ml 
Herceptin;
HSA Human Serum Albumin;
HSA-DC   DC stimulated with pro-inflammatory cytokines in presence of 10 mg/ml 
Human Serum Albumin; 
HSA-Tregs Regulatory T cells pre-treated with HSA;
HSCT Hematopoietic Stem Cell Transplantation;
IFN-γ Interferon γ 
ITP Immune Thrombocytopenic Purpura;
IVIg Intravenous immunoglobulins; 
IVIg-DC  DC stimulated with pro-inflammatory cytokines in presence of 10 mg/ml 
Intravenous Immunoglobulins;
IVIg-Tregs Regulatory T cells pre-treated with IVIg;
MDRD  Modification of Diet in Renal Disease Study formula;
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MHC Major Histocompatibility complex;
MLR Mixed lymphocyte reaction;
MMF mycophenolate mofetil;
Mo-DC Monocyte-derived DC;
MS Multiple Sclerosis 
NCR Natural Cytotoxicity Receptors;
NK cells  Natural Killer cells;
PHA Phytohemagglutinin;
PIDs Primary Immune Deficiencies 
PP1 4-amino-5-(4-methylphenyl)-7-(t-butyl) pyrazole [3,4-d] pyrimidine;
rATG rabbit anti-thymocyte globulin (rATG);
Siglecs Sialic Acid Binding Ig-like Lectins
TAC Tacrolimus ;
TCR T cell Receptor;
Tregs Regulatory T cells;
ZAP70 phophorylated ζ-associated protein 70 
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Soms geloof ik het niet, maar wat ben ik een geluksvogel. Zoveel mensen, die mij gedurende 
mijn promotietraject hebben gesteund en geholpen. Elke dag geniet ik nog met volle teugen 
van “mijn werk” en ik zit vol met nieuwe plannen en ideeën voor de toekomst. Graag wil ik 
iedereen voor hun steun en alle slimme tips bedanken.
Professor Metselaar, beste Herold, met de woorden “Ik weet niet of je wat kan, maar je bent 
wel lekker enthousiast”, heb je mij aangenomen als onderzoeksstudent in 2002. En hiermee 
zette ik ongemerkt de eerste stap van mijn wetenschappelijke carrière. Ik wist toen nog niet 
goed wat mij te wachten stond, maar al snel raakte ik in de ban van de levertransplantatie 
groep. Je directe manier van begeleiden is een verademing. Vaak zeg je dingen, die ik absoluut 
niet wil horen, maar die wel het gewenste effect opleveren. Dank voor je begeleiding, je morele 
steun en alle mogelijkheden die je mij hebt gegeven. De vrijheid in de opzet en ontwikkeling 
van het onderzoek heb ik heel erg gewaardeerd. Ik heb zo ontzettend veel van je geleerd en het 
is voor mij een eer om je als promotor te mogen hebben.
Dr. Kwekkeboom, beste Jaap, onder jouw “wings” heb ik basaal wetenschappelijk onderzoek 
leren doen. Als persoon zijn wij totaal verschillend, maar als een team zijn wij samen “top”. Een 
combinatie van mijn onbezonnen nieuwsgierigheid en jouw precisie en degelijkheid heeft veel 
goed werk opgeleverd. Jij zet voor mij de puntjes, of beter de “de en het-tjes”, op de plekken 
waar ze moeten staan. Dank voor de wijze woorden en de ‘peptalks’, voor alle keren dat het 
tegenzat. Ik heb diepe bewondering voor jou als begeleider en ik hoop dat we in de toekomst 
nog heel veel leuke projecten en proeven kunnen bedenken.
Professor Tilanus, beste Huug, telkens weer, bij elke transplantatie, sta ik versteld van uw 
kunde, expertise en enthousiasme. Ik voel mij altijd bij u thuis, zowel op OK als in de kliniek. Dat 
u een inspiratie bent voor vele jonge chirurgen staat buiten kijf. Dank voor de goede steun en 
adviezen, dank voor het gefluister in mijn oor “Thanya, zet hem op, meid!” en dank voor alles 
wat u voor mij heeft gedaan. Als ik u aan het werk zie, wil ik niets anders dan chirurg worden. 
Het is voor mij een eer om u als voorbeeld te mogen hebben.
Professor Laman, dank voor uw interesse en kritische opmerkingen op mijn proefschrift. 
Ondanks uw drukke schema, nam u rustig de tijd om met mij door de immunologie atlas te 
bladeren. Ons gesprek over cellulaire immuniteit speelt nog iedere keer door mijn hoofd als 
ik het woord “cellular immunity” lees. Beste professor Ten Berge, dank voor het lezen en het 
beoordelen van mijn proefschrift. Als een van de weinige vrouwelijke hoogleraren op trans-
plantatie gebied, heeft u al geruime tijd mijn bewondering. Super, dat u in de commissie plaats 
wilt nemen.
Professor Weimar, u bent een goeroe in de transplantatie wereld, het is een eer om u in de 
grote commissie te mogen hebben. Dank daarvoor.
Professor van Doorn, hartelijk dank dat u bereid bent om plaats te nemen in de grote com-
missie. Als de expert op het gebied van IVIg bent u onmisbaar in dit gezelschap.
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Dr. de Man, beste Rob, uw suggesties op de manuscripten en het proefschrift zijn altijd 
scherp en onderbouwd. U legde de basis voor het HBIg project en onze samenwerking met 
Biotest. Dank voor uw enthousiaste reacties op de geaccepteerde artikelen en presentaties.
Dr. Bayry and professor Kaveri, your “Blood” paper on IVIg and DC is one of the first scientific 
papers I remembered by heart. Never, had I imagined that we would write a review together, 
but we did, and the final outcome was excellent. I hope we can continue this fruitful collabora-
tion in future. 
Professor IJzermans, ik bewonder uw klinische en wetenschappelijke vaardigheden. U, als 
opleider, weet heel goed anderen te inspireren en daardoor het beste uit mensen te halen. Ik 
verheug mij erop om mijn opleiding straks voort te zetten in het Erasmus MC.
Professor Kuipers, dank voor uw interesse en enthousiasme voor dit project. Altijd kan ik bij 
u rekenen op steun en kritische vragen. Het is een groot plezier om op uw afdeling te mogen 
werken.
Dr. van der Laan, beste Luc, bijna was ik jouw AIO geworden. Dank voor je suggesties bij de 
vele werkbesprekingen en artikelen. Je komt altijd heel scherp uit de hoek en dat waardeer ik 
zeer. Zonder jou was ik waarschijnlijk nooit “Rising Star” geworden. Succes met je vele projecten 
en het zal mij niets verbazen als jij de “holy grail” vindt.
Dr. Kazemier, beste Geert, dank voor je suggesties voor de artikelen en voor de wijze woor-
den over de vele dingen. Het oefenen van mijn sollicitatiegesprek met jou, was moeilijker dan 
de sollicitatie zelf. Een betere voorbereiding had ik niet kunnen verzinnen ☺. Ik hoop zoveel 
van je te mogen leren als ik terug ben.
Dr. Tran, beste Khe, als vrouw, moeder én chirurg, ben je voor mij een grote bron van inspi-
ratie. Hoe jij het allemaal weet te combineren, weet ik niet, maar ik wil het ook zo kunnen. Dank 
voor een leuke en leerzame tijd tijdens mijn oudste coschappen en voor je begeleiding tijdens 
de congressen.
Dr. Alwayn, beste Ian, al zit je nu in Canada, ik vind het een hele eer om met je te mogen 
werken. Dank voor je interesse in mijn onderzoek.
Dr. de Jonge, beste Jeroen, levertransplantatie is onze “common factor”. Dank voor je hulp en 
opbeurende woorden, je staat altijd klaar wanneer het nodig is. Super, dank je wel.
Dr. van Hagen, beste Martin, een gesprekje op mijn moeders verjaardag heeft geleid tot een 
fijne samenwerking. Dankzij jou beschikken we nu veel data over IVIg patiënten en ik hoop op 
een succesvolle publicatie in de toekomst.
Dit proefschrift is tot stand gekomen met steun van NWO. De toekenning van de Mozaïek beurs 
was voor mij een grote eer. Ik heb zoveel geleerd van de workshops; hierdoor ben ik altijd 
kritisch blijven denken over mijn werk. Dank voor de mogelijkheden die jullie voor mij hebben 
gecreëerd.
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Dr. Ebers and Dr. Achtstätter, dear Georg and Thomas from Biotest, thank you for your interest 
in the project and the wonderful discussion we had during the meetings. It was a pleasure 
working with both of you.
Drie jaar lang heb ik mijn “ups en downs” beleefd op het MDL lab, ik heb zeer prettig met ieder-
een samengewerkt. Hartelijk dank daarvoor. Naast het harde werken, is de L-vleugel een waar 
“soap serie”. Als ik af en toe mijn “power nap” deed, gebeurde er weer van alles in de koffiekamer 
en op het lab. Altijd weer de eeuwige “strijd” tussen lever en GE, en tussen “LTx” en “Hepatitis”. 
Maar op vrijdagmiddag was het gewoon weer samen borrelen bij Dizzy. Vele (oud)collega’s 
hebben heel veel voor mij betekend en zijn ondertussen vrienden geworden. Graag wil ik in 
het bijzonder noemen:
De LTx groep: Patrick, van jou leerde ik het pipetteren en het labwerk. Samen met jou heb ik 
de vele toevallige bevindingen gedaan, die uiteindelijk tot een artikel hebben geleid. “Serendi-
pity“ noemt men dat, wij weten wel beter. Shanta, jij bent de stille kracht achter de LTx groep, 
dank voor je hulp bij de experimenten. Angela, wat betreft verpakking lijken we op elkaar, maar 
wat betreft inhoud zijn wij totaal verschillend. Achteraf ben ik waarschijnlijk te streng voor je 
geweest, maar tja, ik kon moeilijk afstand nemen van mijn “IVIg baby”. Succes straks met je 
eerste artikel en je proefschrift. Brenda, mijn “partner in crime”, vanaf dag één waren we samen. 
Het begon met een ware teambuilding sessie in een bus vol met bejaarden in Wenen, en het 
eindigde voorlopig met een cocktail aan het zwembad in Rio. Het was super om met je samen 
te werken, en dat etentje staat nog steeds. Dear Scot, somehow you always managed to get 
a role in the MDL-soap ☺. You are an amazing colleague, and sometimes, I have to admit, to 
smart for me to follow. Alice en Antoine, ook al werken jullie niet meer op het lab, ik ben jul-
lie niet vergeten. Dank voor je hulp en interesse in mijn onderzoek. Ozlem, Viviana, Suomi en 
Abdullah, jullie zijn de wetenschappelijke toekomst van de LTx, zet hem op !
Mijn twee paranimfen, jullie zijn beide onmisbaar, dank dat jullie mij vandaag willen steu-
nen. Thonie, jij bent mijn rots in de branding. Altijd stond je voor mij klaar, wanneer ik weer eens 
een “onuitvoerbaar” experiment had bedacht met ’s nachts of in het weekend oogsten, meten 
of spuiten. Mede door jouw toedoen is het proefschrift zo mooi geworden. Jij was degene die 
zorgde dat alles klaarstond als we weer een “mega” experiment hadden. Een betere rechter-
hand had ik mij niet kunnen wensen. Dank voor alles. Lieve Ahmet, “we go way back”. Samen 
college volgen, samen op het lab en nu samen chirurg worden. Jij staat altijd voor mij klaar 
met een luisterend oor en ik kan alles aan je kwijt. Straks samen aan tafel opereren, ik kan niet 
wachten. Je hulp en steun voor dit proefschrift waren onmisbaar. Ik wens je heel veel succes 
met je verdere carrière en je toekomst. 
Mijn lab collega’s: beste Mark, dank voor je hulp bij mijn Nederlandse samenvatting en voor 
alle wetenschappelijke discussies. Ik ken weinig mensen die perfectionistischer zijn dan ik, 
maar jij bent er een van. Jij en Kristien vormen een geweldig paar. Diagnostiek, beste Martine, 
Angela en Jan, ik zat een tijd lang bij jullie op de kamer en het was altijd super gezellig. Ik 
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koester de mooie momenten samen met jullie, waarbij de “knuffeltherapie” en het “klaaguurtje” 
regelmatig voorbij kwamen. Dank voor jullie steun en enthousiasme voor alles wat ik doe. 
Andere collega’s waaronder Marjolein (MOB-je), Leon, Clara, Marjon, Jeroen Stoop, Jeroen Stoof, 
Raymond, Linda, André, Andrea, Yvonne, Marjolein S., Lisette, Chantal, Rekha, Paula, Lianne, 
Eric, Pieter Jan (PJ), Ron en Greta, dank voor de wetenschappelijke discussies, de gezellige uren 
in de koffiekamer, de befaamde karaoke feestjes en borrels.
Het LTx secretariaat, jullie vormen de ruggengraat van de LTx groep. Lara, Anneloes, Marjolein, 
Elly, Sylvia en Fatma, op jullie steun kan ik altijd rekenen. Ik voel mij altijd welkom als ik bij jullie 
ben. Dank voor jullie interesse en ondersteuning. Marjolein, dank voor het regelen van alles 
rondom de promotie, en Sylvia op jouw LTx database kunnen wel 10 AIOS promoveren.
Vele proeven zouden niet zijn gelukt zonder hulp van andere labs. Het Weimar transplantatie 
lab, beste Carla en Nicole, dank voor alles. Ik kon altijd langs komen bij jullie om even wat te 
lenen of voor een praatje. Dank voor jullie interesse in mijn project. Beste Dennis, mijn eerste 
publicatie was samen met jou, dank voor alle tips en trucs voor het promoveren, ze hebben 
geholpen. Veel succes met je verdere carrière. Ook Esmé, Varsha, Thijs, Meindert, Monique en 
Jeroen, dank voor alle gezelligheid tijdens de congressen.
Mevrouw Scherbeijn (afdeling Virologie) dank voor uw hulp bij de proeven uit hoofdstuk 3. 
Dr. de Haas (Sanquin Research) dank voor de 5D2 antilichamen, en Dr. van Kooten (afdeling 
diergeneeskunde, UMC) dank voor het biotinyleren van IVIg.
Being part of the Wood-lab, was an eye-opening experience. Professor Wood, dear Kathryn, 
thank you for giving me the opportunity to perform research in your lab. Dr. Bushell, dear 
Andrew, thank you for being my supervisor and for your help with the Tregs manuscript. I 
have learnt a lot in Oxford and I would like to thank all my colleagues for a wonderful time. 
Dear Nick and Manuela, thank you for your hospitality and your enthusiasm. When I think of 
you two, I miss Oxford, hmmm.. the sunday roast, Manuela’s pudding and your nice garden. 
Dear Ross, Satish and Crissy, we were “the wing D gang”, research was so much fun when you 
guys were around. I enjoyed the “nerd club” and all the fun we had in the tissue culture lab. I 
wish you all good luck with your own research. Dear Shiqiao, our labmeeting discussion led 
to writing a review together. Research is “fun”, isn’t it. Also Ian, Elaine, Joanna, Rob, Ye, Garreth, 
William, Rebecca, Douglas, Matt, Gang and Monica, thank you for making my oxford time so 
memorable. I hope we will meet each other again soon. Dear Dawn, you are the best flatmate 
ever, we made “potato couching” the best event of the day.
Mijn dank gaat uit naar alle collega’s en chirurgen van het Reinier de Graaf Gasthuis, Delft. Dank 
voor jullie interesse in mijn onderzoek en voor alle energie die jullie in mij steken om van mij 
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MC bedanken voor een nuttige en leerzame tijd.
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voor de leuke feestjes en verjaardagen. Sébert, super bedankt voor je hulp bij de samenvat-
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geleerd dat je met hard werken alles kan bereiken. Jullie staan dan ook aan de basis van dit 
proefschrift. Altijd als dingen tegen zitten, kan ik thuis komen om te “resetten”. En bij ons thuis 
gebeurt dit vaak met lekker eten ☺. Dank voor jullie steun, vertrouwen en onuitputtelijke 
liefde. Het is voor mij een groot genot om de trotse blikken in jullie ogen te zien. Lieve Mui, mijn 
lieve zus, bij jou heb ik maar een halve woord nodig. Dank voor alle shopping- en lachsessies. 
Jij en Jeffrey vormen samen een mooi paar. Steven, thanks voor je hulp met de computers 
en succes met je stage straks. Fai, bedankt voor je artistieke input met de afbeeldingen. Je 
omslagontwerp staat als een huis. 
Lieve Hung, jij kent mij als geen ander, je steun is eindeloos en jij bent mijn Yin, zoals ik jouw 
Yang ben. Wanneer ik vol met onzekerheid en frustratie zit, ben jij degene die met één zin alles 
weer in perspectief zet. Je relativeert en laat mij tegelijkertijd stil staan om van de dingen te 
genieten. Dank voor je warmte en je liefde. Zonder jou verliest alles zijn glans. Ik kijk uit naar 
onze toekomst samen.
Dit proefschrift draag ik graag op aan degene bij wie het allemaal begon: mijn grootvader 
Phakai. Mijn lieve en zorgzame opa, die mij Thais leerde lezen op driejarige leeftijd, verdient alle 
lof en hulde. En zo is de cirkel weer rond.
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Name PhD Student: Thanyalak Tha-In
Erasmus MC Department: Gastroenterology and Hepatology
PhD Period:  November 2004 – June 2008
Promotor:  Prof. dr. H.J. Metselaar
Copromotor:  Dr. J. Kwekkeboom
Phd TRaINING
General academic and research skills     year
Basic radiation protection 5A/B     2005
Statistics: classical methods for data analysis    2005
Bioscientific course Module 1-4 (certificate for personal licence)  2005
(Inter)national conferences      year
Annual Meeting NTV 1, Rotterdam, The Netherlands   2003
Annual Meeting NTV 1, Texel, The Netherlands    2004
International Transplantation Society Congress, Vienna, Austria  2004
Stafdag Heelkunde, Rotterdam, The Netherlands   2004
Basic science symposium of TTS 2, Nantes, France   2005
Stafdag Heelkunde, Rotterdam, The Netherlands   2005
ESOT 3 Congress, Geneva, Switzerland     2005
Annual Meeting NVVI 4, Noordwijkerhout, The Netherlands  2006
Annual Meeting NTV 1, Zeewolde, The Netherlands   2006
International Congress of ILTS 5, Milan, Italy    2006
Molmed annual meeting, Rotterdam, The Netherlands   2006
Stafdag Heelkunde, Rotterdam, The Netherlands   2006
Wetenschapsdag Erasmus MC, Rotterdam, The Netherlands  2006
World Transplant Congress, Boston, USA    2006
Annual Meeting NTV 1, Zeewolde, The Netherlands   2007
European Society for Surgical Research, The Netherlands    2007
International Congress of ILTS 5, Rio de Janeiro, Brasil   2007
Najaarsvergadering NVGE/NVH 6, The Netherlands   2007
Sanquin Symposium, Amsterdam, The Netherlands   2007
Stafdag Heelkunde, Rotterdam, The Netherlands   2007
Wiser, NWO 6, Maastricht, The Netherlands    2007
Annual Meeting NTV 1, Zeewolde, The Netherlands   2008
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Basic science symposium of TTS 2, Brussel, Belgium   2008
International Congress of ILTS 5, Paris, France    2008
American Transplant Congress, Toronto, Canada    2008
1 Nederlandse Transplantatie Vereniging
2 The Transplantation Society
3 European Society of Transplantation
4 Nederlandse Vereniging voor Immunologie
5 International Liver Transplantation Society
6 Nederlandse vereniging van Gastroenterologie en Hepatologie
Membership
2008- present Dutch Association for Surgery (NvvH)
2004- present Dutch Association for Gastroenterology (NVGE) 
2004- present Dutch Association for Hepatology (NVH)
2004- present Dutch Association for Gastrointestinal Surgery (NVGIC)
2003- present Dutch Association for Transplantation (NTV)
2006-2007 American Society of Transplantation
Teaching activities       year
Lecture for second year medical students    2005
Lecture for fourth year medical students, teaching laboratory skills  2008
Scientific Awards and Grants
•	 NWO-Mosaic	2005	(The	Netherlands	Organization	for	Scientific	Research	(NWO))
•	 Travel	Grant	Vereniging	Trustfonds	Erasmus	University	Rotterdam	
•	 Travel	Grant	Dutch	Association	for	Transplantation
•	 De	Zilveren	Kreeft	prijs	2005	(best	presentation,	Stafdag	Heelkunde)
•	 Biotest	Research	grant	2006-2007
•	 Young	Investigator	Award	TTS	and	ATC	2006	
•	 Genzyme	Speakers	Award	2006	
•	 Rising	Star	Award	ILTS	2007	
•	 Novartis	Transplantation	Grant	2008	(best	paper	published	in	2007)	
•	 Dr.	W.H.	Posthumus-	Stipend	2008	(promising	female	PhD	student	)
•	 Young	Investigator	Travel	Award	ILTS	2008
•	 Basic	Science	ESOT	Travel	Grant	2009	(best	abstract)
Invited Speaker       year
Meeting werkgroep Immunodeficiëntie, Amsterdam, Netherlands  2007
Immunology Review Club, Leiden, Netherlands    2008
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lIST Of PublICaTION
Modulation of the cellular immune system by intravenous immunoglobulins
T. Tha-In *, J. Bayry *, H. J. Metselaar, S. V Kaveri x, Jaap Kwekkeboom x
*TT and JB are co-first authors, and xSK and JK contributed equally as senior authors to the 
conception of the manuscript.
Trends in Immunology 2008:29:2: 608-615
Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interac-
tion between dendritic cells and natural killer cells
T. Tha-In, H.J. Metselaar, H.W. Tilanus, E.J. Kuipers, R.A. de Man, J. Kwekkeboom 
Blood 2007, 110:3253
Functional Dichotomy of Natural Killer cells in organ transplantation
T. Tha-In, S. Luo, A.R. Bushell, K.J. Wood 
Expert Review in Clinical Immunology 2007:3:3: 261
Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and 
dendritic cells
T. Tha-In, H.J. Metselaar, H.W. Tilanus, P.P.C. Boor, S. Mancham, E.J. Kuipers, R.A. de Man, J. Kwek-
keboom 
Transplantation 2006, 81:1725
Therapeutic anti-HBs immunoglobulins inhibit dendritic cell maturation and T-cell proliferation 
and protect against acute rejection after liver transplantation
J. Kwekkeboom, T. Tha-In, W.M. Tra, W. Hop, P.P.C. Boor, S. Mancham, P.E. Zondervan, A.C.T.M. 
Vossen, R.A. de Man, H.J. Metselaar 
American Journal of Transplantation 2005, 5; 10:2393
Clinical outcome after cyclosporine dose reduction based C2 levels in long term liver transplant 
patients
T. Tha-In, D.A. Hesselink, H.W. Tilanus, L. Elshove, A.L. Wilschut, B.E. Hansen, T. van Gelder, H.J. 
Metselaar
Clinical Transplantation 2005, 19; 4: 537
Intravenous immunoglobulins trigger functional activation of human and mouse 
CD4+CD25+Foxp3+ T cells and promote skin allograft acceptance
T. Tha-In , H. J. Metselaar, A. R. Bushell, J. Kwekkeboom #, K. J. Wood #
#: JK and KJW contributed equally as senior investigators to this study
Submitted for publication 
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Increased incidence of early de novo cancer in liver graft recipients transplanted in recent years: 
an association with cyclosporine by C2 monitoring
S.W. Tjon, J. Sint Nicolaas, J. Kwekkeboom, R.A. de Man, G. Kazemier, H.W. Tilanus, B.E. Hansen, 
L.J.W. van der Laan, T. Tha-In, H.J. Metselaar  
Submitted for publication
Parotidectomy for benign and malignant disease of the parotis: Harmonic scalpel versus con-
ventional cold knife
T. Tha-In, B.M.E. Mees, M.M.F. Franken, I.H. Oei
In preparation
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CuRRICuluM vITaE auCTORIS
The author was born on December 28th , 1979 in Wiang Papao, Thailand. In 1990, at ten years 
of age, she moved to Rotterdam, The Netherlands. After graduating from high school at the 
Einstein Lyceum in 1998, she attended medical school at the Erasmus University Rotterdam. 
During medical school, she worked as a student assistant at the Department of Cardiology, 
Medium Care and Heart transplantation Unit, and performed research electives at the Depart-
ment of Gastroenterology and Hepatology, Liver Transplantation Unit, Erasmus Medical Center 
(Prof. dr. H.J. Metselaar, Prof. dr. E.J. Kuipers). In 2003 and 2004, she performed a clinical subin-
ternship at the Department of Surgery, Hepatobiliary Surgery Unit, Chiang Mai Rai University, 
Thailand (Dr. Chotirosniramit). In 2004, she graduated from medical school cum laude.
After graduation she was offered a position as a PhD student at the Department of Gastro-
enterology and Hepatology, Liver Transplantation Unit of the Erasmus Medical Center. Under 
supervision of Prof. dr. H.J. Metselaar and Dr. J. Kwekkeboom, she focused on the immuno-
modulatory effect of intravenous immunoglobulins after liver transplantation. During her 
PhD training, she was a member of the liver transplantation operating theatre and laboratory 
support team (Prof.dr. H.W. Tilanus).  In 2005, she received the Mosaic grant of The Netherlands 
Organization for Scientific Research (NWO) and an unrestricted grant of Biotest Seralc, Soest, 
The Netherlands, to perform her research.  In 2006 she was awarded with the Young Investigator 
Award at the World Transplant Congress, Boston, U.S.A. and in 2007 she received the prestigious 
Rising Star Award of the International Liver Transplantation Society (ILTS), Rio de Janeiro, Brasil. 
From September 2006 until August 2007, she studied the immunomodulatory effects of IVIg 
in vivo and performed skin allograft transplantation in mice. This was performed in close col-
laboration at the Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom 
(Dr. A.R. Bushell and Prof. K.J. Wood). 
In July 2008 she started her residency in General Surgery at the Reinier de Graaf Gasthuis 
in Delft (Dr. L.P.S. Stassen and Dr. M. van der Elst) and she will complete her residency at the 
Erasmus Medical Center (Prof.dr. J.N.M. IJzermans en Prof.dr. J.J.B. van Lanschot). She remains 
close involved with the IVIg project and is passionate about research.
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A portret of me by Sir Roy Calne, a british surgeon, a true pioneer in organ transplantation and a wellknown artist, during the International 
Congress of ILTS, Milan, Italy (5th of May 2006)
